<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//ACS//DTD ACS Journal DTD v1.02 20061031//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName ACSJournal-v102.dtd?>
<?SourceDTD.Version 1.02?>
<?ConverterInfo.XSLTName acs2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Mol Pharm</journal-id>
    <journal-id journal-id-type="iso-abbrev">Mol Pharm</journal-id>
    <journal-id journal-id-type="publisher-id">mp</journal-id>
    <journal-id journal-id-type="coden">mpohbp</journal-id>
    <journal-title-group>
      <journal-title>Molecular Pharmaceutics</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1543-8384</issn>
    <issn pub-type="epub">1543-8392</issn>
    <publisher>
      <publisher-name>American Chemical Society</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">10853961</article-id>
    <article-id pub-id-type="pmid">38134445</article-id>
    <article-id pub-id-type="doi">10.1021/acs.molpharmaceut.3c00964</article-id>
    <article-categories>
      <subj-group>
        <subject>Article</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>AMALPHI:
A Machine Learning Platform for Predicting
Drug-Induced PhospholIpidosis</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" id="ath1">
        <name>
          <surname>Lomuscio</surname>
          <given-names>Maria
Cristina</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">†</xref>
      </contrib>
      <contrib contrib-type="author" id="ath2">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9292-884X</contrib-id>
        <name>
          <surname>Abate</surname>
          <given-names>Carmen</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">†</xref>
        <xref rid="aff2" ref-type="aff">‡</xref>
      </contrib>
      <contrib contrib-type="author" id="ath3">
        <name>
          <surname>Alberga</surname>
          <given-names>Domenico</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">†</xref>
      </contrib>
      <contrib contrib-type="author" id="ath4">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6221-6155</contrib-id>
        <name>
          <surname>Laghezza</surname>
          <given-names>Antonio</given-names>
        </name>
        <xref rid="aff2" ref-type="aff">‡</xref>
      </contrib>
      <contrib contrib-type="author" id="ath5">
        <name>
          <surname>Corriero</surname>
          <given-names>Nicola</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">†</xref>
      </contrib>
      <contrib contrib-type="author" id="ath6">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5639-7746</contrib-id>
        <name>
          <surname>Colabufo</surname>
          <given-names>Nicola Antonio</given-names>
        </name>
        <xref rid="aff2" ref-type="aff">‡</xref>
      </contrib>
      <contrib contrib-type="author" id="ath7">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5086-2459</contrib-id>
        <name>
          <surname>Saviano</surname>
          <given-names>Michele</given-names>
        </name>
        <xref rid="aff3" ref-type="aff">§</xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes" id="ath8">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4523-2759</contrib-id>
        <name>
          <surname>Delre</surname>
          <given-names>Pietro</given-names>
        </name>
        <xref rid="cor1" ref-type="other">*</xref>
        <xref rid="aff1" ref-type="aff">†</xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes" id="ath9">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4042-2841</contrib-id>
        <name>
          <surname>Mangiatordi</surname>
          <given-names>Giuseppe Felice</given-names>
        </name>
        <xref rid="cor2" ref-type="other">*</xref>
        <xref rid="aff1" ref-type="aff">†</xref>
      </contrib>
      <aff id="aff1"><label>†</label><institution>CNR—Institute
of Crystallography</institution>, Via Amendola 122/o, 70126 Bari, <country>Italy</country></aff>
      <aff id="aff2"><label>‡</label>Department
of Pharmacy-Pharmaceutical Sciences, <institution>University
of the Studies of Bari “Aldo Moro”</institution>, Via E.Orabona 4, 70125 Bari, <country>Italy</country></aff>
      <aff id="aff3"><label>§</label><institution>CNR—Institute
of Crystallography</institution>, Via
Vivaldi 43, 81100 Caserta, <country>Italy</country></aff>
    </contrib-group>
    <author-notes>
      <corresp id="cor1"><label>*</label>Email: <email>pietro.delre@ic.cnr.it</email>.</corresp>
      <corresp id="cor2"><label>*</label>Email: <email>giuseppe.mangiatordi@ic.cnr.it</email>.</corresp>
    </author-notes>
    <pub-date pub-type="epub">
      <day>22</day>
      <month>12</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="collection">
      <day>05</day>
      <month>02</month>
      <year>2024</year>
    </pub-date>
    <volume>21</volume>
    <issue>2</issue>
    <fpage>864</fpage>
    <lpage>872</lpage>
    <history>
      <date date-type="received">
        <day>17</day>
        <month>10</month>
        <year>2023</year>
      </date>
      <date date-type="accepted">
        <day>05</day>
        <month>12</month>
        <year>2023</year>
      </date>
      <date date-type="rev-recd">
        <day>24</day>
        <month>11</month>
        <year>2023</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© 2023 American Chemical Society</copyright-statement>
      <copyright-year>2023</copyright-year>
      <copyright-holder>American Chemical Society</copyright-holder>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
        <license-p>Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>).</license-p>
      </license>
    </permissions>
    <abstract>
      <p content-type="toc-graphic">
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mp3c00964_0005" id="ab-tgr1"/>
      </p>
      <p>Drug-induced phospholipidosis (PLD) involves the accumulation
of
phospholipids in cells of multiple tissues, particularly within lysosomes,
and it is associated with prolonged exposure to druglike compounds,
predominantly cationic amphiphilic drugs (CADs). PLD affects a significant
portion of drugs currently in development and has recently been proven
to be responsible for confounding antiviral data during drug repurposing
for SARS-CoV-2. In these scenarios, it has become crucial to identify
potential safe drug candidates in advance and distinguish them from
those that may lead to false in vitro antiviral activity. In this
work, we developed a series of machine learning classifiers with the
aim of predicting the PLD-inducing potential of drug candidates. The
models were built on a high-quality chemical collection comprising <bold>545</bold> curated small molecules extracted from ChEMBL v30. The
most effective model, obtained using the balanced random forest algorithm,
achieved high performance, including an AUC value computed in validation
as high as 0.90. The model was made freely available through a user-friendly
web platform named AMALPHI (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ba.ic.cnr.it/softwareic/amalphiportal/">https://www.ba.ic.cnr.it/softwareic/amalphiportal/</uri>), which can represent a valuable tool for medicinal chemists interested
in conducting an early evaluation of PLD inducer potential.</p>
    </abstract>
    <kwd-group>
      <kwd>phospholipidosis</kwd>
      <kwd>ligand-based classifiers</kwd>
      <kwd>machine learning</kwd>
      <kwd>SARS-CoV-2</kwd>
    </kwd-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution>Consiglio Nazionale delle Ricerche</institution>
            <institution-id institution-id-type="doi">10.13039/501100004462</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>NA</award-id>
      </award-group>
    </funding-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution>Ministero dell''UniversitÃ  e della Ricerca</institution>
            <institution-id institution-id-type="doi">10.13039/501100021856</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>2022Z3BBPE</award-id>
      </award-group>
    </funding-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution>Regione Puglia</institution>
            <institution-id institution-id-type="doi">10.13039/501100009886</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>NA</award-id>
      </award-group>
    </funding-group>
    <custom-meta-group>
      <custom-meta>
        <meta-name>document-id-old-9</meta-name>
        <meta-value>mp3c00964</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>document-id-new-14</meta-name>
        <meta-value>mp3c00964</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>ccc-price</meta-name>
        <meta-value/>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
</front>
<body>
  <sec id="sec1">
    <title>Introduction</title>
    <p>Phospholipidosis (PLD) is a lysosomal
storage disorder characterized
by excessive accumulation of phospholipids in liver, kidney, brain,
cornea, lung, and other organs.<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> While
it is widely recognized that this phenomenon can arise from prolonged
treatment with cationic amphiphilic drugs (CADs), the exact mechanism
behind this process remains unclear. Various hypotheses have been
explored in the literature, including direct inhibition of lysosomal
phospholipases,<sup><xref ref-type="bibr" rid="ref2">2</xref></sup> binding to phospholipids,<sup><xref ref-type="bibr" rid="ref3">3</xref></sup> the potential regulation of phospholipid synthesis,<sup><xref ref-type="bibr" rid="ref4">4</xref></sup> and the enhanced cholesterol biosynthesis.<sup><xref ref-type="bibr" rid="ref5">5</xref></sup> For a comprehensive review on this topic, the
reader is referred to the recent paper by Breiden et al.<sup><xref ref-type="bibr" rid="ref6">6</xref></sup> Given that a notable proportion (∼5%<sup><xref ref-type="bibr" rid="ref7">7</xref></sup>) of drugs can induce PLD, there has been a growing
interest in recent years to assess the potential of drug candidates
to be inducers of PLD during the early stages of a drug discovery
(DD) process. This proactive evaluation is recognized as valuable,
as compounds that lead to PLD have a reduced likelihood of being successfully
brought to market.<sup><xref ref-type="bibr" rid="ref8">8</xref></sup> Recently, highly significant
correlations have been demonstrated between lipophilicity, the ability
of CADs to induce PLD, and the antiviral activity that these cationic
amphiphilic drugs have shown against multiple viruses such as hepatitis
C virus (HCV), Japanese encephalitis virus (JEV), severe acute respiratory
syndrome coronavirus (SARS-CoV), and Epstein–Barr virus (EBV).<sup><xref ref-type="bibr" rid="ref9">9</xref></sup> In light of the recent COVID-19 pandemic, a publication
in Science by Tummino et al.<sup><xref ref-type="bibr" rid="ref10">10</xref></sup> presented
findings that highlight the pivotal role of PLD in the context of
drugs with anti-SARS-CoV-2 activity, revealing that most of the molecules
return antiviral activity during the drug repurposing campaigns conducted
during the pandemic induce PLD. This adds another layer of complexity
and importance to the understanding and evaluation of PLD in drug
development efforts, particularly in the context of the recent global
health crisis. Based on these data, Tummino et al. speculated that
the anti-SARS-CoV-2 activity observed in vitro for many molecules
would be the consequence of their ability to induce PLD rather than
activity on a specific target (false anti-SARS-CoV-2 activity<sup><xref ref-type="bibr" rid="ref10">10</xref></sup>). This hypothesis was supported by the evidence
that many molecules exhibiting antiviral activity in vitro lost such
activity when transitioning to in vivo conditions. Further support
came from the lack of correlation between the antiviral activity and
the affinity of some ligands that interact with host targets identified
as important in combating SARS-CoV-2 replication (e.g., sigma-1 receptor).<sup><xref ref-type="bibr" rid="ref11">11</xref></sup> Some molecules with high affinity for sigma-1,
for instance, show no antiviral activity.<sup><xref ref-type="bibr" rid="ref12">12</xref></sup> Although PLD in the context of SARS-CoV-2 antiviral assays remains
a subject of ongoing scientific debate with contradictory data,<sup><xref ref-type="bibr" rid="ref13">13</xref>,<xref ref-type="bibr" rid="ref14">14</xref></sup> its importance in the drug development process has been further
underscored. Unfortunately, the available in vitro assays able to
measure the PLD-inducing potential of drug candidates are laborious,
time-consuming, expensive, and, for these reasons, poorly applied
despite the fact that several CADs agents are in clinical use/development.
Furthermore, the gold standard method (transmission electron microscope—TEM)
does not allow the screening of a large number of molecules.<sup><xref ref-type="bibr" rid="ref15">15</xref></sup> Other in vitro approaches include a method consisting
of measuring the binding of dyes to the phospholipids by flow cytometry
or fluorescence microscopy,<sup><xref ref-type="bibr" rid="ref16">16</xref>−<xref ref-type="bibr" rid="ref20">20</xref></sup> as well as a method based on quantifying gene biomarkers linked
to PLD.<sup><xref ref-type="bibr" rid="ref15">15</xref></sup> All these approaches are particularly
expensive and often yield conflicting data.<sup><xref ref-type="bibr" rid="ref21">21</xref>−<xref ref-type="bibr" rid="ref23">23</xref></sup> The development
of in-silico tools able to prioritize safe drug candidates is, therefore,
highly desirable, although it is worth noting that they are not free
from limitations. Especially when not used in conjunction with experiments
or when not starting from highly curated experimental data, they can
lead to a considerable number of false positives, as was clearly seen
during the COVID-19 pandemic.<sup><xref ref-type="bibr" rid="ref24">24</xref></sup> In the
context of antiviral design, if developed effectively, these tools
would provide valid support to the identification of those compounds
with a low probability to provide false antiviral activities during
in vitro assays. Accordingly, several models have been developed in
the past few years to predict the PLD-inducing potential of drug candidates,
based on ligand-based approaches<sup><xref ref-type="bibr" rid="ref7">7</xref>,<xref ref-type="bibr" rid="ref25">25</xref>−<xref ref-type="bibr" rid="ref28">28</xref></sup> or substructure search methods.<sup><xref ref-type="bibr" rid="ref29">29</xref>,<xref ref-type="bibr" rid="ref30">30</xref></sup> Valuable examples
can be found in the papers by Kruhlak et al.<sup><xref ref-type="bibr" rid="ref7">7</xref></sup> and Orogo et al.,<sup><xref ref-type="bibr" rid="ref26">26</xref></sup> reporting quantitative
structure–activity relationship (QSAR) models based on <bold>583</bold> and <bold>743</bold> compounds, respectively, extracted
from the published literature, existing pharmaceutical databases,
and Food and Drug Administration (FDA) internal reports. Of note are
also the papers by Fusani et al. and Schieferdecker et al.<sup><xref ref-type="bibr" rid="ref27">27</xref>,<xref ref-type="bibr" rid="ref28">28</xref></sup> Based on in-house in vitro data, the authors developed machine learning-based
models of PLD-inducing potential. However, despite their good performance
(accuracy &gt; 80%), the developed models are not available; hence,
their
accessibility to potentially interested users is strongly limited.
Building on this background, in the present study, new classifiers
of PLD-inducing potential were developed using four algorithms, namely,
random forest (RF), K-nearest neighbors (KNN), gradient boosting (GB),
and extreme gradient boosting (XGB) starting from <bold>545</bold> compounds extracted from ChEMBL version (v) 30 (PLD-DB) and then
splitting into a training set (TS) and a validation set (VS). The
top-performing classifier was also tested on two external sets (ESs).
Despite the limited data availability, these models demonstrated satisfactory
performance, as evidenced by widely accepted quality metrics, such
as the area under the receiver operating characteristic curve (AUC)
and balanced accuracy (BA). Following an approach successfully employed
by our team for predicting other chemical properties,<sup><xref ref-type="bibr" rid="ref31">31</xref>,<xref ref-type="bibr" rid="ref32">32</xref></sup> the most effective model was incorporated into a user-friendly web
platform named AMALPHI (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ba.ic.cnr.it/softwareic/amalphiportal/">https://www.ba.ic.cnr.it/softwareic/amalphiportal/</uri>). Significantly, this platform does not necessitate expertise in
cheminformatics or programming and can be a valuable resource for
medicinal chemists interested in early evaluations of the PLD inducer
potential. To the best of our knowledge, AMALPHI is the first freely
accessible tool able to efficiently predict the PLD potential of drug
candidates.</p>
  </sec>
  <sec id="sec2">
    <title>Materials and Methods</title>
    <sec id="sec2.1">
      <title>Data Set Preparation</title>
      <p>We extracted <bold>851</bold> entries
from ChEMBL v30 according to the Target ID (CHEMBL1626541) assigned
to the PLD phenotype. Following an approach described elsewhere,<sup><xref ref-type="bibr" rid="ref32">32</xref>,<xref ref-type="bibr" rid="ref33">33</xref></sup> we checked the validity of each SMILES string using an in-house
semiautomated procedure implemented in the KNIME platform. In particular,
this procedure allows for the removal of organometallic and inorganic
compounds, chemicals characterized by unusual elements and mixtures,
neutralizing salts, and stereochemistry. Finally, the OpenBabel node
implemented in KNIME allowed the conversion of retrieved SMILES in
a standardized QSAR-ready format. In doing that, we created the PLD-DB,
consisting of <bold>545</bold> curated entries. It is worth noting
that 70% of the compounds belonging to the PLD-DB data set are approved
drugs, while the remaining ones have yet to progress to the clinical
phase.</p>
      <p>Furthermore, to assess the diversity of molecules in
our data set, we employed a metric called internal diversity (ID—defined
as the mean over the Tanimoto distances between each molecule and
all the others belonging to the same set<sup><xref ref-type="bibr" rid="ref34">34</xref></sup>), which effectively measures the similarity of molecules within
the data set. The resulting ID value of 0.82 indicates that the compounds
in our data set exhibit a high degree of diversity. To classify the
entries as either PLD inducers (P+) or noninducers (P−), we
analyzed the comments field based on the reference CHEMBL ID document.
Annotations selected as referring to P+ were: “active”/
“positive”/ “positive: inducer confirmed by electron
microscopy”/ “positive: weak inducer based on foamy
macrophages and cytoplasmic vacuolations.” Instead, comments
selected as indicating no PLD induction (P−) were: “not
active”/“negative”/“negative: confirmed
by electron microscopy”/“negative: based on the absence
of positive reported data from WMDD.” <bold>295</bold> duplicates
were removed, keeping the P+ or P– class as the most frequent
one. Finally, <bold>11</bold> chemicals were excluded, as their activity
was indicated as “Not determined” in ChEMBL v30. In
doing that, the final curated data set (PDL-DB) comprises <bold>104</bold> P+ and <bold>441</bold> P– for a total of <bold>545</bold> compounds.</p>
    </sec>
    <sec id="sec2.2">
      <title>External Set Preparation</title>
      <p>Two different external sets
(ESs), one consisting of <bold>117</bold> (ES1) and the other consisting
of <bold>20</bold> (ES2) compounds, were built and used in this work.
In particular, Orogo et al.<sup><xref ref-type="bibr" rid="ref26">26</xref></sup> made available
a data set (Or-ds) consisting of <bold>743</bold> compounds that we
used to create ES1. Noteworthy, Or-ds comprises compounds along with
their associated PLD activity and a corresponding data confidence
rate expressed as either high or medium. Compounds associated with
keywords related to electron microscopy confirmation of PLD are considered
to have high confidence, while those associated with keywords and
phrases indicating only the presence of foamy macrophages are considered
to have medium confidence. We kept only those compounds with a high
confidence rating and processed the SMILES strings using the same
semiautomated procedure described above to remove duplicates and compounds
already included in PLD-DB. The second external set (ES2) was built
based on the work by Przybylak et al.<sup><xref ref-type="bibr" rid="ref29">29</xref></sup> The authors used two curated data sets comprising <bold>185</bold> and <bold>331</bold> compounds. These two data sets were merged
and processed following the already described data curation approach.</p>
    </sec>
    <sec id="sec2.3">
      <title>Data Set Splitting</title>
      <p>We employed a rational approach
to split PLD-DB into a TS and a VS. To this aim, we applied the RDkit
Diversity Picker node separately on the two classes (i.e., P+ and
P−). This node automatically generates Morgan fingerprints
(radius 2–2048 bits) for each SMILES string and then picks
80% of the most diverse molecules for each class based on the Tanimoto
distance.<sup><xref ref-type="bibr" rid="ref35">35</xref></sup> In this way, a TS of <bold>431</bold> compounds (80% of each class) and a VS that includes the
remaining <bold>114</bold> compounds were obtained. <xref rid="tbl2" ref-type="other">Table <xref rid="tbl2" ref-type="other">2</xref></xref> summarizes the composition
of the starting TS, VS, and ES as well as the relative imbalanced
ratio (IR) calculated as the ratio between the number of majority
and minority instances.<sup><xref ref-type="bibr" rid="ref36">36</xref></sup> Note that such
a procedure allowed us to keep the ratio between the classes in each
subset. To depict the chemical space covered by TS, VS, and ESs, a
principal component analysis (PCA) was performed based on 36 physicochemical
properties of the molecules calculated by the RDKit Descriptor Calculation
KNIME node and then standardized using the Normalizer KNIME node (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>). The score plot
of the first three principal components (PC1, PC2, and PC3) that account
for 80.8% of the variance shows each ligand belonging to the different
data sets in the resulting 3D chemical space.</p>
      <fig id="fig1" position="float">
        <label>Figure 1</label>
        <caption>
          <p>PCA based on the physicochemical
properties returned by the compounds
belonging to TS, VS, ES1, and ES2.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mp3c00964_0001" id="gr1" position="float"/>
      </fig>
    </sec>
  </sec>
  <sec id="sec3">
    <title>Development of Statistically Based Models</title>
    <sec id="sec3.1">
      <title>Development and Validation</title>
      <p>In this work, four classification
algorithms were used: RF, KNN, GB, and XGB. We employed the following
KNIME nodes: tree ensemble learner, tree ensemble predictor, K-nearest
neighbor, gradient boosted trees learner, gradient boosted trees predictor,
XGBoost tree ensemble learner, XGBoost predictor.<sup><xref ref-type="bibr" rid="ref37">37</xref>−<xref ref-type="bibr" rid="ref39">39</xref></sup> AtomPair fingerprints
(AP—1024 bits) calculated by the RDKit Fingerprint KNIME node
were used to represent each chemical structure belonging to PLD-DB.</p>
      <p>It is worth noting that we opted for AP fingerprints instead of
the previously used Morgan fingerprints due to their acknowledged
higher sensitivity to molecular global features, such as size and
shape.<sup><xref ref-type="bibr" rid="ref40">40</xref></sup></p>
      <p>Noteworthy, an IR equal
to 4.4 was computed for the TS. For this
reason, we created an additional set of models using an undersampling
ensemble learning model (UELM), employing KNN, GB, and XGB. This technique
presents two advantages as it (i) avoids the convergence of algorithms
trained on the majority class ignoring classes with fewer samples,<sup><xref ref-type="bibr" rid="ref41">41</xref></sup> and (ii) preserves information from the majority
class using the ensemble technique. In particular, we used the equal
size sampling node to generate, from the original TS, 50 sub-TS (characterized
by an IR equal to 1) to train 50 models and generate the final ensemble
model, able to make predictions on external data (i.e., VS and ES)
following a majority voting approach. In all cases, we found the optimal
setting (shown in <xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>) for the final model training through hyperparameter tuning performed
based on a 5-fold cross-validation (5-CV). Note that, for each algorithm,
the hyperparameters known to be responsible for the higher impact
on the overall performance<sup><xref ref-type="bibr" rid="ref42">42</xref>,<xref ref-type="bibr" rid="ref43">43</xref></sup> were considered.</p>
      <table-wrap id="tbl1" position="float">
        <label>Table 1</label>
        <caption>
          <title>Optimized Parameters for Each Algorithm</title>
        </caption>
        <table frame="hsides" rules="groups" border="0">
          <colgroup>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
          </colgroup>
          <thead>
            <tr>
              <th style="border:none;" align="center">algorithm</th>
              <th style="border:none;" align="center">optimized
parameters</th>
              <th style="border:none;" align="center">unbalanced TS</th>
              <th style="border:none;" align="center">equal size models</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="6" style="border:none;" align="left">RF</td>
              <td style="border:none;" align="left">split criterion</td>
              <td style="border:none;" align="left">gini index</td>
              <td rowspan="6" style="border:none;" align="left"> </td>
            </tr>
            <tr>
              <td style="border:none;" align="left">attribute
sampling</td>
              <td style="border:none;" align="left">square root</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">set of
attributes for each tree</td>
              <td style="border:none;" align="left">different</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">number of trees</td>
              <td style="border:none;" align="left">423</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">tree depth</td>
              <td style="border:none;" align="left">6</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">equal size sampling</td>
              <td style="border:none;" align="left">yes</td>
            </tr>
            <tr>
              <td rowspan="2" style="border:none;" align="left">kNN</td>
              <td style="border:none;" align="left">number of neighbors to consider</td>
              <td style="border:none;" align="left">5</td>
              <td style="border:none;" align="left">7</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">weight neighbors by distance</td>
              <td style="border:none;" align="left">yes</td>
              <td style="border:none;" align="left">no</td>
            </tr>
            <tr>
              <td rowspan="5" style="border:none;" align="left">GB</td>
              <td style="border:none;" align="left">number
of trees</td>
              <td style="border:none;" align="left">280</td>
              <td style="border:none;" align="left">100</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">learning rate</td>
              <td style="border:none;" align="left">0.98</td>
              <td style="border:none;" align="left">1</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">attribute sampling</td>
              <td style="border:none;" align="left">square root</td>
              <td rowspan="3" style="border:none;" align="left"> </td>
            </tr>
            <tr>
              <td style="border:none;" align="left">set of attributes for each
tree</td>
              <td style="border:none;" align="left">same</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">maximum tree depth</td>
              <td style="border:none;" align="left">8</td>
            </tr>
            <tr>
              <td rowspan="6" style="border:none;" align="left">XGB</td>
              <td style="border:none;" align="left">eta</td>
              <td style="border:none;" align="left">0.589</td>
              <td style="border:none;" align="left">0.28</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">boosting
rounds</td>
              <td style="border:none;" align="left">253</td>
              <td style="border:none;" align="left">100</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">gamma</td>
              <td style="border:none;" align="left">0.182</td>
              <td rowspan="4" style="border:none;" align="left"> </td>
            </tr>
            <tr>
              <td style="border:none;" align="left">lamba</td>
              <td style="border:none;" align="left">4.842</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">alpha</td>
              <td style="border:none;" align="left">0.211</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">maximum depth</td>
              <td style="border:none;" align="left">6</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>To do that, we employed a Bayesian optimization algorithm
for RF
and XGB and a grid search for KNN and GB. Finally, after performance
evaluation, we selected the best-performing model.</p>
    </sec>
    <sec id="sec3.2">
      <title>Applicability Domain</title>
      <p>An applicability domain (AD) was
defined for the TS in order to increase confidence in the predictions.
Notably, AD represents the chemical space from which the models are
built and, therefore, where a prediction can be considered reliable.<sup><xref ref-type="bibr" rid="ref44">44</xref></sup> The domain-similarity KNIME node was employed
to define the AD. This node measures the Euclidean distances between
the compounds belonging to the TS and those subjected to prediction.
In particular, this approach allows defining an AD threshold (ADP)
following these steps: (i) the computation of all the Euclidean distances
between all the possible pairs of compounds belonging to TS, based
on representative descriptors (AP fingerprint in our case); (ii) the
creation of a set of distances that are lower than the average distance
calculated in step 1; (iii) the computation of the mean (d) and standard
deviation (σ) of the distances in the set created in step 2;
and (iv) the definition the ADP (AD threshold) using the equation<disp-formula id="eq1"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mp3c00964_m001" position="anchor"/><label>1</label></disp-formula>where <italic>Z</italic> is an empirical cutoff
value equal to 0.5 by default.<sup><xref ref-type="bibr" rid="ref45">45</xref></sup> In doing
that, we excluded 2 compounds from VS and 16 compounds from ES1, while
all the compounds belonging to ES2 resulted within the AD. <xref rid="tbl2" ref-type="other">Table <xref rid="tbl2" ref-type="other">2</xref></xref> reports the VS, ES1, and ES2 compositions after the application
of the AD filter.</p>
      <table-wrap id="tbl2" position="float">
        <label>Table 2</label>
        <caption>
          <title>Partitioning Schemes Before (Top)
and After (Bottom) the Application of the AD<xref rid="t2fn1" ref-type="table-fn">a</xref></title>
        </caption>
        <table frame="hsides" rules="groups" border="0">
          <colgroup>
            <col align="left"/>
            <col align="char" char="."/>
            <col align="char" char="."/>
            <col align="char" char="."/>
            <col align="char" char="."/>
          </colgroup>
          <thead>
            <tr>
              <th style="border:none;" align="center">data set</th>
              <th style="border:none;" align="center" char=".">#</th>
              <th style="border:none;" align="center" char=".">P–</th>
              <th style="border:none;" align="center" char=".">P+</th>
              <th style="border:none;" align="center" char=".">IR</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td style="border:none;" align="left">TS</td>
              <td style="border:none;" align="char" char=".">431</td>
              <td style="border:none;" align="char" char=".">351</td>
              <td style="border:none;" align="char" char=".">80</td>
              <td style="border:none;" align="char" char=".">4.4</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">VS</td>
              <td style="border:none;" align="char" char=".">114</td>
              <td style="border:none;" align="char" char=".">90</td>
              <td style="border:none;" align="char" char=".">24</td>
              <td style="border:none;" align="char" char=".">3.7</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">ES1</td>
              <td style="border:none;" align="char" char=".">133</td>
              <td style="border:none;" align="char" char=".">112</td>
              <td style="border:none;" align="char" char=".">21</td>
              <td style="border:none;" align="char" char=".">5.3</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">ES2</td>
              <td style="border:none;" align="char" char=".">20</td>
              <td style="border:none;" align="char" char=".">11</td>
              <td style="border:none;" align="char" char=".">9</td>
              <td style="border:none;" align="char" char=".">1.2</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">within the AD</td>
              <td style="border:none;" align="char" char="."> </td>
              <td style="border:none;" align="char" char="."> </td>
              <td style="border:none;" align="char" char="."> </td>
              <td style="border:none;" align="char" char="."> </td>
            </tr>
            <tr>
              <td style="border:none;" align="left">VS</td>
              <td style="border:none;" align="char" char=".">112</td>
              <td style="border:none;" align="char" char=".">88</td>
              <td style="border:none;" align="char" char=".">24</td>
              <td style="border:none;" align="char" char=".">3.6</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">ES1</td>
              <td style="border:none;" align="char" char=".">117</td>
              <td style="border:none;" align="char" char=".">99</td>
              <td style="border:none;" align="char" char=".">18</td>
              <td style="border:none;" align="char" char=".">5.5</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">ES2</td>
              <td style="border:none;" align="char" char=".">20</td>
              <td style="border:none;" align="char" char=".">11</td>
              <td style="border:none;" align="char" char=".">9</td>
              <td style="border:none;" align="char" char=".">1.2</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="t2fn1">
            <label>a</label>
            <p>For PLD-DB, the number of noninducers
(P−) and inducers (P+) chemicals is reported for the training
set (TS), validation set (VS), largest (ES1), and smallest (ES2) external
sets. Notably, the total number of chemicals (#) is also reported.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
    </sec>
    <sec id="sec3.3">
      <title>Performance Evaluation</title>
      <p>Each classifier was evaluated
by using Coopers statistics. In particular, sensitivity (SE), specificity
(SP), and BA were computed as follows<disp-formula id="eq2"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mp3c00964_m002" position="anchor"/><label>2</label></disp-formula><disp-formula id="eq3"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mp3c00964_m003" position="anchor"/><label>3</label></disp-formula><disp-formula id="eq4"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mp3c00964_m004" position="anchor"/><label>4</label></disp-formula>where TP (true positives) and TN (true negatives)
are, respectively, the positive and negative samples correctly classified
by the trained model, whereas FP (false positives) and FN (false negatives)
are the misclassified positive and negative samples, respectively.
Another quality metric, namely, the Matthews correlation coefficient
(MCC), was considered to evaluate model performance. MCC indicates
the quality of binary classification and is generally recognized as
a reliable metric, although it deteriorates when the TS is unbalanced.
MCC ranges between −1 and +1, where a value of +1 means a perfect
classification, 0 indicates a random classification, and −1
is a complete misclassification.<disp-formula id="eq5"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mp3c00964_m005" position="anchor"/><label>5</label></disp-formula>The AUC was also computed by the ROC curve
node<sup><xref ref-type="bibr" rid="ref46">46</xref></sup> to measure the ability of a model
to distinguish P+ from P– samples. This metric ranges between
0 (miss-classifiers) and 1 (ideal-classifiers), reflecting the probability
of positive compounds being ranked earlier than decoy compounds according
to the prediction confidence value estimated by the KNIME Predictor
nodes with respect to each specific algorithm used.<sup><xref ref-type="bibr" rid="ref37">37</xref>−<xref ref-type="bibr" rid="ref39">39</xref></sup> The ROC curve
and, consequently, the AUC will be one of the key metrics we will
primarily consider for selecting the most effective model.<sup><xref ref-type="bibr" rid="ref47">47</xref></sup></p>
      <p>Finally, the positive (+LR) and the negative
likelihood ratio (−LR) were considered and computed as follows<disp-formula id="eq6"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mp3c00964_m006" position="anchor"/><label>6</label></disp-formula>and<disp-formula id="eq7"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mp3c00964_m007" position="anchor"/><label>7</label></disp-formula>The classification model becomes more informative
as the +LR value increases (or the −LR value decreases).</p>
    </sec>
  </sec>
  <sec id="sec4">
    <title>Results and Discussion</title>
    <p>In this work, different classifiers
of PLD-inducing potential were
developed using four ML classification algorithms, namely, RF, KNN,
GB, and XGB, all available in the KNIME analytics platform. To this
end, a highly curated data set (PLD-DB) consisting of <bold>545</bold> compounds was used to train and then to validate the models. More
specifically, PLD-DB was divided into a TS used to perform hyperparameter
tuning based on a 5-fold cross-validation (5-CV) and a VS used to
validate the models obtained with the best parameters identified.
Each compound was described by binary fingerprints, namely, AtomPair
FP.<sup><xref ref-type="bibr" rid="ref48">48</xref></sup> As already mentioned, PLD-DB is an
unbalanced data set with an IR approximately equal to 4. To address
the problem and therefore prevent a significant discrepancy between
SE and SP, different techniques were undertaken. The RF algorithm
was combined with a uniform size sampling strategy (hereinafter referred
to as balanced random forest–BRF) to reduce the bias toward
the majority class while an additional technique named UELM (see the
section <xref rid="sec2" ref-type="other">Materials and Methods</xref> for methodological
details) was implemented for KNN (hereinafter referred to as uKNN),
GB (uGB), and XGB (uXGB) algorithms. In particular, using the equal
size KNIME node, we developed, for each of these algorithms, a final
ensemble model following the approach described in the section “<xref rid="sec3.1" ref-type="other">Models Development and Validation</xref>”. The
final prediction was performed following a majority vote approach.
Furthermore, to wisely evaluate real-life model predictivity, VS was
kept imbalanced, and only compounds within the AD were considered.
Finally, two different ESs were employed to assess the predictivity
of the best model in a real-life case study. The following section
will focus on analyzing the key quality metrics (SE, SP, BA, MCC,
and AUC) calculated for each validation process (internal and external),
aiming to identify the top-performing classifier.</p>
    <sec id="sec4.1">
      <title>Hyperparameterization</title>
      <p><xref rid="tbl3" ref-type="other">Table <xref rid="tbl3" ref-type="other">3</xref></xref> displays the performances achieved using
5-fold cross-validation (5-CV) for each employed algorithm using the
TS extracted from PLD-DB for hyperparameter optimization tuning. In
this step, ensuring satisfactory performance is critical to guarantee
the capability of model generalization, meaning that models fit the
data set accurately, avoiding overfitting or underfitting. As expected,
the classifiers built based on RF, KNN, GB, and XGB returned SP values
significantly higher than SE ones (difference ranging from 0.55 to
0.78). Moreover, in all cases, BA values lower than 0.70 were computed.
A remarkable performance improvement is instead observed when a proper
treatment of the TS imbalance is undertaken as evident looking at
the quality metrics returned by BRF, uKNN, uGB, and uXGB (<xref rid="tbl3" ref-type="other">Table <xref rid="tbl3" ref-type="other">3</xref></xref>). More specifically,
no significant difference is observed between the SE and SP, ranging
from 0.01 (BRF) to 0.08 (uKNN). Furthermore, higher BA and AUC values
were also detected, with BRF returning the best performance (BA =
0.73 and AUC = 0.78). As mentioned in the introduction, building models
of PLD-inducing potential has, as a primary aim, that of directing
the experimental efforts toward safe (P−) molecules. Building
on that, the prediction of dangerous substances as safe should be
avoided. In light of that, we also focused our attention on the computed
−LR values. Notice that this quality metric is independent
of the TS data distribution and is able to provide an estimation of
the decrease in the probability of a compound being a P– with
respect to the initial condition (before querying the relative classifier).
Again, BRF (−LR = 0.37) returned the best performance, followed
by uGB (0.39), uXGB (0.44), and uKNN (0.48), while significantly worse
values were returned by RF (0.84), KNN (0.70), GB (0.80), and XGB
(0.63). In summary, the performed 5-CV provided clear evidence that
resembling approaches are required to reach satisfactory performances.</p>
      <table-wrap id="tbl3" position="float">
        <label>Table 3</label>
        <caption>
          <title>Performances in 5-CV Returned by All
of the Developed Classifiers<xref rid="t3fn1" ref-type="table-fn">a</xref></title>
        </caption>
        <table frame="hsides" rules="groups" border="0">
          <colgroup>
            <col align="left"/>
            <col align="char" char="."/>
            <col align="char" char="."/>
            <col align="char" char="."/>
            <col align="char" char="."/>
            <col align="char" char="."/>
            <col align="char" char="."/>
            <col align="char" char="."/>
            <col align="char" char="."/>
            <col align="char" char="."/>
            <col align="char" char="."/>
            <col align="char" char="."/>
          </colgroup>
          <thead>
            <tr>
              <th style="border:none;" align="center"> </th>
              <th style="border:none;" align="center" char=".">SE</th>
              <th style="border:none;" align="center" char=".">SP</th>
              <th style="border:none;" align="center" char=".">BA</th>
              <th style="border:none;" align="center" char=".">AUC</th>
              <th style="border:none;" align="center" char=".">–LR</th>
              <th style="border:none;" align="center" char=".">+LR</th>
              <th style="border:none;" align="center" char=".">MCC</th>
              <th style="border:none;" align="center" char=".">TP</th>
              <th style="border:none;" align="center" char=".">FP</th>
              <th style="border:none;" align="center" char=".">TN</th>
              <th style="border:none;" align="center" char=".">FN</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td style="border:none;" align="left">RF</td>
              <td style="border:none;" align="char" char=".">0.19</td>
              <td style="border:none;" align="char" char=".">0.97</td>
              <td style="border:none;" align="char" char=".">0.58</td>
              <td style="border:none;" align="char" char=".">0.77</td>
              <td style="border:none;" align="char" char=".">0.84</td>
              <td style="border:none;" align="char" char=".">6.58</td>
              <td style="border:none;" align="char" char=".">0.26</td>
              <td style="border:none;" align="char" char=".">15</td>
              <td style="border:none;" align="char" char=".">10</td>
              <td style="border:none;" align="char" char=".">341</td>
              <td style="border:none;" align="char" char=".">65</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">KNN</td>
              <td style="border:none;" align="char" char=".">0.31</td>
              <td style="border:none;" align="char" char=".">0.95</td>
              <td style="border:none;" align="char" char=".">0.63</td>
              <td style="border:none;" align="char" char=".">0.70</td>
              <td style="border:none;" align="char" char=".">0.72</td>
              <td style="border:none;" align="char" char=".">6.86</td>
              <td style="border:none;" align="char" char=".">0.35</td>
              <td style="border:none;" align="char" char=".">25</td>
              <td style="border:none;" align="char" char=".">16</td>
              <td style="border:none;" align="char" char=".">335</td>
              <td style="border:none;" align="char" char=".">55</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">GB</td>
              <td style="border:none;" align="char" char=".">0.23</td>
              <td style="border:none;" align="char" char=".">0.97</td>
              <td style="border:none;" align="char" char=".">0.60</td>
              <td style="border:none;" align="char" char=".">0.75</td>
              <td style="border:none;" align="char" char=".">0.80</td>
              <td style="border:none;" align="char" char=".">6.58</td>
              <td style="border:none;" align="char" char=".">0.30</td>
              <td style="border:none;" align="char" char=".">18</td>
              <td style="border:none;" align="char" char=".">12</td>
              <td style="border:none;" align="char" char=".">339</td>
              <td style="border:none;" align="char" char=".">62</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">XGB</td>
              <td style="border:none;" align="char" char=".">0.40</td>
              <td style="border:none;" align="char" char=".">0.95</td>
              <td style="border:none;" align="char" char=".">0.68</td>
              <td style="border:none;" align="char" char=".">0.78</td>
              <td style="border:none;" align="char" char=".">0.63</td>
              <td style="border:none;" align="char" char=".">8.26</td>
              <td style="border:none;" align="char" char=".">0.43</td>
              <td style="border:none;" align="char" char=".">32</td>
              <td style="border:none;" align="char" char=".">17</td>
              <td style="border:none;" align="char" char=".">334</td>
              <td style="border:none;" align="char" char=".">48</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">BRF</td>
              <td style="border:none;" align="char" char=".">0.73</td>
              <td style="border:none;" align="char" char=".">0.74</td>
              <td style="border:none;" align="char" char=".">0.73</td>
              <td style="border:none;" align="char" char=".">0.78</td>
              <td style="border:none;" align="char" char=".">0.37</td>
              <td style="border:none;" align="char" char=".">2.77</td>
              <td style="border:none;" align="char" char=".">0.38</td>
              <td style="border:none;" align="char" char=".">58</td>
              <td style="border:none;" align="char" char=".">92</td>
              <td style="border:none;" align="char" char=".">259</td>
              <td style="border:none;" align="char" char=".">22</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">uKNN</td>
              <td style="border:none;" align="char" char=".">0.65</td>
              <td style="border:none;" align="char" char=".">0.73</td>
              <td style="border:none;" align="char" char=".">0.69</td>
              <td style="border:none;" align="char" char=".">0.72</td>
              <td style="border:none;" align="char" char=".">0.48</td>
              <td style="border:none;" align="char" char=".">2.41</td>
              <td style="border:none;" align="char" char=".">0.31</td>
              <td style="border:none;" align="char" char=".">52</td>
              <td style="border:none;" align="char" char=".">96</td>
              <td style="border:none;" align="char" char=".">255</td>
              <td style="border:none;" align="char" char=".">28</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">uGB</td>
              <td style="border:none;" align="char" char=".">0.73</td>
              <td style="border:none;" align="char" char=".">0.70</td>
              <td style="border:none;" align="char" char=".">0.71</td>
              <td style="border:none;" align="char" char=".">0.73</td>
              <td style="border:none;" align="char" char=".">0.39</td>
              <td style="border:none;" align="char" char=".">2.43</td>
              <td style="border:none;" align="char" char=".">0.34</td>
              <td style="border:none;" align="char" char=".">58</td>
              <td style="border:none;" align="char" char=".">105</td>
              <td style="border:none;" align="char" char=".">246</td>
              <td style="border:none;" align="char" char=".">22</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">uXGB</td>
              <td style="border:none;" align="char" char=".">0.68</td>
              <td style="border:none;" align="char" char=".">0.72</td>
              <td style="border:none;" align="char" char=".">0.70</td>
              <td style="border:none;" align="char" char=".">0.72</td>
              <td style="border:none;" align="char" char=".">0.44</td>
              <td style="border:none;" align="char" char=".">2.43</td>
              <td style="border:none;" align="char" char=".">0.32</td>
              <td style="border:none;" align="char" char=".">54</td>
              <td style="border:none;" align="char" char=".">98</td>
              <td style="border:none;" align="char" char=".">253</td>
              <td style="border:none;" align="char" char=".">26</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="t3fn1">
            <label>a</label>
            <p>For each model, the following statistics
are reported: sensitivity (SE), specificity (SP), balanced accuracy
(BA), area under the ROC (AUC), negative likelihood ratio (−LR),
positive likelihood ratio (+LR), Matthews correlation coefficient
(MCC), number of true positives (TPs), false positives (FPs), true
negatives (TNs), and false negatives (FNs).</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
    </sec>
    <sec id="sec4.2">
      <title>Validation</title>
      <p>Aimed at selecting the top-performing classifier,
the models built using BRF, uGB, uXGB, and uKNN were subjected to
a validation using the VS previously extracted from PLD-DB and comprising <bold>112</bold> compounds. Notice that to judiciously evaluate the predictiveness
of the model in real-life scenarios, VS was deliberately left imbalanced,
and the performances were computed considering only those compounds
within the AD. As evident in <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>A, the good performance observed in 5-CV is herein
confirmed for all the models, as indicated by the computed BA values
≈ 0.80, AUC &gt; 0.85, and very low −LR (ranging from
0.07
to 0.18). Importantly, acceptable differences were observed between
SE and SP, ranging from 0.20 to 0.32. <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>B displays a radar plot constructed with
the aim of selecting the top-performing classifier. Taking as a whole,
the obtained data put forward BRF, whose ROC curve is displayed in <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>C, as the model to
be selected, being able to provide the best AUC (0.90), BA (0.81),
and MCC (0.50) values. It is important to emphasize that we conducted
an additional analysis to assess the stability of the built models.
This analysis involved creating an additional set of 100 classifiers
by using different, randomly selected training sets (TS) and validation
sets (VS) while adhering to the data splitting methodology outlined
in the <xref rid="sec2" ref-type="other">Materials and Methods Section</xref>. For
each of these models, we calculated key metrics, including BA, SE,
and SP, and then examined their relative standard deviations to gauge
the stability of the classifiers. The obtained results unequivocally
demonstrate that all of the classifiers exhibit robustness and independence
from the TS and VS composition (standard deviations ≤ 0.07).
To further challenge the BRF model, an additional validation with
two different external sets (ES1 and ES2) was performed. As reported
in <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>A, an acceptable
balance between SE and SP was observed as well as high values of BA
(0.72 and 0.90 for ES1 and ES2, respectively) and AUC (0.75 and 0.94,
respectively). This is also supported by the relative ROC curves displayed
in <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>B,C.</p>
      <fig id="fig2" position="float">
        <label>Figure 2</label>
        <caption>
          <p>Selection of
the top-performing model was based on the performance
obtained in validation. (A) Table reporting the quality metrics returned
by all the developed models: sensitivity (SE), specificity (SP), balanced
accuracy (BA), area under the ROC (AUC), negative likelihood ratio
(−LR), positive likelihood ratio (+LR), Matthews correlation
coefficient (MCC), number of true positives (TPs), false positives
(FPs), true negatives (TNs), and false negatives (FNs); (B) radar
plot comparing the performance of the models; and (C) ROC curve derived
from the probability-based ranking returned by the selected classifier
(BRF).</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mp3c00964_0002" id="gr2" position="float"/>
      </fig>
      <fig id="fig3" position="float">
        <label>Figure 3</label>
        <caption>
          <p>Performance of the selected BRF model on external sets
ES1 and
ES2. (A) Table reporting the computed sensitivity (SE), specificity
(SP), balanced accuracy (BA), area under the ROC (AUC), negative likelihood
ratio (−LR), positive likelihood ratio (+LR), Matthews correlation
coefficient (MCC), number of true positives (TPs), false positives
(FPs), true negatives (TNs), and false negatives (FNs); (B, C) ROC
curve derived from the probability-based ranking returned by BRF on
ES1 and ES2, respectively.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mp3c00964_0003" id="gr3" position="float"/>
      </fig>
    </sec>
  </sec>
  <sec id="sec5">
    <title>AMALPHI: A Freely Accessible Web Platform</title>
    <p>We made available
the top-performing classifier, built using the
BRF algorithm, in a freely accessible web platform called AMALPHI
(A machine learning platform for predicting drug-induced phospholipidosis—<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ba.ic.cnr.it/softwareic/amalphiportal/">https://www.ba.ic.cnr.it/softwareic/amalphiportal/</uri>). Following an approach already employed for other web platforms
developed by our group,<sup><xref ref-type="bibr" rid="ref31">31</xref>,<xref ref-type="bibr" rid="ref32">32</xref></sup> the user can draw a
2D structure of her/his query molecule using the JSME canvas applet<sup><xref ref-type="bibr" rid="ref49">49</xref></sup> or, alternatively, insert the relative SMILES
string directly into the provided text field. Additionally, to facilitate
the use of the platform for virtual screening applications, the user
can upload a .txt file containing a list of SMILES strings. This can
be achieved by clicking on the “MASSIVE” button. Once
the file is uploaded or the query molecule is drawn, AMALPHI generates
predictions regarding the PLD inducer potential of each compound used
as input. The results are displayed as “YES” if the
BRF model predicts the query to be a PLD inducer and conversely as
“NO” if it is not. Notably, information on the reliability
of the performed predictions is also provided, based on the considered
AD. Finally, the user can download the produced output as .csv file.
It is worth noting that a link to download the predictions is sent
to the user’s registered email address. Additionally, the “History”
page maintains a record of all user executions, preserving input SMILES
files and their corresponding output. <xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref> shows an example of an output page generated
by the tool.</p>
    <fig id="fig4" position="float">
      <label>Figure 4</label>
      <caption>
        <p>Example of the output page returned by the AMALPHI web
platform.</p>
      </caption>
      <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mp3c00964_0004" id="gr4" position="float"/>
    </fig>
  </sec>
  <sec id="sec6">
    <title>Conclusions</title>
    <p>In an era where accurate prediction of
pharmacological and toxicological
properties of organic molecules is becoming fundamental to significantly
expedite the drug discovery process in both academia and industry,
expensive and time-consuming traditional approaches are increasingly
giving way to the use of computational technologies. In this regard,
this study focuses on the development of multiple machine learning
models capable of predicting the PLD-inducing potential, employing
different ML algorithms (RF, KNN, GB, and XGB). Following data extraction
from ChEMBL v30 and subsequent analysis of experimental phospholipidosis
data concerning <bold>851</bold> compounds, we applied rigorous data
curation practices to create PLD-DB comprising <bold>545</bold> compounds
and used them to build different PLD-inducing potential classifiers.
The analysis of the obtained validation performances in validation
yields similar values for all of the models trained using techniques
that consider data imbalance (BRF, uKNN, uGB, and uXGB), among which
the top-performing one was BRF, capable of providing the best AUC
(0.90), BA (0.81), and MCC (0.50). Furthermore, external validation
using two different external sets (ES1 and ES2) returned high values
of BA (0.72 and 0.9, respectively) and AUC (0.75 and 0.94, respectively).
Collectively, these promising results led us to make the top-performing
classifier available through a user-friendly web platform developed
by our group and named AMALPHI (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ba.ic.cnr.it/softwareic/amalphiportal/">https://www.ba.ic.cnr.it/softwareic/amalphiportal/</uri>). AMALPHI is the first freely accessible tool capable of efficiently
predicting the PLD potential of drug candidates. It can assist medicinal
chemists in proactively identifying safe drug candidates during the
research and development of pharmacologically active molecules and
in prioritizing drugs with a low probability of exhibiting false in
vitro antiviral activity.</p>
  </sec>
</body>
<back>
  <notes id="notes-1" notes-type="si">
    <title>Supporting Information Available</title>
    <p>The Supporting Information
is available free of charge at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/10.1021/acs.molpharmaceut.3c00964?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.molpharmaceut.3c00964</ext-link>.<list id="silist" list-type="simple"><list-item><p>PLDBD excel file containing the <bold>545</bold> SMILES
strings of the chemicals belonging to the PLDBD data set and the corresponding
experimental values (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.molpharmaceut.3c00964/suppl_file/mp3c00964_si_001.xlsx">XLSX</ext-link>)</p></list-item><list-item><p>ES1 file containing the 117 SMILES strings of the chemicals
belonging to the ES1 data set and the corresponding experimental values
(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.molpharmaceut.3c00964/suppl_file/mp3c00964_si_002.xlsx">XLSX</ext-link>)</p></list-item><list-item><p>ES2
excel file containing the 20 SMILES strings of the
chemicals belonging to the ES2 data set and the corresponding experimental
values (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.molpharmaceut.3c00964/suppl_file/mp3c00964_si_003.xlsx">XLSX</ext-link>)</p></list-item></list></p>
  </notes>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material content-type="local-data" id="sifile1">
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mp3c00964_si_001.xlsx">
        <caption>
          <p>mp3c00964_si_001.xlsx</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="sifile2">
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mp3c00964_si_002.xlsx">
        <caption>
          <p>mp3c00964_si_002.xlsx</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="sifile3">
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mp3c00964_si_003.xlsx">
        <caption>
          <p>mp3c00964_si_003.xlsx</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
  <notes notes-type="COI-statement" id="notes-2">
    <p>The authors
declare no competing financial interest.</p>
  </notes>
  <ack>
    <title>Acknowledgments</title>
    <p>This work was funded by the National Research Council (CNR–Italy)
under the program “PROGETTI DI RICERCA @CNR” (acronym
DATIAMO) and by the European Union (Next Generation EU) under the
program PRIN of the Ministero Dell'Università e della
Ricerca
(Progetti di ricerca di Rilevante Interesse Nazionale 2022–2022Z3BBPE—Development
of broad-spectrum coronavirus antiviral agents acting as allosteric
modulators of the host protein sigma-1). The salary of Dr. Maria Cristina
Lomuscio was funded by REGIONE PUGLIA under the program RIPARTI (assegni
di RIcerca in PARTenariato con le Imprese). The authors thank Dr.
Ivan Mercurio for providing graphical support in creating the AMALPHI
logo and Biofordrug srl (via Dante 95/99, 70019, Triggiano, Bari)
for scientific and technological support.</p>
  </ack>
  <ref-list>
    <title>References</title>
    <ref id="ref1">
      <mixed-citation publication-type="journal" id="cit1"><name><surname>Lüllmann</surname><given-names>H.</given-names></name>; <name><surname>Lüllmann-Rauch</surname><given-names>R.</given-names></name>; <name><surname>Wassermann</surname><given-names>O.</given-names></name><article-title>Drug-Induced
Phospholipidoses. II. Tissue Distribution of the Amphiphilic Drug
Chlorphentermine</article-title>. <source>CRC Crit. Rev. Toxicol.</source><year>1975</year>, <volume>4</volume> (<issue>2</issue>), <fpage>185</fpage>–<lpage>218</lpage>. <pub-id pub-id-type="doi">10.1080/10408447509164014</pub-id>.<pub-id pub-id-type="pmid">2448</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref2">
      <mixed-citation publication-type="journal" id="cit2"><name><surname>Kubo</surname><given-names>M.</given-names></name>; <name><surname>Hostetler</surname><given-names>K. Y.</given-names></name><article-title>Mechanism
of Cationic Amphiphilic Drug Inhibition of
Purified Lysosomal Phospholipase A1</article-title>. <source>Biochemistry</source><year>1985</year>, <volume>24</volume> (<issue>23</issue>), <fpage>6515</fpage>–<lpage>6520</lpage>. <pub-id pub-id-type="doi">10.1021/bi00344a031</pub-id>.<pub-id pub-id-type="pmid">4084534</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref3">
      <mixed-citation publication-type="journal" id="cit3"><name><surname>Lüllmann</surname><given-names>H.</given-names></name>; <name><surname>Lüllmann-Rauch</surname><given-names>R.</given-names></name>; <name><surname>Wassermann</surname><given-names>O.</given-names></name><article-title>Lipidosis
Induced by Amphiphilic Cationic Drugs</article-title>. <source>Biochem.
Pharmacol.</source><year>1978</year>, <volume>27</volume> (<issue>8</issue>), <fpage>1103</fpage>–<lpage>1108</lpage>. <pub-id pub-id-type="doi">10.1016/0006-2952(78)90435-5</pub-id>.<pub-id pub-id-type="pmid">358990</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref4">
      <mixed-citation publication-type="journal" id="cit4"><name><surname>Pappu</surname><given-names>A.</given-names></name>; <name><surname>Hostetler</surname><given-names>K. Y.</given-names></name><article-title>Effect of Cationic Amphiphilic Drugs
on the Hydrolysis
of Acidic and Neutral Phospholipids by Liver Lysosomal Phospholipase
A</article-title>. <source>Biochem. Pharmacol.</source><year>1984</year>, <volume>33</volume> (<issue>10</issue>), <fpage>1639</fpage>–<lpage>1644</lpage>. <pub-id pub-id-type="doi">10.1016/0006-2952(84)90286-7</pub-id>.<pub-id pub-id-type="pmid">6732837</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref5">
      <mixed-citation publication-type="journal" id="cit5"><name><surname>Lowe</surname><given-names>R.</given-names></name>; <name><surname>Mussa</surname><given-names>H. Y.</given-names></name>; <name><surname>Nigsch</surname><given-names>F.</given-names></name>; <name><surname>Glen</surname><given-names>R. C.</given-names></name>; <name><surname>Mitchell</surname><given-names>J. B.</given-names></name><article-title>Predicting
the Mechanism of Phospholipidosis</article-title>. <source>J. Cheminf.</source><year>2012</year>, <volume>4</volume> (<issue>1</issue>), <fpage>2</fpage><pub-id pub-id-type="doi">10.1186/1758-2946-4-2</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref6">
      <mixed-citation publication-type="journal" id="cit6"><name><surname>Breiden</surname><given-names>B.</given-names></name>; <name><surname>Sandhoff</surname><given-names>K.</given-names></name><article-title>Emerging Mechanisms
of Drug-Induced Phospholipidosis</article-title>. <source>Biol. Chem.</source><year>2019</year>, <volume>401</volume> (<issue>1</issue>), <fpage>31</fpage>–<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1515/hsz-2019-0270</pub-id>.<pub-id pub-id-type="pmid">31408430</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref7">
      <mixed-citation publication-type="journal" id="cit7"><name><surname>Kruhlak</surname><given-names>N. L.</given-names></name>; <name><surname>Choi</surname><given-names>S. S.</given-names></name>; <name><surname>Contrera</surname><given-names>J. F.</given-names></name>; <name><surname>Weaver</surname><given-names>J. L.</given-names></name>; <name><surname>Willard</surname><given-names>J. M.</given-names></name>; <name><surname>Hastings</surname><given-names>K. L.</given-names></name>; <name><surname>Sancilio</surname><given-names>L. F.</given-names></name><article-title>Development of a Phospholipidosis
Database and Predictive Quantitative Structure-Activity Relationship
(QSAR) Models</article-title>. <source>Toxicol. Mech. Methods</source><year>2008</year>, <volume>18</volume> (<issue>2–3</issue>), <fpage>217</fpage>–<lpage>227</lpage>. <pub-id pub-id-type="doi">10.1080/15376510701857262</pub-id>.<pub-id pub-id-type="pmid">20020916</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref8">
      <mixed-citation publication-type="journal" id="cit8"><name><surname>Ettlin</surname><given-names>R. A.</given-names></name>; <name><surname>Kuroda</surname><given-names>J.</given-names></name>; <name><surname>Plassmann</surname><given-names>S.</given-names></name>; <name><surname>Hayashi</surname><given-names>M.</given-names></name>; <name><surname>Prentice</surname><given-names>D. E.</given-names></name><article-title>Successful
Drug Development Despite Adverse Preclinical Findings Part 2: Examples</article-title>. <source>J. Toxicol. Pathol.</source><year>2010</year>, <volume>23</volume> (<issue>4</issue>), <fpage>213</fpage>–<lpage>234</lpage>. <pub-id pub-id-type="doi">10.1293/tox.23.213</pub-id>.<pub-id pub-id-type="pmid">22272032</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref9">
      <mixed-citation publication-type="journal" id="cit9"><name><surname>Gunesch</surname><given-names>A. P.</given-names></name>; <name><surname>Zapatero-Belinchón</surname><given-names>F. J.</given-names></name>; <name><surname>Pinkert</surname><given-names>L.</given-names></name>; <name><surname>Steinmann</surname><given-names>E.</given-names></name>; <name><surname>Manns</surname><given-names>M. P.</given-names></name>; <name><surname>Schneider</surname><given-names>G.</given-names></name>; <name><surname>Pietschmann</surname><given-names>T.</given-names></name>; <name><surname>Brönstrup</surname><given-names>M.</given-names></name>; <name><surname>von Hahn</surname><given-names>T.</given-names></name><article-title>Filovirus Antiviral
Activity of Cationic
Amphiphilic Drugs Is Associated with Lipophilicity and Ability To
Induce Phospholipidosis</article-title>. <source>Antimicrob. Agents
Chemother.</source><year>2020</year>, <volume>64</volume> (<issue>8</issue>), <fpage>10</fpage>–<lpage>1128</lpage>. <pub-id pub-id-type="doi">10.1128/aac.00143-20</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref10">
      <mixed-citation publication-type="journal" id="cit10"><name><surname>Tummino</surname><given-names>T. A.</given-names></name>; <name><surname>Rezelj</surname><given-names>V. V.</given-names></name>; <name><surname>Fischer</surname><given-names>B.</given-names></name>; <name><surname>Fischer</surname><given-names>A.</given-names></name>; <name><surname>O’Meara</surname><given-names>M. J.</given-names></name>; <name><surname>Monel</surname><given-names>B.</given-names></name>; <name><surname>Vallet</surname><given-names>T.</given-names></name>; <name><surname>White</surname><given-names>K. M.</given-names></name>; <name><surname>Zhang</surname><given-names>Z.</given-names></name>; <name><surname>Alon</surname><given-names>A.</given-names></name>; <name><surname>Schadt</surname><given-names>H.</given-names></name>; <name><surname>O’Donnell</surname><given-names>H. R.</given-names></name>; <name><surname>Lyu</surname><given-names>J.</given-names></name>; <name><surname>Rosales</surname><given-names>R.</given-names></name>; <name><surname>McGovern</surname><given-names>B. L.</given-names></name>; <name><surname>Rathnasinghe</surname><given-names>R.</given-names></name>; <name><surname>Jangra</surname><given-names>S.</given-names></name>; <name><surname>Schotsaert</surname><given-names>M.</given-names></name>; <name><surname>Galarneau</surname><given-names>J.-R.</given-names></name>; <name><surname>Krogan</surname><given-names>N. J.</given-names></name>; <name><surname>Urban</surname><given-names>L.</given-names></name>; <name><surname>Shokat</surname><given-names>K. M.</given-names></name>; <name><surname>Kruse</surname><given-names>A. C.</given-names></name>; <name><surname>García-Sastre</surname><given-names>A.</given-names></name>; <name><surname>Schwartz</surname><given-names>O.</given-names></name>; <name><surname>Moretti</surname><given-names>F.</given-names></name>; <name><surname>Vignuzzi</surname><given-names>M.</given-names></name>; <name><surname>Pognan</surname><given-names>F.</given-names></name>; <name><surname>Shoichet</surname><given-names>B. K.</given-names></name><article-title>Drug-Induced
Phospholipidosis Confounds
Drug Repurposing for SARS-CoV-2</article-title>. <source>Science</source><year>2021</year>, <volume>373</volume> (<issue>6554</issue>), <fpage>541</fpage>–<lpage>547</lpage>. <pub-id pub-id-type="doi">10.1126/science.abi4708</pub-id>.<pub-id pub-id-type="pmid">34326236</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref11">
      <mixed-citation publication-type="journal" id="cit11"><name><surname>Gordon</surname><given-names>D. E.</given-names></name>; <name><surname>Jang</surname><given-names>G. M.</given-names></name>; <name><surname>Bouhaddou</surname><given-names>M.</given-names></name>; <name><surname>Xu</surname><given-names>J.</given-names></name>; <name><surname>Obernier</surname><given-names>K.</given-names></name>; <name><surname>White</surname><given-names>K. M.</given-names></name>; <name><surname>O’Meara</surname><given-names>M. J.</given-names></name>; <name><surname>Rezelj</surname><given-names>V. V.</given-names></name>; <name><surname>Guo</surname><given-names>J. Z.</given-names></name>; <name><surname>Swaney</surname><given-names>D. L.</given-names></name>; <name><surname>Tummino</surname><given-names>T. A.</given-names></name>; <name><surname>Hüttenhain</surname><given-names>R.</given-names></name>; <name><surname>Kaake</surname><given-names>R. M.</given-names></name>; <name><surname>Richards</surname><given-names>A. L.</given-names></name>; <name><surname>Tutuncuoglu</surname><given-names>B.</given-names></name>; <name><surname>Foussard</surname><given-names>H.</given-names></name>; <name><surname>Batra</surname><given-names>J.</given-names></name>; <name><surname>Haas</surname><given-names>K.</given-names></name>; <name><surname>Modak</surname><given-names>M.</given-names></name>; <name><surname>Kim</surname><given-names>M.</given-names></name>; <name><surname>Haas</surname><given-names>P.</given-names></name>; <name><surname>Polacco</surname><given-names>B. J.</given-names></name>; <name><surname>Braberg</surname><given-names>H.</given-names></name>; <name><surname>Fabius</surname><given-names>J. M.</given-names></name>; <name><surname>Eckhardt</surname><given-names>M.</given-names></name>; <name><surname>Soucheray</surname><given-names>M.</given-names></name>; <name><surname>Bennett</surname><given-names>M. J.</given-names></name>; <name><surname>Cakir</surname><given-names>M.</given-names></name>; <name><surname>McGregor</surname><given-names>M. J.</given-names></name>; <name><surname>Li</surname><given-names>Q.</given-names></name>; <name><surname>Meyer</surname><given-names>B.</given-names></name>; <name><surname>Roesch</surname><given-names>F.</given-names></name>; <name><surname>Vallet</surname><given-names>T.</given-names></name>; <name><surname>Mac Kain</surname><given-names>A.</given-names></name>; <name><surname>Miorin</surname><given-names>L.</given-names></name>; <name><surname>Moreno</surname><given-names>E.</given-names></name>; <name><surname>Naing</surname><given-names>Z. Z. C.</given-names></name>; <name><surname>Zhou</surname><given-names>Y.</given-names></name>; <name><surname>Peng</surname><given-names>S.</given-names></name>; <name><surname>Shi</surname><given-names>Y.</given-names></name>; <name><surname>Zhang</surname><given-names>Z.</given-names></name>; <name><surname>Shen</surname><given-names>W.</given-names></name>; <name><surname>Kirby</surname><given-names>I. T.</given-names></name>; <name><surname>Melnyk</surname><given-names>J. E.</given-names></name>; <name><surname>Chorba</surname><given-names>J. S.</given-names></name>; <name><surname>Lou</surname><given-names>K.</given-names></name>; <name><surname>Dai</surname><given-names>S. A.</given-names></name>; <name><surname>Barrio-Hernandez</surname><given-names>I.</given-names></name>; <name><surname>Memon</surname><given-names>D.</given-names></name>; <name><surname>Hernandez-Armenta</surname><given-names>C.</given-names></name>; <name><surname>Lyu</surname><given-names>J.</given-names></name>; <name><surname>Mathy</surname><given-names>C. J. P.</given-names></name>; <name><surname>Perica</surname><given-names>T.</given-names></name>; <name><surname>Pilla</surname><given-names>K. B.</given-names></name>; <name><surname>Ganesan</surname><given-names>S. J.</given-names></name>; <name><surname>Saltzberg</surname><given-names>D. J.</given-names></name>; <name><surname>Rakesh</surname><given-names>R.</given-names></name>; <name><surname>Liu</surname><given-names>X.</given-names></name>; <name><surname>Rosenthal</surname><given-names>S. B.</given-names></name>; <name><surname>Calviello</surname><given-names>L.</given-names></name>; <name><surname>Venkataramanan</surname><given-names>S.</given-names></name>; <name><surname>Liboy-Lugo</surname><given-names>J.</given-names></name>; <name><surname>Lin</surname><given-names>Y.</given-names></name>; <name><surname>Huang</surname><given-names>X.-P.</given-names></name>; <name><surname>Liu</surname><given-names>Y.</given-names></name>; <name><surname>Wankowicz</surname><given-names>S. A.</given-names></name>; <name><surname>Bohn</surname><given-names>M.</given-names></name>; <name><surname>Safari</surname><given-names>M.</given-names></name>; <name><surname>Ugur</surname><given-names>F. S.</given-names></name>; <name><surname>Koh</surname><given-names>C.</given-names></name>; <name><surname>Savar</surname><given-names>N. S.</given-names></name>; <name><surname>Tran</surname><given-names>Q. D.</given-names></name>; <name><surname>Shengjuler</surname><given-names>D.</given-names></name>; <name><surname>Fletcher</surname><given-names>S. J.</given-names></name>; <name><surname>O’Neal</surname><given-names>M. C.</given-names></name>; <name><surname>Cai</surname><given-names>Y.</given-names></name>; <name><surname>Chang</surname><given-names>J. C. J.</given-names></name>; <name><surname>Broadhurst</surname><given-names>D. J.</given-names></name>; <name><surname>Klippsten</surname><given-names>S.</given-names></name>; <name><surname>Sharp</surname><given-names>P. P.</given-names></name>; <name><surname>Wenzell</surname><given-names>N. A.</given-names></name>; <name><surname>Kuzuoglu-Ozturk</surname><given-names>D.</given-names></name>; <name><surname>Wang</surname><given-names>H.-Y.</given-names></name>; <name><surname>Trenker</surname><given-names>R.</given-names></name>; <name><surname>Young</surname><given-names>J. M.</given-names></name>; <name><surname>Cavero</surname><given-names>D. A.</given-names></name>; <name><surname>Hiatt</surname><given-names>J.</given-names></name>; <name><surname>Roth</surname><given-names>T. L.</given-names></name>; <name><surname>Rathore</surname><given-names>U.</given-names></name>; <name><surname>Subramanian</surname><given-names>A.</given-names></name>; <name><surname>Noack</surname><given-names>J.</given-names></name>; <name><surname>Hubert</surname><given-names>M.</given-names></name>; <name><surname>Stroud</surname><given-names>R. M.</given-names></name>; <name><surname>Frankel</surname><given-names>A. D.</given-names></name>; <name><surname>Rosenberg</surname><given-names>O. S.</given-names></name>; <name><surname>Verba</surname><given-names>K. A.</given-names></name>; <name><surname>Agard</surname><given-names>D. A.</given-names></name>; <name><surname>Ott</surname><given-names>M.</given-names></name>; <name><surname>Emerman</surname><given-names>M.</given-names></name>; <name><surname>Jura</surname><given-names>N.</given-names></name>; <name><surname>von Zastrow</surname><given-names>M.</given-names></name>; <name><surname>Verdin</surname><given-names>E.</given-names></name>; <name><surname>Ashworth</surname><given-names>A.</given-names></name>; <name><surname>Schwartz</surname><given-names>O.</given-names></name>; <name><surname>d’Enfert</surname><given-names>C.</given-names></name>; <name><surname>Mukherjee</surname><given-names>S.</given-names></name>; <name><surname>Jacobson</surname><given-names>M.</given-names></name>; <name><surname>Malik</surname><given-names>H. S.</given-names></name>; <name><surname>Fujimori</surname><given-names>D. G.</given-names></name>; <name><surname>Ideker</surname><given-names>T.</given-names></name>; <name><surname>Craik</surname><given-names>C. S.</given-names></name>; <name><surname>Floor</surname><given-names>S. N.</given-names></name>; <name><surname>Fraser</surname><given-names>J. S.</given-names></name>; <name><surname>Gross</surname><given-names>J. D.</given-names></name>; <name><surname>Sali</surname><given-names>A.</given-names></name>; <name><surname>Roth</surname><given-names>B. L.</given-names></name>; <name><surname>Ruggero</surname><given-names>D.</given-names></name>; <name><surname>Taunton</surname><given-names>J.</given-names></name>; <name><surname>Kortemme</surname><given-names>T.</given-names></name>; <name><surname>Beltrao</surname><given-names>P.</given-names></name>; <name><surname>Vignuzzi</surname><given-names>M.</given-names></name>; <name><surname>García-Sastre</surname><given-names>A.</given-names></name>; <name><surname>Shokat</surname><given-names>K. M.</given-names></name>; <name><surname>Shoichet</surname><given-names>B. K.</given-names></name>; <name><surname>Krogan</surname><given-names>N. J.</given-names></name><article-title>A SARS-CoV-2
Protein Interaction Map Reveals Targets for Drug Repurposing</article-title>. <source>Nature</source><year>2020</year>, <volume>583</volume> (<issue>7816</issue>), <fpage>459</fpage>–<lpage>468</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2286-9</pub-id>.<pub-id pub-id-type="pmid">32353859</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref12">
      <mixed-citation publication-type="journal" id="cit12"><name><surname>Abatematteo</surname><given-names>F. S.</given-names></name>; <name><surname>Delre</surname><given-names>P.</given-names></name>; <name><surname>Mercurio</surname><given-names>I.</given-names></name>; <name><surname>Rezelj</surname><given-names>V. V.</given-names></name>; <name><surname>Siliqi</surname><given-names>D.</given-names></name>; <name><surname>Beaucourt</surname><given-names>S.</given-names></name>; <name><surname>Lattanzi</surname><given-names>G.</given-names></name>; <name><surname>Colabufo</surname><given-names>N. A.</given-names></name>; <name><surname>Leopoldo</surname><given-names>M.</given-names></name>; <name><surname>Saviano</surname><given-names>M.</given-names></name>; <name><surname>Vignuzzi</surname><given-names>M.</given-names></name>; <name><surname>Mangiatordi</surname><given-names>G. F.</given-names></name>; <name><surname>Abate</surname><given-names>C.</given-names></name><article-title>A Conformational Rearrangement
of the SARS-CoV-2 Host Protein Sigma-1
Is Required for Antiviral Activity: Insights from a Combined in-Silico/in-Vitro
Approach</article-title>. <source>Sci. Rep.</source><year>2023</year>, <volume>13</volume> (<issue>1</issue>), <elocation-id>12798</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-023-39662-w</pub-id>.<pub-id pub-id-type="pmid">37550340</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref13">
      <mixed-citation publication-type="journal" id="cit13"><name><surname>Diesendorf</surname><given-names>V.</given-names></name>; <name><surname>Roll</surname><given-names>V.</given-names></name>; <name><surname>Geiger</surname><given-names>N.</given-names></name>; <name><surname>Fähr</surname><given-names>S.</given-names></name>; <name><surname>Obernolte</surname><given-names>H.</given-names></name>; <name><surname>Sewald</surname><given-names>K.</given-names></name>; <name><surname>Bodem</surname><given-names>J.</given-names></name><article-title>Drug-Induced Phospholipidosis
Is Not Correlated with the Inhibition of SARS-CoV-2 - Inhibition of
SARS-CoV-2 Is Cell Line-Specific</article-title>. <source>Front. Cell
Infect. Microbiol.</source><year>2023</year>, <volume>13</volume>, <elocation-id>1100028</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2023.1100028</pub-id>.<pub-id pub-id-type="pmid">37637460</pub-id></mixed-citation>
    </ref>
    <ref id="ref14">
      <mixed-citation publication-type="journal" id="cit14"><name><surname>Lane</surname><given-names>T. R.</given-names></name>; <name><surname>Ekins</surname><given-names>S.</given-names></name><article-title>Defending Antiviral Cationic Amphiphilic
Drugs That May Cause Drug-Induced
Phospholipidosis</article-title>. <source>J. Chem. Inf. Model.</source><year>2021</year>, <volume>61</volume> (<issue>9</issue>), <fpage>4125</fpage>–<lpage>4130</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.1c00903</pub-id>.<pub-id pub-id-type="pmid">34516123</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref15">
      <mixed-citation publication-type="journal" id="cit15"><name><surname>Atienzar</surname><given-names>F.</given-names></name>; <name><surname>Gerets</surname><given-names>H.</given-names></name>; <name><surname>Dufrane</surname><given-names>S.</given-names></name>; <name><surname>Tilmant</surname><given-names>K.</given-names></name>; <name><surname>Cornet</surname><given-names>M.</given-names></name>; <name><surname>Dhalluin</surname><given-names>S.</given-names></name>; <name><surname>Ruty</surname><given-names>B.</given-names></name>; <name><surname>Rose</surname><given-names>G.</given-names></name>; <name><surname>Canning</surname><given-names>M.</given-names></name><article-title>Determination
of Phospholipidosis Potential Based on Gene Expression Analysis in
HepG2 Cells</article-title>. <source>Toxicol. Sci.</source><year>2006</year>, <volume>96</volume> (<issue>1</issue>), <fpage>101</fpage>–<lpage>114</lpage>. <pub-id pub-id-type="doi">10.1093/toxsci/kfl184</pub-id>.<pub-id pub-id-type="pmid">17175557</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref16">
      <mixed-citation publication-type="journal" id="cit16"><name><surname>Ulrich</surname><given-names>R. G.</given-names></name>; <name><surname>Kilgore</surname><given-names>K. S.</given-names></name>; <name><surname>Sun</surname><given-names>E. L.</given-names></name>; <name><surname>Cramer</surname><given-names>C. T.</given-names></name>; <name><surname>Ginsberg</surname><given-names>L. C.</given-names></name><article-title>An in Vitro
Fluorescence Assay for the Detection of Drug-Induced Cytoplasmic Lamellar
Bodies</article-title>. <source>Toxicol. Methods</source><year>1991</year>, <volume>1</volume> (<issue>2</issue>), <fpage>89</fpage>–<lpage>105</lpage>. <pub-id pub-id-type="doi">10.3109/15376519109044560</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref17">
      <mixed-citation publication-type="journal" id="cit17"><name><surname>Gum</surname><given-names>R. J.</given-names></name>; <name><surname>Hickman</surname><given-names>D.</given-names></name>; <name><surname>Fagerland</surname><given-names>J. A.</given-names></name>; <name><surname>Heindel</surname><given-names>M. A.</given-names></name>; <name><surname>Gagne</surname><given-names>G. D.</given-names></name>; <name><surname>Schmidt</surname><given-names>J. M.</given-names></name>; <name><surname>Michaelides</surname><given-names>M. R.</given-names></name>; <name><surname>Davidsen</surname><given-names>S. K.</given-names></name>; <name><surname>Ulrich</surname><given-names>R. G.</given-names></name><article-title>Analysis
of Two Matrix Metalloproteinase Inhibitors and Their Metabolites for
Induction of Phospholipidosis in Rat and Human Hepatocytes(1)</article-title>. <source>Biochem. Pharmacol.</source><year>2001</year>, <volume>62</volume> (<issue>12</issue>), <fpage>1661</fpage>–<lpage>1673</lpage>. <pub-id pub-id-type="doi">10.1016/S0006-2952(01)00823-1</pub-id>.<pub-id pub-id-type="pmid">11755120</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref18">
      <mixed-citation publication-type="journal" id="cit18"><name><surname>Casartelli</surname><given-names>A.</given-names></name>; <name><surname>Bonato</surname><given-names>M.</given-names></name>; <name><surname>Cristofori</surname><given-names>P.</given-names></name>; <name><surname>Crivellente</surname><given-names>F.</given-names></name>; <name><surname>Dal Negro</surname><given-names>G.</given-names></name>; <name><surname>Masotto</surname><given-names>I.</given-names></name>; <name><surname>Mutinelli</surname><given-names>C.</given-names></name>; <name><surname>Valko</surname><given-names>K.</given-names></name>; <name><surname>Bonfante</surname><given-names>V.</given-names></name><article-title>A Cell-Based Approach for the Early
Assessment of the Phospholipidogenic Potential in Pharmaceutical Research
and Drug Development</article-title>. <source>Cell Biol. Toxicol.</source><year>2003</year>, <volume>19</volume> (<issue>3</issue>), <fpage>161</fpage>–<lpage>176</lpage>. <pub-id pub-id-type="doi">10.1023/A:1024778329320</pub-id>.<pub-id pub-id-type="pmid">12945744</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref19">
      <mixed-citation publication-type="journal" id="cit19"><name><surname>Kasahara</surname><given-names>T.</given-names></name>; <name><surname>Tomita</surname><given-names>K.</given-names></name>; <name><surname>Murano</surname><given-names>H.</given-names></name>; <name><surname>Harada</surname><given-names>T.</given-names></name>; <name><surname>Tsubakimoto</surname><given-names>K.</given-names></name>; <name><surname>Ogihara</surname><given-names>T.</given-names></name>; <name><surname>Ohnishi</surname><given-names>S.</given-names></name>; <name><surname>Kakinuma</surname><given-names>C.</given-names></name><article-title>Establishment of an
in Vitro High-Throughput Screening Assay for Detecting Phospholipidosis-Inducing
Potential</article-title>. <source>Toxicol. Sci.</source><year>2006</year>, <volume>90</volume> (<issue>1</issue>), <fpage>133</fpage>–<lpage>141</lpage>. <pub-id pub-id-type="doi">10.1093/toxsci/kfj067</pub-id>.<pub-id pub-id-type="pmid">16338956</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref20">
      <mixed-citation publication-type="journal" id="cit20"><name><surname>Morelli</surname><given-names>J. K.</given-names></name>; <name><surname>Buehrle</surname><given-names>M.</given-names></name>; <name><surname>Pognan</surname><given-names>F.</given-names></name>; <name><surname>Barone</surname><given-names>L. R.</given-names></name>; <name><surname>Fieles</surname><given-names>W.</given-names></name>; <name><surname>Ciaccio</surname><given-names>P. J.</given-names></name><article-title>Validation of an
in Vitro Screen for Phospholipidosis
Using a High-Content Biology Platform</article-title>. <source>Cell
Biol. Toxicol.</source><year>2006</year>, <volume>22</volume> (<issue>1</issue>), <fpage>15</fpage>–<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1007/s10565-006-0176-z</pub-id>.<pub-id pub-id-type="pmid">16463016</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref21">
      <mixed-citation publication-type="journal" id="cit21"><name><surname>Sawada</surname><given-names>H.</given-names></name>; <name><surname>Takami</surname><given-names>K.</given-names></name>; <name><surname>Asahi</surname><given-names>S.</given-names></name><article-title>A Toxicogenomic Approach
to Drug-Induced
Phospholipidosis: Analysis of Its Induction Mechanism and Establishment
of a Novel in Vitro Screening System</article-title>. <source>Toxicol.
Sci.</source><year>2004</year>, <volume>83</volume> (<issue>2</issue>), <fpage>282</fpage>–<lpage>292</lpage>. <pub-id pub-id-type="doi">10.1093/toxsci/kfh264</pub-id>.<pub-id pub-id-type="pmid">15342952</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref22">
      <mixed-citation publication-type="journal" id="cit22"><name><surname>Reasor</surname><given-names>M. J.</given-names></name>; <name><surname>Hastings</surname><given-names>K. L.</given-names></name>; <name><surname>Ulrich</surname><given-names>R. G.</given-names></name><article-title>Drug-Induced
Phospholipidosis: Issues
and Future Directions</article-title>. <source>Expert Opin. Drug Saf.</source><year>2006</year>, <volume>5</volume> (<issue>4</issue>), <fpage>567</fpage>–<lpage>583</lpage>. <pub-id pub-id-type="doi">10.1517/14740338.5.4.567</pub-id>.<pub-id pub-id-type="pmid">16774494</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref23">
      <mixed-citation publication-type="journal" id="cit23"><name><surname>Goracci</surname><given-names>L.</given-names></name>; <name><surname>Ceccarelli</surname><given-names>M.</given-names></name>; <name><surname>Bonelli</surname><given-names>D.</given-names></name>; <name><surname>Cruciani</surname><given-names>G.</given-names></name><article-title>Modeling Phospholipidosis
Induction: Reliability and Warnings</article-title>. <source>J. Chem.
Inf. Model.</source><year>2013</year>, <volume>53</volume> (<issue>6</issue>), <fpage>1436</fpage>–<lpage>1446</lpage>. <pub-id pub-id-type="doi">10.1021/ci400113t</pub-id>.<pub-id pub-id-type="pmid">23692521</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref24">
      <mixed-citation publication-type="journal" id="cit24"><name><surname>Macip</surname><given-names>G.</given-names></name>; <name><surname>Garcia-Segura</surname><given-names>P.</given-names></name>; <name><surname>Mestres-Truyol</surname><given-names>J.</given-names></name>; <name><surname>Saldivar-Espinoza</surname><given-names>B.</given-names></name>; <name><surname>Ojeda-Montes</surname><given-names>M. J.</given-names></name>; <name><surname>Gimeno</surname><given-names>A.</given-names></name>; <name><surname>Cereto-Massagué</surname><given-names>A.</given-names></name>; <name><surname>Garcia-Vallvé</surname><given-names>S.</given-names></name>; <name><surname>Pujadas</surname><given-names>G.</given-names></name><article-title>Haste Makes Waste: A Critical Review
of Docking-based Virtual Screening in Drug Repurposing for SARS-CoV-2
Main Protease (M-pro) Inhibition</article-title>. <source>Med. Res.
Rev.</source><year>2022</year>, <volume>42</volume> (<issue>2</issue>), <fpage>744</fpage>–<lpage>769</lpage>. <pub-id pub-id-type="doi">10.1002/med.21862</pub-id>.<pub-id pub-id-type="pmid">34697818</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref25">
      <mixed-citation publication-type="journal" id="cit25"><name><surname>Lowe</surname><given-names>R.</given-names></name>; <name><surname>Glen</surname><given-names>R. C.</given-names></name>; <name><surname>Mitchell</surname><given-names>J. B. O.</given-names></name><article-title>Predicting Phospholipidosis Using
Machine Learning</article-title>. <source>Mol. Pharm.</source><year>2010</year>, <volume>7</volume> (<issue>5</issue>), <fpage>1708</fpage>–<lpage>1714</lpage>. <pub-id pub-id-type="doi">10.1021/mp100103e</pub-id>.<pub-id pub-id-type="pmid">20799726</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref26">
      <mixed-citation publication-type="journal" id="cit26"><name><surname>Orogo</surname><given-names>A. M.</given-names></name>; <name><surname>Choi</surname><given-names>S. S.</given-names></name>; <name><surname>Minnier</surname><given-names>B. L.</given-names></name>; <name><surname>Kruhlak</surname><given-names>N. L.</given-names></name><article-title>Construction and
Consensus Performance of (Q)SAR Models for Predicting Phospholipidosis
Using a Dataset of 743 Compounds</article-title>. <source>Mol. Inf.</source><year>2012</year>, <volume>31</volume> (<issue>10</issue>), <fpage>725</fpage>–<lpage>739</lpage>. <pub-id pub-id-type="doi">10.1002/minf.201200048</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref27">
      <mixed-citation publication-type="journal" id="cit27"><name><surname>Fusani</surname><given-names>L.</given-names></name>; <name><surname>Brown</surname><given-names>M.</given-names></name>; <name><surname>Chen</surname><given-names>H.</given-names></name>; <name><surname>Ahlberg</surname><given-names>E.</given-names></name>; <name><surname>Noeske</surname><given-names>T.</given-names></name><article-title>Predicting
the Risk of Phospholipidosis with in Silico Models and an Image-Based
in Vitro Screen</article-title>. <source>Mol. Pharm.</source><year>2017</year>, <volume>14</volume> (<issue>12</issue>), <fpage>4346</fpage>–<lpage>4352</lpage>. <pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.7b00388</pub-id>.<pub-id pub-id-type="pmid">29077420</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref28">
      <mixed-citation publication-type="journal" id="cit28"><name><surname>Schieferdecker</surname><given-names>S.</given-names></name>; <name><surname>Eberlein</surname><given-names>A.</given-names></name>; <name><surname>Vock</surname><given-names>E.</given-names></name>; <name><surname>Beilmann</surname><given-names>M.</given-names></name><article-title>Development of an in
Silico Consensus Model for the Prediction of the Phospholipigenic
Potential of Small Molecules</article-title>. <source>Comput. Toxicol.</source><year>2022</year>, <volume>22</volume>, <elocation-id>100226</elocation-id><pub-id pub-id-type="doi">10.1016/j.comtox.2022.100226</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref29">
      <mixed-citation publication-type="journal" id="cit29"><name><surname>Przybylak</surname><given-names>K. R.</given-names></name>; <name><surname>Alzahrani</surname><given-names>A. R.</given-names></name>; <name><surname>Cronin</surname><given-names>M. T. D.</given-names></name><article-title>How Does the Quality of Phospholipidosis
Data Influence the Predictivity of Structural Alerts?</article-title>. <source>J. Chem. Inf. Model.</source><year>2014</year>, <volume>54</volume> (<issue>8</issue>), <fpage>2224</fpage>–<lpage>2232</lpage>. <pub-id pub-id-type="doi">10.1021/ci500233k</pub-id>.<pub-id pub-id-type="pmid">25062434</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref30">
      <mixed-citation publication-type="journal" id="cit30"><name><surname>Lagorce</surname><given-names>D.</given-names></name>; <name><surname>Bouslama</surname><given-names>L.</given-names></name>; <name><surname>Becot</surname><given-names>J.</given-names></name>; <name><surname>Miteva</surname><given-names>M. A.</given-names></name>; <name><surname>Villoutreix</surname><given-names>B. O.</given-names></name><article-title>FAF-Drugs4:
Free ADME-Tox Filtering Computations for Chemical Biology and Early
Stages Drug Discovery</article-title>. <source>Bioinformatics</source><year>2017</year>, <volume>33</volume> (<issue>22</issue>), <fpage>3658</fpage>–<lpage>3660</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/btx491</pub-id>.<pub-id pub-id-type="pmid">28961788</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref31">
      <mixed-citation publication-type="journal" id="cit31"><name><surname>Creanza</surname><given-names>T. M.</given-names></name>; <name><surname>Lamanna</surname><given-names>G.</given-names></name>; <name><surname>Delre</surname><given-names>P.</given-names></name>; <name><surname>Contino</surname><given-names>M.</given-names></name>; <name><surname>Corriero</surname><given-names>N.</given-names></name>; <name><surname>Saviano</surname><given-names>M.</given-names></name>; <name><surname>Mangiatordi</surname><given-names>G. F.</given-names></name>; <name><surname>Ancona</surname><given-names>N.</given-names></name><article-title>DeLA-Drug: A Deep Learning
Algorithm for Automated Design of Druglike Analogues</article-title>. <source>J. Chem. Inf. Model.</source><year>2022</year>, <volume>62</volume> (<issue>6</issue>), <fpage>1411</fpage>–<lpage>1424</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.2c00205</pub-id>.<pub-id pub-id-type="pmid">35294184</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref32">
      <mixed-citation publication-type="journal" id="cit32"><name><surname>Delre</surname><given-names>P.</given-names></name>; <name><surname>Contino</surname><given-names>M.</given-names></name>; <name><surname>Alberga</surname><given-names>D.</given-names></name>; <name><surname>Saviano</surname><given-names>M.</given-names></name>; <name><surname>Corriero</surname><given-names>N.</given-names></name>; <name><surname>Mangiatordi</surname><given-names>G. F.</given-names></name><article-title>ALPACA:
A Machine Learning Platform for Affinity and
Selectivity Profiling of CAnnabinoids Receptors Modulators</article-title>. <source>Comput. Biol. Med.</source><year>2023</year>, <volume>164</volume>, <elocation-id>107314</elocation-id><pub-id pub-id-type="doi">10.1016/j.compbiomed.2023.107314</pub-id>.<pub-id pub-id-type="pmid">37572442</pub-id></mixed-citation>
    </ref>
    <ref id="ref33">
      <mixed-citation publication-type="journal" id="cit33"><name><surname>Delre</surname><given-names>P.</given-names></name>; <name><surname>Lavado</surname><given-names>G. J.</given-names></name>; <name><surname>Lamanna</surname><given-names>G.</given-names></name>; <name><surname>Saviano</surname><given-names>M.</given-names></name>; <name><surname>Roncaglioni</surname><given-names>A.</given-names></name>; <name><surname>Benfenati</surname><given-names>E.</given-names></name>; <name><surname>Mangiatordi</surname><given-names>G. F.</given-names></name>; <name><surname>Gadaleta</surname><given-names>D.</given-names></name><article-title>Ligand-Based Prediction
of hERG-Mediated Cardiotoxicity Based on the Integration of Different
Machine Learning Techniques</article-title>. <source>Front. Pharmacol.</source><year>2022</year>, <volume>13</volume>, <elocation-id>951083</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2022.951083</pub-id>.<pub-id pub-id-type="pmid">36133824</pub-id></mixed-citation>
    </ref>
    <ref id="ref34">
      <mixed-citation publication-type="undeclared" id="cit34"><person-group person-group-type="allauthors"><name><surname>Benhenda</surname><given-names>M.</given-names></name></person-group><article-title>ChemGAN Challenge
for Drug Discovery: Can AI Reproduce Natural Chemical Diversity?</article-title><source>arXiv</source><year>2017</year><pub-id pub-id-type="doi">10.48550/arXiv.1708.08227</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref35">
      <mixed-citation publication-type="book" id="cit35"><article-title>RDKit Diversity Picker - RDKit Nodes Feature
- KNIME</article-title>. <source>Knime relase 4.6.1: RDKit Nodes Feature</source>; <publisher-name>NIBR</publisher-name><year>2022</year>.</mixed-citation>
    </ref>
    <ref id="ref36">
      <mixed-citation publication-type="journal" id="cit36"><name><surname>Zhu</surname><given-names>R.</given-names></name>; <name><surname>Guo</surname><given-names>Y.</given-names></name>; <name><surname>Xue</surname><given-names>J.-H.</given-names></name><article-title>Adjusting the Imbalance Ratio by
the Dimensionality
of Imbalanced Data</article-title>. <source>Pattern Recognition Letters</source><year>2020</year>, <volume>133</volume>, <fpage>217</fpage>–<lpage>223</lpage>. <pub-id pub-id-type="doi">10.1016/j.patrec.2020.03.004</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref37">
      <mixed-citation publication-type="book" id="cit37"><article-title>Ensamble Learning Wrappers - KNIME</article-title>. In <source>Knime
Relase 4.6.1: KNIME Ensamble Learning Wrappers</source>; <publisher-name>KNIME AG</publisher-name>: <publisher-loc>Zurich</publisher-loc>, <year>2022</year>.</mixed-citation>
    </ref>
    <ref id="ref38">
      <mixed-citation publication-type="book" id="cit38"><article-title>K Nearest Neighbor
- Base Nodes - KNIME</article-title>. In <source>Knime Relase 4.6.1:
KNIME Base nodes</source>; <publisher-name>KNIME
AG</publisher-name>: <publisher-loc>Zurich</publisher-loc>, <year>2022</year>.</mixed-citation>
    </ref>
    <ref id="ref39">
      <mixed-citation publication-type="book" id="cit39"><article-title>XGBoost Integration
- KNIME</article-title>. In <source>Knime Relase
4.6.1: KNIME XGBoost Integration</source>; <publisher-name>KNIME AG</publisher-name>: <publisher-loc>Zurich</publisher-loc>, <year>2022</year>.</mixed-citation>
    </ref>
    <ref id="ref40">
      <mixed-citation publication-type="journal" id="cit40"><name><surname>Capecchi</surname><given-names>A.</given-names></name>; <name><surname>Probst</surname><given-names>D.</given-names></name>; <name><surname>Reymond</surname><given-names>J.-L.</given-names></name><article-title>One Molecular Fingerprint
to Rule
Them All: Drugs, Biomolecules, and the Metabolome</article-title>. <source>J. Cheminf.</source><year>2020</year>, <volume>12</volume> (<issue>1</issue>), <fpage>43</fpage><pub-id pub-id-type="doi">10.1186/s13321-020-00445-4</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref41">
      <mixed-citation publication-type="journal" id="cit41"><name><surname>Lu</surname><given-names>W.</given-names></name>; <name><surname>Li</surname><given-names>Z.</given-names></name>; <name><surname>Chu</surname><given-names>J.</given-names></name><article-title>Adaptive Ensemble Undersampling-Boost:
A Novel Learning
Framework for Imbalanced Data</article-title>. <source>J. Syst. Software</source><year>2017</year>, <volume>132</volume>, <fpage>272</fpage>–<lpage>282</lpage>. <pub-id pub-id-type="doi">10.1016/j.jss.2017.07.006</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref42">
      <mixed-citation publication-type="book" id="cit42"><person-group person-group-type="allauthors"><name><surname>Agrawal</surname><given-names>T.</given-names></name></person-group><article-title>Introduction to
Hyperparameters</article-title>. In <source>Hyperparameter Optimization
in Machine Learning: Make Your Machine Learning and Deep Learning
Models More Efficient</source>; <person-group person-group-type="editor"><name><surname>Agrawal</surname><given-names>T.</given-names></name></person-group>, Ed.; <publisher-name>Apress</publisher-name>: <publisher-loc>Berkeley,
CA</publisher-loc>, <year>2021</year>; pp <fpage>1</fpage>–<lpage>30</lpage><pub-id pub-id-type="doi">10.1007/978-1-4842-6579-6_1</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref43">
      <mixed-citation publication-type="undeclared" id="cit43"><person-group person-group-type="allauthors"><name><surname>Probst</surname><given-names>P.</given-names></name>; <name><surname>Bischl</surname><given-names>B.</given-names></name>; <name><surname>Boulesteix</surname><given-names>A.-L.</given-names></name></person-group><article-title>Tunability:
Importance of Hyperparameters of Machine Learning Algorithms</article-title>. <year>2018</year><pub-id pub-id-type="doi">10.48550/arXiv.1802.09596</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref44">
      <mixed-citation publication-type="journal" id="cit44"><name><surname>Gadaleta</surname><given-names>D.</given-names></name>; <name><surname>Mangiatordi</surname><given-names>G. F.</given-names></name>; <name><surname>Catto</surname><given-names>M.</given-names></name>; <name><surname>Carotti</surname><given-names>A.</given-names></name>; <name><surname>Nicolotti</surname><given-names>O.</given-names></name><article-title>Applicability
Domain for QSAR Models: Where Theory Meets Reality</article-title>. <source>Int. J. Quant. Struct.-Prop. Relat.</source><year>2016</year>, <volume>1</volume> (<issue>1</issue>), <fpage>45</fpage>–<lpage>63</lpage>. <pub-id pub-id-type="doi">10.4018/IJQSPR.2016010102</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref45">
      <mixed-citation publication-type="journal" id="cit45"><name><surname>Melagraki</surname><given-names>G.</given-names></name>; <name><surname>Afantitis</surname><given-names>A.</given-names></name>; <name><surname>Sarimveis</surname><given-names>H.</given-names></name>; <name><surname>Igglessi-Markopoulou</surname><given-names>O.</given-names></name>; <name><surname>Koutentis</surname><given-names>P. A.</given-names></name>; <name><surname>Kollias</surname><given-names>G.</given-names></name><article-title>In Silico Exploration for Identifying
Structure–Activity Relationship of MEK Inhibition and Oral
Bioavailability for Isothiazole Derivatives</article-title>. <source>Chem. Biol. Drug Des.</source><year>2010</year>, <volume>76</volume> (<issue>5</issue>), <fpage>397</fpage>–<lpage>406</lpage>. <pub-id pub-id-type="doi">10.1111/j.1747-0285.2010.01029.x</pub-id>.<pub-id pub-id-type="pmid">20925691</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref46">
      <mixed-citation publication-type="book" id="cit46"><article-title>ROC Curve - JavaScript Views - KNIME</article-title>. In <source>Knime Relase 4.6.1: KNIME JavaScript Views</source>; <publisher-name>KNIME AG</publisher-name>: <publisher-loc>Zurich</publisher-loc>, <year>2022</year>.</mixed-citation>
    </ref>
    <ref id="ref47">
      <mixed-citation publication-type="book" id="cit47"><person-group person-group-type="allauthors"><name><surname>Ling</surname><given-names>C. X.</given-names></name>; <name><surname>Huang</surname><given-names>J.</given-names></name>; <name><surname>Zhang</surname><given-names>H.</given-names></name></person-group><article-title>AUC: A Better Measure than
Accuracy in Comparing Learning Algorithms</article-title>. In <source>Advances in Artificial Intelligence</source>; <person-group person-group-type="editor"><name><surname>Xiang</surname><given-names>Y.</given-names></name>; <name><surname>Chaib-draa</surname><given-names>B.</given-names></name></person-group>, Eds.; <publisher-name>Springer</publisher-name>: <publisher-loc>Berlin, Heidelberg</publisher-loc>, <year>2003</year>; pp <fpage>329</fpage>–<lpage>341</lpage><pub-id pub-id-type="doi">10.1007/3-540-44886-1_25</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref48">
      <mixed-citation publication-type="journal" id="cit48"><name><surname>Carhart</surname><given-names>R. E.</given-names></name>; <name><surname>Smith</surname><given-names>D. H.</given-names></name>; <name><surname>Venkataraghavan</surname><given-names>R.</given-names></name><article-title>Atom Pairs
as Molecular Features
in Structure-Activity Studies: Definition and Applications</article-title>. <source>J. Chem. Inf. Comput. Sci.</source><year>1985</year>, <volume>25</volume> (<issue>2</issue>), <fpage>64</fpage>–<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1021/ci00046a002</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref49">
      <mixed-citation publication-type="journal" id="cit49"><name><surname>Bienfait</surname><given-names>B.</given-names></name>; <name><surname>Ertl</surname><given-names>P.</given-names></name><article-title>JSME: A Free Molecule
Editor in JavaScript</article-title>. <source>J. Cheminf.</source><year>2013</year>, <volume>5</volume> (<issue>1</issue>), <fpage>24</fpage><pub-id pub-id-type="doi">10.1186/1758-2946-5-24</pub-id>.</mixed-citation>
    </ref>
  </ref-list>
</back>
<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//ACS//DTD ACS Journal DTD v1.02 20061031//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName ACSJournal-v102.dtd?>
<?SourceDTD.Version 1.02?>
<?ConverterInfo.XSLTName acs2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Mol Pharm</journal-id>
    <journal-id journal-id-type="iso-abbrev">Mol Pharm</journal-id>
    <journal-id journal-id-type="publisher-id">mp</journal-id>
    <journal-id journal-id-type="coden">mpohbp</journal-id>
    <journal-title-group>
      <journal-title>Molecular Pharmaceutics</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1543-8384</issn>
    <issn pub-type="epub">1543-8392</issn>
    <publisher>
      <publisher-name>American Chemical Society</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">10853961</article-id>
    <article-id pub-id-type="pmid">38134445</article-id>
    <article-id pub-id-type="doi">10.1021/acs.molpharmaceut.3c00964</article-id>
    <article-categories>
      <subj-group>
        <subject>Article</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>AMALPHI:
A Machine Learning Platform for Predicting
Drug-Induced PhospholIpidosis</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" id="ath1">
        <name>
          <surname>Lomuscio</surname>
          <given-names>Maria
Cristina</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">†</xref>
      </contrib>
      <contrib contrib-type="author" id="ath2">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9292-884X</contrib-id>
        <name>
          <surname>Abate</surname>
          <given-names>Carmen</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">†</xref>
        <xref rid="aff2" ref-type="aff">‡</xref>
      </contrib>
      <contrib contrib-type="author" id="ath3">
        <name>
          <surname>Alberga</surname>
          <given-names>Domenico</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">†</xref>
      </contrib>
      <contrib contrib-type="author" id="ath4">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6221-6155</contrib-id>
        <name>
          <surname>Laghezza</surname>
          <given-names>Antonio</given-names>
        </name>
        <xref rid="aff2" ref-type="aff">‡</xref>
      </contrib>
      <contrib contrib-type="author" id="ath5">
        <name>
          <surname>Corriero</surname>
          <given-names>Nicola</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">†</xref>
      </contrib>
      <contrib contrib-type="author" id="ath6">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5639-7746</contrib-id>
        <name>
          <surname>Colabufo</surname>
          <given-names>Nicola Antonio</given-names>
        </name>
        <xref rid="aff2" ref-type="aff">‡</xref>
      </contrib>
      <contrib contrib-type="author" id="ath7">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5086-2459</contrib-id>
        <name>
          <surname>Saviano</surname>
          <given-names>Michele</given-names>
        </name>
        <xref rid="aff3" ref-type="aff">§</xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes" id="ath8">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4523-2759</contrib-id>
        <name>
          <surname>Delre</surname>
          <given-names>Pietro</given-names>
        </name>
        <xref rid="cor1" ref-type="other">*</xref>
        <xref rid="aff1" ref-type="aff">†</xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes" id="ath9">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4042-2841</contrib-id>
        <name>
          <surname>Mangiatordi</surname>
          <given-names>Giuseppe Felice</given-names>
        </name>
        <xref rid="cor2" ref-type="other">*</xref>
        <xref rid="aff1" ref-type="aff">†</xref>
      </contrib>
      <aff id="aff1"><label>†</label><institution>CNR—Institute
of Crystallography</institution>, Via Amendola 122/o, 70126 Bari, <country>Italy</country></aff>
      <aff id="aff2"><label>‡</label>Department
of Pharmacy-Pharmaceutical Sciences, <institution>University
of the Studies of Bari “Aldo Moro”</institution>, Via E.Orabona 4, 70125 Bari, <country>Italy</country></aff>
      <aff id="aff3"><label>§</label><institution>CNR—Institute
of Crystallography</institution>, Via
Vivaldi 43, 81100 Caserta, <country>Italy</country></aff>
    </contrib-group>
    <author-notes>
      <corresp id="cor1"><label>*</label>Email: <email>pietro.delre@ic.cnr.it</email>.</corresp>
      <corresp id="cor2"><label>*</label>Email: <email>giuseppe.mangiatordi@ic.cnr.it</email>.</corresp>
    </author-notes>
    <pub-date pub-type="epub">
      <day>22</day>
      <month>12</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="collection">
      <day>05</day>
      <month>02</month>
      <year>2024</year>
    </pub-date>
    <volume>21</volume>
    <issue>2</issue>
    <fpage>864</fpage>
    <lpage>872</lpage>
    <history>
      <date date-type="received">
        <day>17</day>
        <month>10</month>
        <year>2023</year>
      </date>
      <date date-type="accepted">
        <day>05</day>
        <month>12</month>
        <year>2023</year>
      </date>
      <date date-type="rev-recd">
        <day>24</day>
        <month>11</month>
        <year>2023</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© 2023 American Chemical Society</copyright-statement>
      <copyright-year>2023</copyright-year>
      <copyright-holder>American Chemical Society</copyright-holder>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
        <license-p>Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>).</license-p>
      </license>
    </permissions>
    <abstract>
      <p content-type="toc-graphic">
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mp3c00964_0005" id="ab-tgr1"/>
      </p>
      <p>Drug-induced phospholipidosis (PLD) involves the accumulation
of
phospholipids in cells of multiple tissues, particularly within lysosomes,
and it is associated with prolonged exposure to druglike compounds,
predominantly cationic amphiphilic drugs (CADs). PLD affects a significant
portion of drugs currently in development and has recently been proven
to be responsible for confounding antiviral data during drug repurposing
for SARS-CoV-2. In these scenarios, it has become crucial to identify
potential safe drug candidates in advance and distinguish them from
those that may lead to false in vitro antiviral activity. In this
work, we developed a series of machine learning classifiers with the
aim of predicting the PLD-inducing potential of drug candidates. The
models were built on a high-quality chemical collection comprising <bold>545</bold> curated small molecules extracted from ChEMBL v30. The
most effective model, obtained using the balanced random forest algorithm,
achieved high performance, including an AUC value computed in validation
as high as 0.90. The model was made freely available through a user-friendly
web platform named AMALPHI (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ba.ic.cnr.it/softwareic/amalphiportal/">https://www.ba.ic.cnr.it/softwareic/amalphiportal/</uri>), which can represent a valuable tool for medicinal chemists interested
in conducting an early evaluation of PLD inducer potential.</p>
    </abstract>
    <kwd-group>
      <kwd>phospholipidosis</kwd>
      <kwd>ligand-based classifiers</kwd>
      <kwd>machine learning</kwd>
      <kwd>SARS-CoV-2</kwd>
    </kwd-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution>Consiglio Nazionale delle Ricerche</institution>
            <institution-id institution-id-type="doi">10.13039/501100004462</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>NA</award-id>
      </award-group>
    </funding-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution>Ministero dell''UniversitÃ  e della Ricerca</institution>
            <institution-id institution-id-type="doi">10.13039/501100021856</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>2022Z3BBPE</award-id>
      </award-group>
    </funding-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution>Regione Puglia</institution>
            <institution-id institution-id-type="doi">10.13039/501100009886</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>NA</award-id>
      </award-group>
    </funding-group>
    <custom-meta-group>
      <custom-meta>
        <meta-name>document-id-old-9</meta-name>
        <meta-value>mp3c00964</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>document-id-new-14</meta-name>
        <meta-value>mp3c00964</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>ccc-price</meta-name>
        <meta-value/>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
</front>
<body>
  <sec id="sec1">
    <title>Introduction</title>
    <p>Phospholipidosis (PLD) is a lysosomal
storage disorder characterized
by excessive accumulation of phospholipids in liver, kidney, brain,
cornea, lung, and other organs.<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> While
it is widely recognized that this phenomenon can arise from prolonged
treatment with cationic amphiphilic drugs (CADs), the exact mechanism
behind this process remains unclear. Various hypotheses have been
explored in the literature, including direct inhibition of lysosomal
phospholipases,<sup><xref ref-type="bibr" rid="ref2">2</xref></sup> binding to phospholipids,<sup><xref ref-type="bibr" rid="ref3">3</xref></sup> the potential regulation of phospholipid synthesis,<sup><xref ref-type="bibr" rid="ref4">4</xref></sup> and the enhanced cholesterol biosynthesis.<sup><xref ref-type="bibr" rid="ref5">5</xref></sup> For a comprehensive review on this topic, the
reader is referred to the recent paper by Breiden et al.<sup><xref ref-type="bibr" rid="ref6">6</xref></sup> Given that a notable proportion (∼5%<sup><xref ref-type="bibr" rid="ref7">7</xref></sup>) of drugs can induce PLD, there has been a growing
interest in recent years to assess the potential of drug candidates
to be inducers of PLD during the early stages of a drug discovery
(DD) process. This proactive evaluation is recognized as valuable,
as compounds that lead to PLD have a reduced likelihood of being successfully
brought to market.<sup><xref ref-type="bibr" rid="ref8">8</xref></sup> Recently, highly significant
correlations have been demonstrated between lipophilicity, the ability
of CADs to induce PLD, and the antiviral activity that these cationic
amphiphilic drugs have shown against multiple viruses such as hepatitis
C virus (HCV), Japanese encephalitis virus (JEV), severe acute respiratory
syndrome coronavirus (SARS-CoV), and Epstein–Barr virus (EBV).<sup><xref ref-type="bibr" rid="ref9">9</xref></sup> In light of the recent COVID-19 pandemic, a publication
in Science by Tummino et al.<sup><xref ref-type="bibr" rid="ref10">10</xref></sup> presented
findings that highlight the pivotal role of PLD in the context of
drugs with anti-SARS-CoV-2 activity, revealing that most of the molecules
return antiviral activity during the drug repurposing campaigns conducted
during the pandemic induce PLD. This adds another layer of complexity
and importance to the understanding and evaluation of PLD in drug
development efforts, particularly in the context of the recent global
health crisis. Based on these data, Tummino et al. speculated that
the anti-SARS-CoV-2 activity observed in vitro for many molecules
would be the consequence of their ability to induce PLD rather than
activity on a specific target (false anti-SARS-CoV-2 activity<sup><xref ref-type="bibr" rid="ref10">10</xref></sup>). This hypothesis was supported by the evidence
that many molecules exhibiting antiviral activity in vitro lost such
activity when transitioning to in vivo conditions. Further support
came from the lack of correlation between the antiviral activity and
the affinity of some ligands that interact with host targets identified
as important in combating SARS-CoV-2 replication (e.g., sigma-1 receptor).<sup><xref ref-type="bibr" rid="ref11">11</xref></sup> Some molecules with high affinity for sigma-1,
for instance, show no antiviral activity.<sup><xref ref-type="bibr" rid="ref12">12</xref></sup> Although PLD in the context of SARS-CoV-2 antiviral assays remains
a subject of ongoing scientific debate with contradictory data,<sup><xref ref-type="bibr" rid="ref13">13</xref>,<xref ref-type="bibr" rid="ref14">14</xref></sup> its importance in the drug development process has been further
underscored. Unfortunately, the available in vitro assays able to
measure the PLD-inducing potential of drug candidates are laborious,
time-consuming, expensive, and, for these reasons, poorly applied
despite the fact that several CADs agents are in clinical use/development.
Furthermore, the gold standard method (transmission electron microscope—TEM)
does not allow the screening of a large number of molecules.<sup><xref ref-type="bibr" rid="ref15">15</xref></sup> Other in vitro approaches include a method consisting
of measuring the binding of dyes to the phospholipids by flow cytometry
or fluorescence microscopy,<sup><xref ref-type="bibr" rid="ref16">16</xref>−<xref ref-type="bibr" rid="ref20">20</xref></sup> as well as a method based on quantifying gene biomarkers linked
to PLD.<sup><xref ref-type="bibr" rid="ref15">15</xref></sup> All these approaches are particularly
expensive and often yield conflicting data.<sup><xref ref-type="bibr" rid="ref21">21</xref>−<xref ref-type="bibr" rid="ref23">23</xref></sup> The development
of in-silico tools able to prioritize safe drug candidates is, therefore,
highly desirable, although it is worth noting that they are not free
from limitations. Especially when not used in conjunction with experiments
or when not starting from highly curated experimental data, they can
lead to a considerable number of false positives, as was clearly seen
during the COVID-19 pandemic.<sup><xref ref-type="bibr" rid="ref24">24</xref></sup> In the
context of antiviral design, if developed effectively, these tools
would provide valid support to the identification of those compounds
with a low probability to provide false antiviral activities during
in vitro assays. Accordingly, several models have been developed in
the past few years to predict the PLD-inducing potential of drug candidates,
based on ligand-based approaches<sup><xref ref-type="bibr" rid="ref7">7</xref>,<xref ref-type="bibr" rid="ref25">25</xref>−<xref ref-type="bibr" rid="ref28">28</xref></sup> or substructure search methods.<sup><xref ref-type="bibr" rid="ref29">29</xref>,<xref ref-type="bibr" rid="ref30">30</xref></sup> Valuable examples
can be found in the papers by Kruhlak et al.<sup><xref ref-type="bibr" rid="ref7">7</xref></sup> and Orogo et al.,<sup><xref ref-type="bibr" rid="ref26">26</xref></sup> reporting quantitative
structure–activity relationship (QSAR) models based on <bold>583</bold> and <bold>743</bold> compounds, respectively, extracted
from the published literature, existing pharmaceutical databases,
and Food and Drug Administration (FDA) internal reports. Of note are
also the papers by Fusani et al. and Schieferdecker et al.<sup><xref ref-type="bibr" rid="ref27">27</xref>,<xref ref-type="bibr" rid="ref28">28</xref></sup> Based on in-house in vitro data, the authors developed machine learning-based
models of PLD-inducing potential. However, despite their good performance
(accuracy &gt; 80%), the developed models are not available; hence,
their
accessibility to potentially interested users is strongly limited.
Building on this background, in the present study, new classifiers
of PLD-inducing potential were developed using four algorithms, namely,
random forest (RF), K-nearest neighbors (KNN), gradient boosting (GB),
and extreme gradient boosting (XGB) starting from <bold>545</bold> compounds extracted from ChEMBL version (v) 30 (PLD-DB) and then
splitting into a training set (TS) and a validation set (VS). The
top-performing classifier was also tested on two external sets (ESs).
Despite the limited data availability, these models demonstrated satisfactory
performance, as evidenced by widely accepted quality metrics, such
as the area under the receiver operating characteristic curve (AUC)
and balanced accuracy (BA). Following an approach successfully employed
by our team for predicting other chemical properties,<sup><xref ref-type="bibr" rid="ref31">31</xref>,<xref ref-type="bibr" rid="ref32">32</xref></sup> the most effective model was incorporated into a user-friendly web
platform named AMALPHI (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ba.ic.cnr.it/softwareic/amalphiportal/">https://www.ba.ic.cnr.it/softwareic/amalphiportal/</uri>). Significantly, this platform does not necessitate expertise in
cheminformatics or programming and can be a valuable resource for
medicinal chemists interested in early evaluations of the PLD inducer
potential. To the best of our knowledge, AMALPHI is the first freely
accessible tool able to efficiently predict the PLD potential of drug
candidates.</p>
  </sec>
  <sec id="sec2">
    <title>Materials and Methods</title>
    <sec id="sec2.1">
      <title>Data Set Preparation</title>
      <p>We extracted <bold>851</bold> entries
from ChEMBL v30 according to the Target ID (CHEMBL1626541) assigned
to the PLD phenotype. Following an approach described elsewhere,<sup><xref ref-type="bibr" rid="ref32">32</xref>,<xref ref-type="bibr" rid="ref33">33</xref></sup> we checked the validity of each SMILES string using an in-house
semiautomated procedure implemented in the KNIME platform. In particular,
this procedure allows for the removal of organometallic and inorganic
compounds, chemicals characterized by unusual elements and mixtures,
neutralizing salts, and stereochemistry. Finally, the OpenBabel node
implemented in KNIME allowed the conversion of retrieved SMILES in
a standardized QSAR-ready format. In doing that, we created the PLD-DB,
consisting of <bold>545</bold> curated entries. It is worth noting
that 70% of the compounds belonging to the PLD-DB data set are approved
drugs, while the remaining ones have yet to progress to the clinical
phase.</p>
      <p>Furthermore, to assess the diversity of molecules in
our data set, we employed a metric called internal diversity (ID—defined
as the mean over the Tanimoto distances between each molecule and
all the others belonging to the same set<sup><xref ref-type="bibr" rid="ref34">34</xref></sup>), which effectively measures the similarity of molecules within
the data set. The resulting ID value of 0.82 indicates that the compounds
in our data set exhibit a high degree of diversity. To classify the
entries as either PLD inducers (P+) or noninducers (P−), we
analyzed the comments field based on the reference CHEMBL ID document.
Annotations selected as referring to P+ were: “active”/
“positive”/ “positive: inducer confirmed by electron
microscopy”/ “positive: weak inducer based on foamy
macrophages and cytoplasmic vacuolations.” Instead, comments
selected as indicating no PLD induction (P−) were: “not
active”/“negative”/“negative: confirmed
by electron microscopy”/“negative: based on the absence
of positive reported data from WMDD.” <bold>295</bold> duplicates
were removed, keeping the P+ or P– class as the most frequent
one. Finally, <bold>11</bold> chemicals were excluded, as their activity
was indicated as “Not determined” in ChEMBL v30. In
doing that, the final curated data set (PDL-DB) comprises <bold>104</bold> P+ and <bold>441</bold> P– for a total of <bold>545</bold> compounds.</p>
    </sec>
    <sec id="sec2.2">
      <title>External Set Preparation</title>
      <p>Two different external sets
(ESs), one consisting of <bold>117</bold> (ES1) and the other consisting
of <bold>20</bold> (ES2) compounds, were built and used in this work.
In particular, Orogo et al.<sup><xref ref-type="bibr" rid="ref26">26</xref></sup> made available
a data set (Or-ds) consisting of <bold>743</bold> compounds that we
used to create ES1. Noteworthy, Or-ds comprises compounds along with
their associated PLD activity and a corresponding data confidence
rate expressed as either high or medium. Compounds associated with
keywords related to electron microscopy confirmation of PLD are considered
to have high confidence, while those associated with keywords and
phrases indicating only the presence of foamy macrophages are considered
to have medium confidence. We kept only those compounds with a high
confidence rating and processed the SMILES strings using the same
semiautomated procedure described above to remove duplicates and compounds
already included in PLD-DB. The second external set (ES2) was built
based on the work by Przybylak et al.<sup><xref ref-type="bibr" rid="ref29">29</xref></sup> The authors used two curated data sets comprising <bold>185</bold> and <bold>331</bold> compounds. These two data sets were merged
and processed following the already described data curation approach.</p>
    </sec>
    <sec id="sec2.3">
      <title>Data Set Splitting</title>
      <p>We employed a rational approach
to split PLD-DB into a TS and a VS. To this aim, we applied the RDkit
Diversity Picker node separately on the two classes (i.e., P+ and
P−). This node automatically generates Morgan fingerprints
(radius 2–2048 bits) for each SMILES string and then picks
80% of the most diverse molecules for each class based on the Tanimoto
distance.<sup><xref ref-type="bibr" rid="ref35">35</xref></sup> In this way, a TS of <bold>431</bold> compounds (80% of each class) and a VS that includes the
remaining <bold>114</bold> compounds were obtained. <xref rid="tbl2" ref-type="other">Table <xref rid="tbl2" ref-type="other">2</xref></xref> summarizes the composition
of the starting TS, VS, and ES as well as the relative imbalanced
ratio (IR) calculated as the ratio between the number of majority
and minority instances.<sup><xref ref-type="bibr" rid="ref36">36</xref></sup> Note that such
a procedure allowed us to keep the ratio between the classes in each
subset. To depict the chemical space covered by TS, VS, and ESs, a
principal component analysis (PCA) was performed based on 36 physicochemical
properties of the molecules calculated by the RDKit Descriptor Calculation
KNIME node and then standardized using the Normalizer KNIME node (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>). The score plot
of the first three principal components (PC1, PC2, and PC3) that account
for 80.8% of the variance shows each ligand belonging to the different
data sets in the resulting 3D chemical space.</p>
      <fig id="fig1" position="float">
        <label>Figure 1</label>
        <caption>
          <p>PCA based on the physicochemical
properties returned by the compounds
belonging to TS, VS, ES1, and ES2.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mp3c00964_0001" id="gr1" position="float"/>
      </fig>
    </sec>
  </sec>
  <sec id="sec3">
    <title>Development of Statistically Based Models</title>
    <sec id="sec3.1">
      <title>Development and Validation</title>
      <p>In this work, four classification
algorithms were used: RF, KNN, GB, and XGB. We employed the following
KNIME nodes: tree ensemble learner, tree ensemble predictor, K-nearest
neighbor, gradient boosted trees learner, gradient boosted trees predictor,
XGBoost tree ensemble learner, XGBoost predictor.<sup><xref ref-type="bibr" rid="ref37">37</xref>−<xref ref-type="bibr" rid="ref39">39</xref></sup> AtomPair fingerprints
(AP—1024 bits) calculated by the RDKit Fingerprint KNIME node
were used to represent each chemical structure belonging to PLD-DB.</p>
      <p>It is worth noting that we opted for AP fingerprints instead of
the previously used Morgan fingerprints due to their acknowledged
higher sensitivity to molecular global features, such as size and
shape.<sup><xref ref-type="bibr" rid="ref40">40</xref></sup></p>
      <p>Noteworthy, an IR equal
to 4.4 was computed for the TS. For this
reason, we created an additional set of models using an undersampling
ensemble learning model (UELM), employing KNN, GB, and XGB. This technique
presents two advantages as it (i) avoids the convergence of algorithms
trained on the majority class ignoring classes with fewer samples,<sup><xref ref-type="bibr" rid="ref41">41</xref></sup> and (ii) preserves information from the majority
class using the ensemble technique. In particular, we used the equal
size sampling node to generate, from the original TS, 50 sub-TS (characterized
by an IR equal to 1) to train 50 models and generate the final ensemble
model, able to make predictions on external data (i.e., VS and ES)
following a majority voting approach. In all cases, we found the optimal
setting (shown in <xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>) for the final model training through hyperparameter tuning performed
based on a 5-fold cross-validation (5-CV). Note that, for each algorithm,
the hyperparameters known to be responsible for the higher impact
on the overall performance<sup><xref ref-type="bibr" rid="ref42">42</xref>,<xref ref-type="bibr" rid="ref43">43</xref></sup> were considered.</p>
      <table-wrap id="tbl1" position="float">
        <label>Table 1</label>
        <caption>
          <title>Optimized Parameters for Each Algorithm</title>
        </caption>
        <table frame="hsides" rules="groups" border="0">
          <colgroup>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
          </colgroup>
          <thead>
            <tr>
              <th style="border:none;" align="center">algorithm</th>
              <th style="border:none;" align="center">optimized
parameters</th>
              <th style="border:none;" align="center">unbalanced TS</th>
              <th style="border:none;" align="center">equal size models</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="6" style="border:none;" align="left">RF</td>
              <td style="border:none;" align="left">split criterion</td>
              <td style="border:none;" align="left">gini index</td>
              <td rowspan="6" style="border:none;" align="left"> </td>
            </tr>
            <tr>
              <td style="border:none;" align="left">attribute
sampling</td>
              <td style="border:none;" align="left">square root</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">set of
attributes for each tree</td>
              <td style="border:none;" align="left">different</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">number of trees</td>
              <td style="border:none;" align="left">423</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">tree depth</td>
              <td style="border:none;" align="left">6</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">equal size sampling</td>
              <td style="border:none;" align="left">yes</td>
            </tr>
            <tr>
              <td rowspan="2" style="border:none;" align="left">kNN</td>
              <td style="border:none;" align="left">number of neighbors to consider</td>
              <td style="border:none;" align="left">5</td>
              <td style="border:none;" align="left">7</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">weight neighbors by distance</td>
              <td style="border:none;" align="left">yes</td>
              <td style="border:none;" align="left">no</td>
            </tr>
            <tr>
              <td rowspan="5" style="border:none;" align="left">GB</td>
              <td style="border:none;" align="left">number
of trees</td>
              <td style="border:none;" align="left">280</td>
              <td style="border:none;" align="left">100</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">learning rate</td>
              <td style="border:none;" align="left">0.98</td>
              <td style="border:none;" align="left">1</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">attribute sampling</td>
              <td style="border:none;" align="left">square root</td>
              <td rowspan="3" style="border:none;" align="left"> </td>
            </tr>
            <tr>
              <td style="border:none;" align="left">set of attributes for each
tree</td>
              <td style="border:none;" align="left">same</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">maximum tree depth</td>
              <td style="border:none;" align="left">8</td>
            </tr>
            <tr>
              <td rowspan="6" style="border:none;" align="left">XGB</td>
              <td style="border:none;" align="left">eta</td>
              <td style="border:none;" align="left">0.589</td>
              <td style="border:none;" align="left">0.28</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">boosting
rounds</td>
              <td style="border:none;" align="left">253</td>
              <td style="border:none;" align="left">100</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">gamma</td>
              <td style="border:none;" align="left">0.182</td>
              <td rowspan="4" style="border:none;" align="left"> </td>
            </tr>
            <tr>
              <td style="border:none;" align="left">lamba</td>
              <td style="border:none;" align="left">4.842</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">alpha</td>
              <td style="border:none;" align="left">0.211</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">maximum depth</td>
              <td style="border:none;" align="left">6</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>To do that, we employed a Bayesian optimization algorithm
for RF
and XGB and a grid search for KNN and GB. Finally, after performance
evaluation, we selected the best-performing model.</p>
    </sec>
    <sec id="sec3.2">
      <title>Applicability Domain</title>
      <p>An applicability domain (AD) was
defined for the TS in order to increase confidence in the predictions.
Notably, AD represents the chemical space from which the models are
built and, therefore, where a prediction can be considered reliable.<sup><xref ref-type="bibr" rid="ref44">44</xref></sup> The domain-similarity KNIME node was employed
to define the AD. This node measures the Euclidean distances between
the compounds belonging to the TS and those subjected to prediction.
In particular, this approach allows defining an AD threshold (ADP)
following these steps: (i) the computation of all the Euclidean distances
between all the possible pairs of compounds belonging to TS, based
on representative descriptors (AP fingerprint in our case); (ii) the
creation of a set of distances that are lower than the average distance
calculated in step 1; (iii) the computation of the mean (d) and standard
deviation (σ) of the distances in the set created in step 2;
and (iv) the definition the ADP (AD threshold) using the equation<disp-formula id="eq1"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mp3c00964_m001" position="anchor"/><label>1</label></disp-formula>where <italic>Z</italic> is an empirical cutoff
value equal to 0.5 by default.<sup><xref ref-type="bibr" rid="ref45">45</xref></sup> In doing
that, we excluded 2 compounds from VS and 16 compounds from ES1, while
all the compounds belonging to ES2 resulted within the AD. <xref rid="tbl2" ref-type="other">Table <xref rid="tbl2" ref-type="other">2</xref></xref> reports the VS, ES1, and ES2 compositions after the application
of the AD filter.</p>
      <table-wrap id="tbl2" position="float">
        <label>Table 2</label>
        <caption>
          <title>Partitioning Schemes Before (Top)
and After (Bottom) the Application of the AD<xref rid="t2fn1" ref-type="table-fn">a</xref></title>
        </caption>
        <table frame="hsides" rules="groups" border="0">
          <colgroup>
            <col align="left"/>
            <col align="char" char="."/>
            <col align="char" char="."/>
            <col align="char" char="."/>
            <col align="char" char="."/>
          </colgroup>
          <thead>
            <tr>
              <th style="border:none;" align="center">data set</th>
              <th style="border:none;" align="center" char=".">#</th>
              <th style="border:none;" align="center" char=".">P–</th>
              <th style="border:none;" align="center" char=".">P+</th>
              <th style="border:none;" align="center" char=".">IR</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td style="border:none;" align="left">TS</td>
              <td style="border:none;" align="char" char=".">431</td>
              <td style="border:none;" align="char" char=".">351</td>
              <td style="border:none;" align="char" char=".">80</td>
              <td style="border:none;" align="char" char=".">4.4</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">VS</td>
              <td style="border:none;" align="char" char=".">114</td>
              <td style="border:none;" align="char" char=".">90</td>
              <td style="border:none;" align="char" char=".">24</td>
              <td style="border:none;" align="char" char=".">3.7</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">ES1</td>
              <td style="border:none;" align="char" char=".">133</td>
              <td style="border:none;" align="char" char=".">112</td>
              <td style="border:none;" align="char" char=".">21</td>
              <td style="border:none;" align="char" char=".">5.3</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">ES2</td>
              <td style="border:none;" align="char" char=".">20</td>
              <td style="border:none;" align="char" char=".">11</td>
              <td style="border:none;" align="char" char=".">9</td>
              <td style="border:none;" align="char" char=".">1.2</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">within the AD</td>
              <td style="border:none;" align="char" char="."> </td>
              <td style="border:none;" align="char" char="."> </td>
              <td style="border:none;" align="char" char="."> </td>
              <td style="border:none;" align="char" char="."> </td>
            </tr>
            <tr>
              <td style="border:none;" align="left">VS</td>
              <td style="border:none;" align="char" char=".">112</td>
              <td style="border:none;" align="char" char=".">88</td>
              <td style="border:none;" align="char" char=".">24</td>
              <td style="border:none;" align="char" char=".">3.6</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">ES1</td>
              <td style="border:none;" align="char" char=".">117</td>
              <td style="border:none;" align="char" char=".">99</td>
              <td style="border:none;" align="char" char=".">18</td>
              <td style="border:none;" align="char" char=".">5.5</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">ES2</td>
              <td style="border:none;" align="char" char=".">20</td>
              <td style="border:none;" align="char" char=".">11</td>
              <td style="border:none;" align="char" char=".">9</td>
              <td style="border:none;" align="char" char=".">1.2</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="t2fn1">
            <label>a</label>
            <p>For PLD-DB, the number of noninducers
(P−) and inducers (P+) chemicals is reported for the training
set (TS), validation set (VS), largest (ES1), and smallest (ES2) external
sets. Notably, the total number of chemicals (#) is also reported.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
    </sec>
    <sec id="sec3.3">
      <title>Performance Evaluation</title>
      <p>Each classifier was evaluated
by using Coopers statistics. In particular, sensitivity (SE), specificity
(SP), and BA were computed as follows<disp-formula id="eq2"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mp3c00964_m002" position="anchor"/><label>2</label></disp-formula><disp-formula id="eq3"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mp3c00964_m003" position="anchor"/><label>3</label></disp-formula><disp-formula id="eq4"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mp3c00964_m004" position="anchor"/><label>4</label></disp-formula>where TP (true positives) and TN (true negatives)
are, respectively, the positive and negative samples correctly classified
by the trained model, whereas FP (false positives) and FN (false negatives)
are the misclassified positive and negative samples, respectively.
Another quality metric, namely, the Matthews correlation coefficient
(MCC), was considered to evaluate model performance. MCC indicates
the quality of binary classification and is generally recognized as
a reliable metric, although it deteriorates when the TS is unbalanced.
MCC ranges between −1 and +1, where a value of +1 means a perfect
classification, 0 indicates a random classification, and −1
is a complete misclassification.<disp-formula id="eq5"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mp3c00964_m005" position="anchor"/><label>5</label></disp-formula>The AUC was also computed by the ROC curve
node<sup><xref ref-type="bibr" rid="ref46">46</xref></sup> to measure the ability of a model
to distinguish P+ from P– samples. This metric ranges between
0 (miss-classifiers) and 1 (ideal-classifiers), reflecting the probability
of positive compounds being ranked earlier than decoy compounds according
to the prediction confidence value estimated by the KNIME Predictor
nodes with respect to each specific algorithm used.<sup><xref ref-type="bibr" rid="ref37">37</xref>−<xref ref-type="bibr" rid="ref39">39</xref></sup> The ROC curve
and, consequently, the AUC will be one of the key metrics we will
primarily consider for selecting the most effective model.<sup><xref ref-type="bibr" rid="ref47">47</xref></sup></p>
      <p>Finally, the positive (+LR) and the negative
likelihood ratio (−LR) were considered and computed as follows<disp-formula id="eq6"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mp3c00964_m006" position="anchor"/><label>6</label></disp-formula>and<disp-formula id="eq7"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mp3c00964_m007" position="anchor"/><label>7</label></disp-formula>The classification model becomes more informative
as the +LR value increases (or the −LR value decreases).</p>
    </sec>
  </sec>
  <sec id="sec4">
    <title>Results and Discussion</title>
    <p>In this work, different classifiers
of PLD-inducing potential were
developed using four ML classification algorithms, namely, RF, KNN,
GB, and XGB, all available in the KNIME analytics platform. To this
end, a highly curated data set (PLD-DB) consisting of <bold>545</bold> compounds was used to train and then to validate the models. More
specifically, PLD-DB was divided into a TS used to perform hyperparameter
tuning based on a 5-fold cross-validation (5-CV) and a VS used to
validate the models obtained with the best parameters identified.
Each compound was described by binary fingerprints, namely, AtomPair
FP.<sup><xref ref-type="bibr" rid="ref48">48</xref></sup> As already mentioned, PLD-DB is an
unbalanced data set with an IR approximately equal to 4. To address
the problem and therefore prevent a significant discrepancy between
SE and SP, different techniques were undertaken. The RF algorithm
was combined with a uniform size sampling strategy (hereinafter referred
to as balanced random forest–BRF) to reduce the bias toward
the majority class while an additional technique named UELM (see the
section <xref rid="sec2" ref-type="other">Materials and Methods</xref> for methodological
details) was implemented for KNN (hereinafter referred to as uKNN),
GB (uGB), and XGB (uXGB) algorithms. In particular, using the equal
size KNIME node, we developed, for each of these algorithms, a final
ensemble model following the approach described in the section “<xref rid="sec3.1" ref-type="other">Models Development and Validation</xref>”. The
final prediction was performed following a majority vote approach.
Furthermore, to wisely evaluate real-life model predictivity, VS was
kept imbalanced, and only compounds within the AD were considered.
Finally, two different ESs were employed to assess the predictivity
of the best model in a real-life case study. The following section
will focus on analyzing the key quality metrics (SE, SP, BA, MCC,
and AUC) calculated for each validation process (internal and external),
aiming to identify the top-performing classifier.</p>
    <sec id="sec4.1">
      <title>Hyperparameterization</title>
      <p><xref rid="tbl3" ref-type="other">Table <xref rid="tbl3" ref-type="other">3</xref></xref> displays the performances achieved using
5-fold cross-validation (5-CV) for each employed algorithm using the
TS extracted from PLD-DB for hyperparameter optimization tuning. In
this step, ensuring satisfactory performance is critical to guarantee
the capability of model generalization, meaning that models fit the
data set accurately, avoiding overfitting or underfitting. As expected,
the classifiers built based on RF, KNN, GB, and XGB returned SP values
significantly higher than SE ones (difference ranging from 0.55 to
0.78). Moreover, in all cases, BA values lower than 0.70 were computed.
A remarkable performance improvement is instead observed when a proper
treatment of the TS imbalance is undertaken as evident looking at
the quality metrics returned by BRF, uKNN, uGB, and uXGB (<xref rid="tbl3" ref-type="other">Table <xref rid="tbl3" ref-type="other">3</xref></xref>). More specifically,
no significant difference is observed between the SE and SP, ranging
from 0.01 (BRF) to 0.08 (uKNN). Furthermore, higher BA and AUC values
were also detected, with BRF returning the best performance (BA =
0.73 and AUC = 0.78). As mentioned in the introduction, building models
of PLD-inducing potential has, as a primary aim, that of directing
the experimental efforts toward safe (P−) molecules. Building
on that, the prediction of dangerous substances as safe should be
avoided. In light of that, we also focused our attention on the computed
−LR values. Notice that this quality metric is independent
of the TS data distribution and is able to provide an estimation of
the decrease in the probability of a compound being a P– with
respect to the initial condition (before querying the relative classifier).
Again, BRF (−LR = 0.37) returned the best performance, followed
by uGB (0.39), uXGB (0.44), and uKNN (0.48), while significantly worse
values were returned by RF (0.84), KNN (0.70), GB (0.80), and XGB
(0.63). In summary, the performed 5-CV provided clear evidence that
resembling approaches are required to reach satisfactory performances.</p>
      <table-wrap id="tbl3" position="float">
        <label>Table 3</label>
        <caption>
          <title>Performances in 5-CV Returned by All
of the Developed Classifiers<xref rid="t3fn1" ref-type="table-fn">a</xref></title>
        </caption>
        <table frame="hsides" rules="groups" border="0">
          <colgroup>
            <col align="left"/>
            <col align="char" char="."/>
            <col align="char" char="."/>
            <col align="char" char="."/>
            <col align="char" char="."/>
            <col align="char" char="."/>
            <col align="char" char="."/>
            <col align="char" char="."/>
            <col align="char" char="."/>
            <col align="char" char="."/>
            <col align="char" char="."/>
            <col align="char" char="."/>
          </colgroup>
          <thead>
            <tr>
              <th style="border:none;" align="center"> </th>
              <th style="border:none;" align="center" char=".">SE</th>
              <th style="border:none;" align="center" char=".">SP</th>
              <th style="border:none;" align="center" char=".">BA</th>
              <th style="border:none;" align="center" char=".">AUC</th>
              <th style="border:none;" align="center" char=".">–LR</th>
              <th style="border:none;" align="center" char=".">+LR</th>
              <th style="border:none;" align="center" char=".">MCC</th>
              <th style="border:none;" align="center" char=".">TP</th>
              <th style="border:none;" align="center" char=".">FP</th>
              <th style="border:none;" align="center" char=".">TN</th>
              <th style="border:none;" align="center" char=".">FN</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td style="border:none;" align="left">RF</td>
              <td style="border:none;" align="char" char=".">0.19</td>
              <td style="border:none;" align="char" char=".">0.97</td>
              <td style="border:none;" align="char" char=".">0.58</td>
              <td style="border:none;" align="char" char=".">0.77</td>
              <td style="border:none;" align="char" char=".">0.84</td>
              <td style="border:none;" align="char" char=".">6.58</td>
              <td style="border:none;" align="char" char=".">0.26</td>
              <td style="border:none;" align="char" char=".">15</td>
              <td style="border:none;" align="char" char=".">10</td>
              <td style="border:none;" align="char" char=".">341</td>
              <td style="border:none;" align="char" char=".">65</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">KNN</td>
              <td style="border:none;" align="char" char=".">0.31</td>
              <td style="border:none;" align="char" char=".">0.95</td>
              <td style="border:none;" align="char" char=".">0.63</td>
              <td style="border:none;" align="char" char=".">0.70</td>
              <td style="border:none;" align="char" char=".">0.72</td>
              <td style="border:none;" align="char" char=".">6.86</td>
              <td style="border:none;" align="char" char=".">0.35</td>
              <td style="border:none;" align="char" char=".">25</td>
              <td style="border:none;" align="char" char=".">16</td>
              <td style="border:none;" align="char" char=".">335</td>
              <td style="border:none;" align="char" char=".">55</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">GB</td>
              <td style="border:none;" align="char" char=".">0.23</td>
              <td style="border:none;" align="char" char=".">0.97</td>
              <td style="border:none;" align="char" char=".">0.60</td>
              <td style="border:none;" align="char" char=".">0.75</td>
              <td style="border:none;" align="char" char=".">0.80</td>
              <td style="border:none;" align="char" char=".">6.58</td>
              <td style="border:none;" align="char" char=".">0.30</td>
              <td style="border:none;" align="char" char=".">18</td>
              <td style="border:none;" align="char" char=".">12</td>
              <td style="border:none;" align="char" char=".">339</td>
              <td style="border:none;" align="char" char=".">62</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">XGB</td>
              <td style="border:none;" align="char" char=".">0.40</td>
              <td style="border:none;" align="char" char=".">0.95</td>
              <td style="border:none;" align="char" char=".">0.68</td>
              <td style="border:none;" align="char" char=".">0.78</td>
              <td style="border:none;" align="char" char=".">0.63</td>
              <td style="border:none;" align="char" char=".">8.26</td>
              <td style="border:none;" align="char" char=".">0.43</td>
              <td style="border:none;" align="char" char=".">32</td>
              <td style="border:none;" align="char" char=".">17</td>
              <td style="border:none;" align="char" char=".">334</td>
              <td style="border:none;" align="char" char=".">48</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">BRF</td>
              <td style="border:none;" align="char" char=".">0.73</td>
              <td style="border:none;" align="char" char=".">0.74</td>
              <td style="border:none;" align="char" char=".">0.73</td>
              <td style="border:none;" align="char" char=".">0.78</td>
              <td style="border:none;" align="char" char=".">0.37</td>
              <td style="border:none;" align="char" char=".">2.77</td>
              <td style="border:none;" align="char" char=".">0.38</td>
              <td style="border:none;" align="char" char=".">58</td>
              <td style="border:none;" align="char" char=".">92</td>
              <td style="border:none;" align="char" char=".">259</td>
              <td style="border:none;" align="char" char=".">22</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">uKNN</td>
              <td style="border:none;" align="char" char=".">0.65</td>
              <td style="border:none;" align="char" char=".">0.73</td>
              <td style="border:none;" align="char" char=".">0.69</td>
              <td style="border:none;" align="char" char=".">0.72</td>
              <td style="border:none;" align="char" char=".">0.48</td>
              <td style="border:none;" align="char" char=".">2.41</td>
              <td style="border:none;" align="char" char=".">0.31</td>
              <td style="border:none;" align="char" char=".">52</td>
              <td style="border:none;" align="char" char=".">96</td>
              <td style="border:none;" align="char" char=".">255</td>
              <td style="border:none;" align="char" char=".">28</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">uGB</td>
              <td style="border:none;" align="char" char=".">0.73</td>
              <td style="border:none;" align="char" char=".">0.70</td>
              <td style="border:none;" align="char" char=".">0.71</td>
              <td style="border:none;" align="char" char=".">0.73</td>
              <td style="border:none;" align="char" char=".">0.39</td>
              <td style="border:none;" align="char" char=".">2.43</td>
              <td style="border:none;" align="char" char=".">0.34</td>
              <td style="border:none;" align="char" char=".">58</td>
              <td style="border:none;" align="char" char=".">105</td>
              <td style="border:none;" align="char" char=".">246</td>
              <td style="border:none;" align="char" char=".">22</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">uXGB</td>
              <td style="border:none;" align="char" char=".">0.68</td>
              <td style="border:none;" align="char" char=".">0.72</td>
              <td style="border:none;" align="char" char=".">0.70</td>
              <td style="border:none;" align="char" char=".">0.72</td>
              <td style="border:none;" align="char" char=".">0.44</td>
              <td style="border:none;" align="char" char=".">2.43</td>
              <td style="border:none;" align="char" char=".">0.32</td>
              <td style="border:none;" align="char" char=".">54</td>
              <td style="border:none;" align="char" char=".">98</td>
              <td style="border:none;" align="char" char=".">253</td>
              <td style="border:none;" align="char" char=".">26</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="t3fn1">
            <label>a</label>
            <p>For each model, the following statistics
are reported: sensitivity (SE), specificity (SP), balanced accuracy
(BA), area under the ROC (AUC), negative likelihood ratio (−LR),
positive likelihood ratio (+LR), Matthews correlation coefficient
(MCC), number of true positives (TPs), false positives (FPs), true
negatives (TNs), and false negatives (FNs).</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
    </sec>
    <sec id="sec4.2">
      <title>Validation</title>
      <p>Aimed at selecting the top-performing classifier,
the models built using BRF, uGB, uXGB, and uKNN were subjected to
a validation using the VS previously extracted from PLD-DB and comprising <bold>112</bold> compounds. Notice that to judiciously evaluate the predictiveness
of the model in real-life scenarios, VS was deliberately left imbalanced,
and the performances were computed considering only those compounds
within the AD. As evident in <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>A, the good performance observed in 5-CV is herein
confirmed for all the models, as indicated by the computed BA values
≈ 0.80, AUC &gt; 0.85, and very low −LR (ranging from
0.07
to 0.18). Importantly, acceptable differences were observed between
SE and SP, ranging from 0.20 to 0.32. <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>B displays a radar plot constructed with
the aim of selecting the top-performing classifier. Taking as a whole,
the obtained data put forward BRF, whose ROC curve is displayed in <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>C, as the model to
be selected, being able to provide the best AUC (0.90), BA (0.81),
and MCC (0.50) values. It is important to emphasize that we conducted
an additional analysis to assess the stability of the built models.
This analysis involved creating an additional set of 100 classifiers
by using different, randomly selected training sets (TS) and validation
sets (VS) while adhering to the data splitting methodology outlined
in the <xref rid="sec2" ref-type="other">Materials and Methods Section</xref>. For
each of these models, we calculated key metrics, including BA, SE,
and SP, and then examined their relative standard deviations to gauge
the stability of the classifiers. The obtained results unequivocally
demonstrate that all of the classifiers exhibit robustness and independence
from the TS and VS composition (standard deviations ≤ 0.07).
To further challenge the BRF model, an additional validation with
two different external sets (ES1 and ES2) was performed. As reported
in <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>A, an acceptable
balance between SE and SP was observed as well as high values of BA
(0.72 and 0.90 for ES1 and ES2, respectively) and AUC (0.75 and 0.94,
respectively). This is also supported by the relative ROC curves displayed
in <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>B,C.</p>
      <fig id="fig2" position="float">
        <label>Figure 2</label>
        <caption>
          <p>Selection of
the top-performing model was based on the performance
obtained in validation. (A) Table reporting the quality metrics returned
by all the developed models: sensitivity (SE), specificity (SP), balanced
accuracy (BA), area under the ROC (AUC), negative likelihood ratio
(−LR), positive likelihood ratio (+LR), Matthews correlation
coefficient (MCC), number of true positives (TPs), false positives
(FPs), true negatives (TNs), and false negatives (FNs); (B) radar
plot comparing the performance of the models; and (C) ROC curve derived
from the probability-based ranking returned by the selected classifier
(BRF).</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mp3c00964_0002" id="gr2" position="float"/>
      </fig>
      <fig id="fig3" position="float">
        <label>Figure 3</label>
        <caption>
          <p>Performance of the selected BRF model on external sets
ES1 and
ES2. (A) Table reporting the computed sensitivity (SE), specificity
(SP), balanced accuracy (BA), area under the ROC (AUC), negative likelihood
ratio (−LR), positive likelihood ratio (+LR), Matthews correlation
coefficient (MCC), number of true positives (TPs), false positives
(FPs), true negatives (TNs), and false negatives (FNs); (B, C) ROC
curve derived from the probability-based ranking returned by BRF on
ES1 and ES2, respectively.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mp3c00964_0003" id="gr3" position="float"/>
      </fig>
    </sec>
  </sec>
  <sec id="sec5">
    <title>AMALPHI: A Freely Accessible Web Platform</title>
    <p>We made available
the top-performing classifier, built using the
BRF algorithm, in a freely accessible web platform called AMALPHI
(A machine learning platform for predicting drug-induced phospholipidosis—<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ba.ic.cnr.it/softwareic/amalphiportal/">https://www.ba.ic.cnr.it/softwareic/amalphiportal/</uri>). Following an approach already employed for other web platforms
developed by our group,<sup><xref ref-type="bibr" rid="ref31">31</xref>,<xref ref-type="bibr" rid="ref32">32</xref></sup> the user can draw a
2D structure of her/his query molecule using the JSME canvas applet<sup><xref ref-type="bibr" rid="ref49">49</xref></sup> or, alternatively, insert the relative SMILES
string directly into the provided text field. Additionally, to facilitate
the use of the platform for virtual screening applications, the user
can upload a .txt file containing a list of SMILES strings. This can
be achieved by clicking on the “MASSIVE” button. Once
the file is uploaded or the query molecule is drawn, AMALPHI generates
predictions regarding the PLD inducer potential of each compound used
as input. The results are displayed as “YES” if the
BRF model predicts the query to be a PLD inducer and conversely as
“NO” if it is not. Notably, information on the reliability
of the performed predictions is also provided, based on the considered
AD. Finally, the user can download the produced output as .csv file.
It is worth noting that a link to download the predictions is sent
to the user’s registered email address. Additionally, the “History”
page maintains a record of all user executions, preserving input SMILES
files and their corresponding output. <xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref> shows an example of an output page generated
by the tool.</p>
    <fig id="fig4" position="float">
      <label>Figure 4</label>
      <caption>
        <p>Example of the output page returned by the AMALPHI web
platform.</p>
      </caption>
      <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mp3c00964_0004" id="gr4" position="float"/>
    </fig>
  </sec>
  <sec id="sec6">
    <title>Conclusions</title>
    <p>In an era where accurate prediction of
pharmacological and toxicological
properties of organic molecules is becoming fundamental to significantly
expedite the drug discovery process in both academia and industry,
expensive and time-consuming traditional approaches are increasingly
giving way to the use of computational technologies. In this regard,
this study focuses on the development of multiple machine learning
models capable of predicting the PLD-inducing potential, employing
different ML algorithms (RF, KNN, GB, and XGB). Following data extraction
from ChEMBL v30 and subsequent analysis of experimental phospholipidosis
data concerning <bold>851</bold> compounds, we applied rigorous data
curation practices to create PLD-DB comprising <bold>545</bold> compounds
and used them to build different PLD-inducing potential classifiers.
The analysis of the obtained validation performances in validation
yields similar values for all of the models trained using techniques
that consider data imbalance (BRF, uKNN, uGB, and uXGB), among which
the top-performing one was BRF, capable of providing the best AUC
(0.90), BA (0.81), and MCC (0.50). Furthermore, external validation
using two different external sets (ES1 and ES2) returned high values
of BA (0.72 and 0.9, respectively) and AUC (0.75 and 0.94, respectively).
Collectively, these promising results led us to make the top-performing
classifier available through a user-friendly web platform developed
by our group and named AMALPHI (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ba.ic.cnr.it/softwareic/amalphiportal/">https://www.ba.ic.cnr.it/softwareic/amalphiportal/</uri>). AMALPHI is the first freely accessible tool capable of efficiently
predicting the PLD potential of drug candidates. It can assist medicinal
chemists in proactively identifying safe drug candidates during the
research and development of pharmacologically active molecules and
in prioritizing drugs with a low probability of exhibiting false in
vitro antiviral activity.</p>
  </sec>
</body>
<back>
  <notes id="notes-1" notes-type="si">
    <title>Supporting Information Available</title>
    <p>The Supporting Information
is available free of charge at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/10.1021/acs.molpharmaceut.3c00964?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.molpharmaceut.3c00964</ext-link>.<list id="silist" list-type="simple"><list-item><p>PLDBD excel file containing the <bold>545</bold> SMILES
strings of the chemicals belonging to the PLDBD data set and the corresponding
experimental values (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.molpharmaceut.3c00964/suppl_file/mp3c00964_si_001.xlsx">XLSX</ext-link>)</p></list-item><list-item><p>ES1 file containing the 117 SMILES strings of the chemicals
belonging to the ES1 data set and the corresponding experimental values
(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.molpharmaceut.3c00964/suppl_file/mp3c00964_si_002.xlsx">XLSX</ext-link>)</p></list-item><list-item><p>ES2
excel file containing the 20 SMILES strings of the
chemicals belonging to the ES2 data set and the corresponding experimental
values (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.molpharmaceut.3c00964/suppl_file/mp3c00964_si_003.xlsx">XLSX</ext-link>)</p></list-item></list></p>
  </notes>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material content-type="local-data" id="sifile1">
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mp3c00964_si_001.xlsx">
        <caption>
          <p>mp3c00964_si_001.xlsx</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="sifile2">
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mp3c00964_si_002.xlsx">
        <caption>
          <p>mp3c00964_si_002.xlsx</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="sifile3">
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mp3c00964_si_003.xlsx">
        <caption>
          <p>mp3c00964_si_003.xlsx</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
  <notes notes-type="COI-statement" id="notes-2">
    <p>The authors
declare no competing financial interest.</p>
  </notes>
  <ack>
    <title>Acknowledgments</title>
    <p>This work was funded by the National Research Council (CNR–Italy)
under the program “PROGETTI DI RICERCA @CNR” (acronym
DATIAMO) and by the European Union (Next Generation EU) under the
program PRIN of the Ministero Dell'Università e della
Ricerca
(Progetti di ricerca di Rilevante Interesse Nazionale 2022–2022Z3BBPE—Development
of broad-spectrum coronavirus antiviral agents acting as allosteric
modulators of the host protein sigma-1). The salary of Dr. Maria Cristina
Lomuscio was funded by REGIONE PUGLIA under the program RIPARTI (assegni
di RIcerca in PARTenariato con le Imprese). The authors thank Dr.
Ivan Mercurio for providing graphical support in creating the AMALPHI
logo and Biofordrug srl (via Dante 95/99, 70019, Triggiano, Bari)
for scientific and technological support.</p>
  </ack>
  <ref-list>
    <title>References</title>
    <ref id="ref1">
      <mixed-citation publication-type="journal" id="cit1"><name><surname>Lüllmann</surname><given-names>H.</given-names></name>; <name><surname>Lüllmann-Rauch</surname><given-names>R.</given-names></name>; <name><surname>Wassermann</surname><given-names>O.</given-names></name><article-title>Drug-Induced
Phospholipidoses. II. Tissue Distribution of the Amphiphilic Drug
Chlorphentermine</article-title>. <source>CRC Crit. Rev. Toxicol.</source><year>1975</year>, <volume>4</volume> (<issue>2</issue>), <fpage>185</fpage>–<lpage>218</lpage>. <pub-id pub-id-type="doi">10.1080/10408447509164014</pub-id>.<pub-id pub-id-type="pmid">2448</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref2">
      <mixed-citation publication-type="journal" id="cit2"><name><surname>Kubo</surname><given-names>M.</given-names></name>; <name><surname>Hostetler</surname><given-names>K. Y.</given-names></name><article-title>Mechanism
of Cationic Amphiphilic Drug Inhibition of
Purified Lysosomal Phospholipase A1</article-title>. <source>Biochemistry</source><year>1985</year>, <volume>24</volume> (<issue>23</issue>), <fpage>6515</fpage>–<lpage>6520</lpage>. <pub-id pub-id-type="doi">10.1021/bi00344a031</pub-id>.<pub-id pub-id-type="pmid">4084534</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref3">
      <mixed-citation publication-type="journal" id="cit3"><name><surname>Lüllmann</surname><given-names>H.</given-names></name>; <name><surname>Lüllmann-Rauch</surname><given-names>R.</given-names></name>; <name><surname>Wassermann</surname><given-names>O.</given-names></name><article-title>Lipidosis
Induced by Amphiphilic Cationic Drugs</article-title>. <source>Biochem.
Pharmacol.</source><year>1978</year>, <volume>27</volume> (<issue>8</issue>), <fpage>1103</fpage>–<lpage>1108</lpage>. <pub-id pub-id-type="doi">10.1016/0006-2952(78)90435-5</pub-id>.<pub-id pub-id-type="pmid">358990</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref4">
      <mixed-citation publication-type="journal" id="cit4"><name><surname>Pappu</surname><given-names>A.</given-names></name>; <name><surname>Hostetler</surname><given-names>K. Y.</given-names></name><article-title>Effect of Cationic Amphiphilic Drugs
on the Hydrolysis
of Acidic and Neutral Phospholipids by Liver Lysosomal Phospholipase
A</article-title>. <source>Biochem. Pharmacol.</source><year>1984</year>, <volume>33</volume> (<issue>10</issue>), <fpage>1639</fpage>–<lpage>1644</lpage>. <pub-id pub-id-type="doi">10.1016/0006-2952(84)90286-7</pub-id>.<pub-id pub-id-type="pmid">6732837</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref5">
      <mixed-citation publication-type="journal" id="cit5"><name><surname>Lowe</surname><given-names>R.</given-names></name>; <name><surname>Mussa</surname><given-names>H. Y.</given-names></name>; <name><surname>Nigsch</surname><given-names>F.</given-names></name>; <name><surname>Glen</surname><given-names>R. C.</given-names></name>; <name><surname>Mitchell</surname><given-names>J. B.</given-names></name><article-title>Predicting
the Mechanism of Phospholipidosis</article-title>. <source>J. Cheminf.</source><year>2012</year>, <volume>4</volume> (<issue>1</issue>), <fpage>2</fpage><pub-id pub-id-type="doi">10.1186/1758-2946-4-2</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref6">
      <mixed-citation publication-type="journal" id="cit6"><name><surname>Breiden</surname><given-names>B.</given-names></name>; <name><surname>Sandhoff</surname><given-names>K.</given-names></name><article-title>Emerging Mechanisms
of Drug-Induced Phospholipidosis</article-title>. <source>Biol. Chem.</source><year>2019</year>, <volume>401</volume> (<issue>1</issue>), <fpage>31</fpage>–<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1515/hsz-2019-0270</pub-id>.<pub-id pub-id-type="pmid">31408430</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref7">
      <mixed-citation publication-type="journal" id="cit7"><name><surname>Kruhlak</surname><given-names>N. L.</given-names></name>; <name><surname>Choi</surname><given-names>S. S.</given-names></name>; <name><surname>Contrera</surname><given-names>J. F.</given-names></name>; <name><surname>Weaver</surname><given-names>J. L.</given-names></name>; <name><surname>Willard</surname><given-names>J. M.</given-names></name>; <name><surname>Hastings</surname><given-names>K. L.</given-names></name>; <name><surname>Sancilio</surname><given-names>L. F.</given-names></name><article-title>Development of a Phospholipidosis
Database and Predictive Quantitative Structure-Activity Relationship
(QSAR) Models</article-title>. <source>Toxicol. Mech. Methods</source><year>2008</year>, <volume>18</volume> (<issue>2–3</issue>), <fpage>217</fpage>–<lpage>227</lpage>. <pub-id pub-id-type="doi">10.1080/15376510701857262</pub-id>.<pub-id pub-id-type="pmid">20020916</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref8">
      <mixed-citation publication-type="journal" id="cit8"><name><surname>Ettlin</surname><given-names>R. A.</given-names></name>; <name><surname>Kuroda</surname><given-names>J.</given-names></name>; <name><surname>Plassmann</surname><given-names>S.</given-names></name>; <name><surname>Hayashi</surname><given-names>M.</given-names></name>; <name><surname>Prentice</surname><given-names>D. E.</given-names></name><article-title>Successful
Drug Development Despite Adverse Preclinical Findings Part 2: Examples</article-title>. <source>J. Toxicol. Pathol.</source><year>2010</year>, <volume>23</volume> (<issue>4</issue>), <fpage>213</fpage>–<lpage>234</lpage>. <pub-id pub-id-type="doi">10.1293/tox.23.213</pub-id>.<pub-id pub-id-type="pmid">22272032</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref9">
      <mixed-citation publication-type="journal" id="cit9"><name><surname>Gunesch</surname><given-names>A. P.</given-names></name>; <name><surname>Zapatero-Belinchón</surname><given-names>F. J.</given-names></name>; <name><surname>Pinkert</surname><given-names>L.</given-names></name>; <name><surname>Steinmann</surname><given-names>E.</given-names></name>; <name><surname>Manns</surname><given-names>M. P.</given-names></name>; <name><surname>Schneider</surname><given-names>G.</given-names></name>; <name><surname>Pietschmann</surname><given-names>T.</given-names></name>; <name><surname>Brönstrup</surname><given-names>M.</given-names></name>; <name><surname>von Hahn</surname><given-names>T.</given-names></name><article-title>Filovirus Antiviral
Activity of Cationic
Amphiphilic Drugs Is Associated with Lipophilicity and Ability To
Induce Phospholipidosis</article-title>. <source>Antimicrob. Agents
Chemother.</source><year>2020</year>, <volume>64</volume> (<issue>8</issue>), <fpage>10</fpage>–<lpage>1128</lpage>. <pub-id pub-id-type="doi">10.1128/aac.00143-20</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref10">
      <mixed-citation publication-type="journal" id="cit10"><name><surname>Tummino</surname><given-names>T. A.</given-names></name>; <name><surname>Rezelj</surname><given-names>V. V.</given-names></name>; <name><surname>Fischer</surname><given-names>B.</given-names></name>; <name><surname>Fischer</surname><given-names>A.</given-names></name>; <name><surname>O’Meara</surname><given-names>M. J.</given-names></name>; <name><surname>Monel</surname><given-names>B.</given-names></name>; <name><surname>Vallet</surname><given-names>T.</given-names></name>; <name><surname>White</surname><given-names>K. M.</given-names></name>; <name><surname>Zhang</surname><given-names>Z.</given-names></name>; <name><surname>Alon</surname><given-names>A.</given-names></name>; <name><surname>Schadt</surname><given-names>H.</given-names></name>; <name><surname>O’Donnell</surname><given-names>H. R.</given-names></name>; <name><surname>Lyu</surname><given-names>J.</given-names></name>; <name><surname>Rosales</surname><given-names>R.</given-names></name>; <name><surname>McGovern</surname><given-names>B. L.</given-names></name>; <name><surname>Rathnasinghe</surname><given-names>R.</given-names></name>; <name><surname>Jangra</surname><given-names>S.</given-names></name>; <name><surname>Schotsaert</surname><given-names>M.</given-names></name>; <name><surname>Galarneau</surname><given-names>J.-R.</given-names></name>; <name><surname>Krogan</surname><given-names>N. J.</given-names></name>; <name><surname>Urban</surname><given-names>L.</given-names></name>; <name><surname>Shokat</surname><given-names>K. M.</given-names></name>; <name><surname>Kruse</surname><given-names>A. C.</given-names></name>; <name><surname>García-Sastre</surname><given-names>A.</given-names></name>; <name><surname>Schwartz</surname><given-names>O.</given-names></name>; <name><surname>Moretti</surname><given-names>F.</given-names></name>; <name><surname>Vignuzzi</surname><given-names>M.</given-names></name>; <name><surname>Pognan</surname><given-names>F.</given-names></name>; <name><surname>Shoichet</surname><given-names>B. K.</given-names></name><article-title>Drug-Induced
Phospholipidosis Confounds
Drug Repurposing for SARS-CoV-2</article-title>. <source>Science</source><year>2021</year>, <volume>373</volume> (<issue>6554</issue>), <fpage>541</fpage>–<lpage>547</lpage>. <pub-id pub-id-type="doi">10.1126/science.abi4708</pub-id>.<pub-id pub-id-type="pmid">34326236</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref11">
      <mixed-citation publication-type="journal" id="cit11"><name><surname>Gordon</surname><given-names>D. E.</given-names></name>; <name><surname>Jang</surname><given-names>G. M.</given-names></name>; <name><surname>Bouhaddou</surname><given-names>M.</given-names></name>; <name><surname>Xu</surname><given-names>J.</given-names></name>; <name><surname>Obernier</surname><given-names>K.</given-names></name>; <name><surname>White</surname><given-names>K. M.</given-names></name>; <name><surname>O’Meara</surname><given-names>M. J.</given-names></name>; <name><surname>Rezelj</surname><given-names>V. V.</given-names></name>; <name><surname>Guo</surname><given-names>J. Z.</given-names></name>; <name><surname>Swaney</surname><given-names>D. L.</given-names></name>; <name><surname>Tummino</surname><given-names>T. A.</given-names></name>; <name><surname>Hüttenhain</surname><given-names>R.</given-names></name>; <name><surname>Kaake</surname><given-names>R. M.</given-names></name>; <name><surname>Richards</surname><given-names>A. L.</given-names></name>; <name><surname>Tutuncuoglu</surname><given-names>B.</given-names></name>; <name><surname>Foussard</surname><given-names>H.</given-names></name>; <name><surname>Batra</surname><given-names>J.</given-names></name>; <name><surname>Haas</surname><given-names>K.</given-names></name>; <name><surname>Modak</surname><given-names>M.</given-names></name>; <name><surname>Kim</surname><given-names>M.</given-names></name>; <name><surname>Haas</surname><given-names>P.</given-names></name>; <name><surname>Polacco</surname><given-names>B. J.</given-names></name>; <name><surname>Braberg</surname><given-names>H.</given-names></name>; <name><surname>Fabius</surname><given-names>J. M.</given-names></name>; <name><surname>Eckhardt</surname><given-names>M.</given-names></name>; <name><surname>Soucheray</surname><given-names>M.</given-names></name>; <name><surname>Bennett</surname><given-names>M. J.</given-names></name>; <name><surname>Cakir</surname><given-names>M.</given-names></name>; <name><surname>McGregor</surname><given-names>M. J.</given-names></name>; <name><surname>Li</surname><given-names>Q.</given-names></name>; <name><surname>Meyer</surname><given-names>B.</given-names></name>; <name><surname>Roesch</surname><given-names>F.</given-names></name>; <name><surname>Vallet</surname><given-names>T.</given-names></name>; <name><surname>Mac Kain</surname><given-names>A.</given-names></name>; <name><surname>Miorin</surname><given-names>L.</given-names></name>; <name><surname>Moreno</surname><given-names>E.</given-names></name>; <name><surname>Naing</surname><given-names>Z. Z. C.</given-names></name>; <name><surname>Zhou</surname><given-names>Y.</given-names></name>; <name><surname>Peng</surname><given-names>S.</given-names></name>; <name><surname>Shi</surname><given-names>Y.</given-names></name>; <name><surname>Zhang</surname><given-names>Z.</given-names></name>; <name><surname>Shen</surname><given-names>W.</given-names></name>; <name><surname>Kirby</surname><given-names>I. T.</given-names></name>; <name><surname>Melnyk</surname><given-names>J. E.</given-names></name>; <name><surname>Chorba</surname><given-names>J. S.</given-names></name>; <name><surname>Lou</surname><given-names>K.</given-names></name>; <name><surname>Dai</surname><given-names>S. A.</given-names></name>; <name><surname>Barrio-Hernandez</surname><given-names>I.</given-names></name>; <name><surname>Memon</surname><given-names>D.</given-names></name>; <name><surname>Hernandez-Armenta</surname><given-names>C.</given-names></name>; <name><surname>Lyu</surname><given-names>J.</given-names></name>; <name><surname>Mathy</surname><given-names>C. J. P.</given-names></name>; <name><surname>Perica</surname><given-names>T.</given-names></name>; <name><surname>Pilla</surname><given-names>K. B.</given-names></name>; <name><surname>Ganesan</surname><given-names>S. J.</given-names></name>; <name><surname>Saltzberg</surname><given-names>D. J.</given-names></name>; <name><surname>Rakesh</surname><given-names>R.</given-names></name>; <name><surname>Liu</surname><given-names>X.</given-names></name>; <name><surname>Rosenthal</surname><given-names>S. B.</given-names></name>; <name><surname>Calviello</surname><given-names>L.</given-names></name>; <name><surname>Venkataramanan</surname><given-names>S.</given-names></name>; <name><surname>Liboy-Lugo</surname><given-names>J.</given-names></name>; <name><surname>Lin</surname><given-names>Y.</given-names></name>; <name><surname>Huang</surname><given-names>X.-P.</given-names></name>; <name><surname>Liu</surname><given-names>Y.</given-names></name>; <name><surname>Wankowicz</surname><given-names>S. A.</given-names></name>; <name><surname>Bohn</surname><given-names>M.</given-names></name>; <name><surname>Safari</surname><given-names>M.</given-names></name>; <name><surname>Ugur</surname><given-names>F. S.</given-names></name>; <name><surname>Koh</surname><given-names>C.</given-names></name>; <name><surname>Savar</surname><given-names>N. S.</given-names></name>; <name><surname>Tran</surname><given-names>Q. D.</given-names></name>; <name><surname>Shengjuler</surname><given-names>D.</given-names></name>; <name><surname>Fletcher</surname><given-names>S. J.</given-names></name>; <name><surname>O’Neal</surname><given-names>M. C.</given-names></name>; <name><surname>Cai</surname><given-names>Y.</given-names></name>; <name><surname>Chang</surname><given-names>J. C. J.</given-names></name>; <name><surname>Broadhurst</surname><given-names>D. J.</given-names></name>; <name><surname>Klippsten</surname><given-names>S.</given-names></name>; <name><surname>Sharp</surname><given-names>P. P.</given-names></name>; <name><surname>Wenzell</surname><given-names>N. A.</given-names></name>; <name><surname>Kuzuoglu-Ozturk</surname><given-names>D.</given-names></name>; <name><surname>Wang</surname><given-names>H.-Y.</given-names></name>; <name><surname>Trenker</surname><given-names>R.</given-names></name>; <name><surname>Young</surname><given-names>J. M.</given-names></name>; <name><surname>Cavero</surname><given-names>D. A.</given-names></name>; <name><surname>Hiatt</surname><given-names>J.</given-names></name>; <name><surname>Roth</surname><given-names>T. L.</given-names></name>; <name><surname>Rathore</surname><given-names>U.</given-names></name>; <name><surname>Subramanian</surname><given-names>A.</given-names></name>; <name><surname>Noack</surname><given-names>J.</given-names></name>; <name><surname>Hubert</surname><given-names>M.</given-names></name>; <name><surname>Stroud</surname><given-names>R. M.</given-names></name>; <name><surname>Frankel</surname><given-names>A. D.</given-names></name>; <name><surname>Rosenberg</surname><given-names>O. S.</given-names></name>; <name><surname>Verba</surname><given-names>K. A.</given-names></name>; <name><surname>Agard</surname><given-names>D. A.</given-names></name>; <name><surname>Ott</surname><given-names>M.</given-names></name>; <name><surname>Emerman</surname><given-names>M.</given-names></name>; <name><surname>Jura</surname><given-names>N.</given-names></name>; <name><surname>von Zastrow</surname><given-names>M.</given-names></name>; <name><surname>Verdin</surname><given-names>E.</given-names></name>; <name><surname>Ashworth</surname><given-names>A.</given-names></name>; <name><surname>Schwartz</surname><given-names>O.</given-names></name>; <name><surname>d’Enfert</surname><given-names>C.</given-names></name>; <name><surname>Mukherjee</surname><given-names>S.</given-names></name>; <name><surname>Jacobson</surname><given-names>M.</given-names></name>; <name><surname>Malik</surname><given-names>H. S.</given-names></name>; <name><surname>Fujimori</surname><given-names>D. G.</given-names></name>; <name><surname>Ideker</surname><given-names>T.</given-names></name>; <name><surname>Craik</surname><given-names>C. S.</given-names></name>; <name><surname>Floor</surname><given-names>S. N.</given-names></name>; <name><surname>Fraser</surname><given-names>J. S.</given-names></name>; <name><surname>Gross</surname><given-names>J. D.</given-names></name>; <name><surname>Sali</surname><given-names>A.</given-names></name>; <name><surname>Roth</surname><given-names>B. L.</given-names></name>; <name><surname>Ruggero</surname><given-names>D.</given-names></name>; <name><surname>Taunton</surname><given-names>J.</given-names></name>; <name><surname>Kortemme</surname><given-names>T.</given-names></name>; <name><surname>Beltrao</surname><given-names>P.</given-names></name>; <name><surname>Vignuzzi</surname><given-names>M.</given-names></name>; <name><surname>García-Sastre</surname><given-names>A.</given-names></name>; <name><surname>Shokat</surname><given-names>K. M.</given-names></name>; <name><surname>Shoichet</surname><given-names>B. K.</given-names></name>; <name><surname>Krogan</surname><given-names>N. J.</given-names></name><article-title>A SARS-CoV-2
Protein Interaction Map Reveals Targets for Drug Repurposing</article-title>. <source>Nature</source><year>2020</year>, <volume>583</volume> (<issue>7816</issue>), <fpage>459</fpage>–<lpage>468</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2286-9</pub-id>.<pub-id pub-id-type="pmid">32353859</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref12">
      <mixed-citation publication-type="journal" id="cit12"><name><surname>Abatematteo</surname><given-names>F. S.</given-names></name>; <name><surname>Delre</surname><given-names>P.</given-names></name>; <name><surname>Mercurio</surname><given-names>I.</given-names></name>; <name><surname>Rezelj</surname><given-names>V. V.</given-names></name>; <name><surname>Siliqi</surname><given-names>D.</given-names></name>; <name><surname>Beaucourt</surname><given-names>S.</given-names></name>; <name><surname>Lattanzi</surname><given-names>G.</given-names></name>; <name><surname>Colabufo</surname><given-names>N. A.</given-names></name>; <name><surname>Leopoldo</surname><given-names>M.</given-names></name>; <name><surname>Saviano</surname><given-names>M.</given-names></name>; <name><surname>Vignuzzi</surname><given-names>M.</given-names></name>; <name><surname>Mangiatordi</surname><given-names>G. F.</given-names></name>; <name><surname>Abate</surname><given-names>C.</given-names></name><article-title>A Conformational Rearrangement
of the SARS-CoV-2 Host Protein Sigma-1
Is Required for Antiviral Activity: Insights from a Combined in-Silico/in-Vitro
Approach</article-title>. <source>Sci. Rep.</source><year>2023</year>, <volume>13</volume> (<issue>1</issue>), <elocation-id>12798</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-023-39662-w</pub-id>.<pub-id pub-id-type="pmid">37550340</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref13">
      <mixed-citation publication-type="journal" id="cit13"><name><surname>Diesendorf</surname><given-names>V.</given-names></name>; <name><surname>Roll</surname><given-names>V.</given-names></name>; <name><surname>Geiger</surname><given-names>N.</given-names></name>; <name><surname>Fähr</surname><given-names>S.</given-names></name>; <name><surname>Obernolte</surname><given-names>H.</given-names></name>; <name><surname>Sewald</surname><given-names>K.</given-names></name>; <name><surname>Bodem</surname><given-names>J.</given-names></name><article-title>Drug-Induced Phospholipidosis
Is Not Correlated with the Inhibition of SARS-CoV-2 - Inhibition of
SARS-CoV-2 Is Cell Line-Specific</article-title>. <source>Front. Cell
Infect. Microbiol.</source><year>2023</year>, <volume>13</volume>, <elocation-id>1100028</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2023.1100028</pub-id>.<pub-id pub-id-type="pmid">37637460</pub-id></mixed-citation>
    </ref>
    <ref id="ref14">
      <mixed-citation publication-type="journal" id="cit14"><name><surname>Lane</surname><given-names>T. R.</given-names></name>; <name><surname>Ekins</surname><given-names>S.</given-names></name><article-title>Defending Antiviral Cationic Amphiphilic
Drugs That May Cause Drug-Induced
Phospholipidosis</article-title>. <source>J. Chem. Inf. Model.</source><year>2021</year>, <volume>61</volume> (<issue>9</issue>), <fpage>4125</fpage>–<lpage>4130</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.1c00903</pub-id>.<pub-id pub-id-type="pmid">34516123</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref15">
      <mixed-citation publication-type="journal" id="cit15"><name><surname>Atienzar</surname><given-names>F.</given-names></name>; <name><surname>Gerets</surname><given-names>H.</given-names></name>; <name><surname>Dufrane</surname><given-names>S.</given-names></name>; <name><surname>Tilmant</surname><given-names>K.</given-names></name>; <name><surname>Cornet</surname><given-names>M.</given-names></name>; <name><surname>Dhalluin</surname><given-names>S.</given-names></name>; <name><surname>Ruty</surname><given-names>B.</given-names></name>; <name><surname>Rose</surname><given-names>G.</given-names></name>; <name><surname>Canning</surname><given-names>M.</given-names></name><article-title>Determination
of Phospholipidosis Potential Based on Gene Expression Analysis in
HepG2 Cells</article-title>. <source>Toxicol. Sci.</source><year>2006</year>, <volume>96</volume> (<issue>1</issue>), <fpage>101</fpage>–<lpage>114</lpage>. <pub-id pub-id-type="doi">10.1093/toxsci/kfl184</pub-id>.<pub-id pub-id-type="pmid">17175557</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref16">
      <mixed-citation publication-type="journal" id="cit16"><name><surname>Ulrich</surname><given-names>R. G.</given-names></name>; <name><surname>Kilgore</surname><given-names>K. S.</given-names></name>; <name><surname>Sun</surname><given-names>E. L.</given-names></name>; <name><surname>Cramer</surname><given-names>C. T.</given-names></name>; <name><surname>Ginsberg</surname><given-names>L. C.</given-names></name><article-title>An in Vitro
Fluorescence Assay for the Detection of Drug-Induced Cytoplasmic Lamellar
Bodies</article-title>. <source>Toxicol. Methods</source><year>1991</year>, <volume>1</volume> (<issue>2</issue>), <fpage>89</fpage>–<lpage>105</lpage>. <pub-id pub-id-type="doi">10.3109/15376519109044560</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref17">
      <mixed-citation publication-type="journal" id="cit17"><name><surname>Gum</surname><given-names>R. J.</given-names></name>; <name><surname>Hickman</surname><given-names>D.</given-names></name>; <name><surname>Fagerland</surname><given-names>J. A.</given-names></name>; <name><surname>Heindel</surname><given-names>M. A.</given-names></name>; <name><surname>Gagne</surname><given-names>G. D.</given-names></name>; <name><surname>Schmidt</surname><given-names>J. M.</given-names></name>; <name><surname>Michaelides</surname><given-names>M. R.</given-names></name>; <name><surname>Davidsen</surname><given-names>S. K.</given-names></name>; <name><surname>Ulrich</surname><given-names>R. G.</given-names></name><article-title>Analysis
of Two Matrix Metalloproteinase Inhibitors and Their Metabolites for
Induction of Phospholipidosis in Rat and Human Hepatocytes(1)</article-title>. <source>Biochem. Pharmacol.</source><year>2001</year>, <volume>62</volume> (<issue>12</issue>), <fpage>1661</fpage>–<lpage>1673</lpage>. <pub-id pub-id-type="doi">10.1016/S0006-2952(01)00823-1</pub-id>.<pub-id pub-id-type="pmid">11755120</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref18">
      <mixed-citation publication-type="journal" id="cit18"><name><surname>Casartelli</surname><given-names>A.</given-names></name>; <name><surname>Bonato</surname><given-names>M.</given-names></name>; <name><surname>Cristofori</surname><given-names>P.</given-names></name>; <name><surname>Crivellente</surname><given-names>F.</given-names></name>; <name><surname>Dal Negro</surname><given-names>G.</given-names></name>; <name><surname>Masotto</surname><given-names>I.</given-names></name>; <name><surname>Mutinelli</surname><given-names>C.</given-names></name>; <name><surname>Valko</surname><given-names>K.</given-names></name>; <name><surname>Bonfante</surname><given-names>V.</given-names></name><article-title>A Cell-Based Approach for the Early
Assessment of the Phospholipidogenic Potential in Pharmaceutical Research
and Drug Development</article-title>. <source>Cell Biol. Toxicol.</source><year>2003</year>, <volume>19</volume> (<issue>3</issue>), <fpage>161</fpage>–<lpage>176</lpage>. <pub-id pub-id-type="doi">10.1023/A:1024778329320</pub-id>.<pub-id pub-id-type="pmid">12945744</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref19">
      <mixed-citation publication-type="journal" id="cit19"><name><surname>Kasahara</surname><given-names>T.</given-names></name>; <name><surname>Tomita</surname><given-names>K.</given-names></name>; <name><surname>Murano</surname><given-names>H.</given-names></name>; <name><surname>Harada</surname><given-names>T.</given-names></name>; <name><surname>Tsubakimoto</surname><given-names>K.</given-names></name>; <name><surname>Ogihara</surname><given-names>T.</given-names></name>; <name><surname>Ohnishi</surname><given-names>S.</given-names></name>; <name><surname>Kakinuma</surname><given-names>C.</given-names></name><article-title>Establishment of an
in Vitro High-Throughput Screening Assay for Detecting Phospholipidosis-Inducing
Potential</article-title>. <source>Toxicol. Sci.</source><year>2006</year>, <volume>90</volume> (<issue>1</issue>), <fpage>133</fpage>–<lpage>141</lpage>. <pub-id pub-id-type="doi">10.1093/toxsci/kfj067</pub-id>.<pub-id pub-id-type="pmid">16338956</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref20">
      <mixed-citation publication-type="journal" id="cit20"><name><surname>Morelli</surname><given-names>J. K.</given-names></name>; <name><surname>Buehrle</surname><given-names>M.</given-names></name>; <name><surname>Pognan</surname><given-names>F.</given-names></name>; <name><surname>Barone</surname><given-names>L. R.</given-names></name>; <name><surname>Fieles</surname><given-names>W.</given-names></name>; <name><surname>Ciaccio</surname><given-names>P. J.</given-names></name><article-title>Validation of an
in Vitro Screen for Phospholipidosis
Using a High-Content Biology Platform</article-title>. <source>Cell
Biol. Toxicol.</source><year>2006</year>, <volume>22</volume> (<issue>1</issue>), <fpage>15</fpage>–<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1007/s10565-006-0176-z</pub-id>.<pub-id pub-id-type="pmid">16463016</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref21">
      <mixed-citation publication-type="journal" id="cit21"><name><surname>Sawada</surname><given-names>H.</given-names></name>; <name><surname>Takami</surname><given-names>K.</given-names></name>; <name><surname>Asahi</surname><given-names>S.</given-names></name><article-title>A Toxicogenomic Approach
to Drug-Induced
Phospholipidosis: Analysis of Its Induction Mechanism and Establishment
of a Novel in Vitro Screening System</article-title>. <source>Toxicol.
Sci.</source><year>2004</year>, <volume>83</volume> (<issue>2</issue>), <fpage>282</fpage>–<lpage>292</lpage>. <pub-id pub-id-type="doi">10.1093/toxsci/kfh264</pub-id>.<pub-id pub-id-type="pmid">15342952</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref22">
      <mixed-citation publication-type="journal" id="cit22"><name><surname>Reasor</surname><given-names>M. J.</given-names></name>; <name><surname>Hastings</surname><given-names>K. L.</given-names></name>; <name><surname>Ulrich</surname><given-names>R. G.</given-names></name><article-title>Drug-Induced
Phospholipidosis: Issues
and Future Directions</article-title>. <source>Expert Opin. Drug Saf.</source><year>2006</year>, <volume>5</volume> (<issue>4</issue>), <fpage>567</fpage>–<lpage>583</lpage>. <pub-id pub-id-type="doi">10.1517/14740338.5.4.567</pub-id>.<pub-id pub-id-type="pmid">16774494</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref23">
      <mixed-citation publication-type="journal" id="cit23"><name><surname>Goracci</surname><given-names>L.</given-names></name>; <name><surname>Ceccarelli</surname><given-names>M.</given-names></name>; <name><surname>Bonelli</surname><given-names>D.</given-names></name>; <name><surname>Cruciani</surname><given-names>G.</given-names></name><article-title>Modeling Phospholipidosis
Induction: Reliability and Warnings</article-title>. <source>J. Chem.
Inf. Model.</source><year>2013</year>, <volume>53</volume> (<issue>6</issue>), <fpage>1436</fpage>–<lpage>1446</lpage>. <pub-id pub-id-type="doi">10.1021/ci400113t</pub-id>.<pub-id pub-id-type="pmid">23692521</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref24">
      <mixed-citation publication-type="journal" id="cit24"><name><surname>Macip</surname><given-names>G.</given-names></name>; <name><surname>Garcia-Segura</surname><given-names>P.</given-names></name>; <name><surname>Mestres-Truyol</surname><given-names>J.</given-names></name>; <name><surname>Saldivar-Espinoza</surname><given-names>B.</given-names></name>; <name><surname>Ojeda-Montes</surname><given-names>M. J.</given-names></name>; <name><surname>Gimeno</surname><given-names>A.</given-names></name>; <name><surname>Cereto-Massagué</surname><given-names>A.</given-names></name>; <name><surname>Garcia-Vallvé</surname><given-names>S.</given-names></name>; <name><surname>Pujadas</surname><given-names>G.</given-names></name><article-title>Haste Makes Waste: A Critical Review
of Docking-based Virtual Screening in Drug Repurposing for SARS-CoV-2
Main Protease (M-pro) Inhibition</article-title>. <source>Med. Res.
Rev.</source><year>2022</year>, <volume>42</volume> (<issue>2</issue>), <fpage>744</fpage>–<lpage>769</lpage>. <pub-id pub-id-type="doi">10.1002/med.21862</pub-id>.<pub-id pub-id-type="pmid">34697818</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref25">
      <mixed-citation publication-type="journal" id="cit25"><name><surname>Lowe</surname><given-names>R.</given-names></name>; <name><surname>Glen</surname><given-names>R. C.</given-names></name>; <name><surname>Mitchell</surname><given-names>J. B. O.</given-names></name><article-title>Predicting Phospholipidosis Using
Machine Learning</article-title>. <source>Mol. Pharm.</source><year>2010</year>, <volume>7</volume> (<issue>5</issue>), <fpage>1708</fpage>–<lpage>1714</lpage>. <pub-id pub-id-type="doi">10.1021/mp100103e</pub-id>.<pub-id pub-id-type="pmid">20799726</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref26">
      <mixed-citation publication-type="journal" id="cit26"><name><surname>Orogo</surname><given-names>A. M.</given-names></name>; <name><surname>Choi</surname><given-names>S. S.</given-names></name>; <name><surname>Minnier</surname><given-names>B. L.</given-names></name>; <name><surname>Kruhlak</surname><given-names>N. L.</given-names></name><article-title>Construction and
Consensus Performance of (Q)SAR Models for Predicting Phospholipidosis
Using a Dataset of 743 Compounds</article-title>. <source>Mol. Inf.</source><year>2012</year>, <volume>31</volume> (<issue>10</issue>), <fpage>725</fpage>–<lpage>739</lpage>. <pub-id pub-id-type="doi">10.1002/minf.201200048</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref27">
      <mixed-citation publication-type="journal" id="cit27"><name><surname>Fusani</surname><given-names>L.</given-names></name>; <name><surname>Brown</surname><given-names>M.</given-names></name>; <name><surname>Chen</surname><given-names>H.</given-names></name>; <name><surname>Ahlberg</surname><given-names>E.</given-names></name>; <name><surname>Noeske</surname><given-names>T.</given-names></name><article-title>Predicting
the Risk of Phospholipidosis with in Silico Models and an Image-Based
in Vitro Screen</article-title>. <source>Mol. Pharm.</source><year>2017</year>, <volume>14</volume> (<issue>12</issue>), <fpage>4346</fpage>–<lpage>4352</lpage>. <pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.7b00388</pub-id>.<pub-id pub-id-type="pmid">29077420</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref28">
      <mixed-citation publication-type="journal" id="cit28"><name><surname>Schieferdecker</surname><given-names>S.</given-names></name>; <name><surname>Eberlein</surname><given-names>A.</given-names></name>; <name><surname>Vock</surname><given-names>E.</given-names></name>; <name><surname>Beilmann</surname><given-names>M.</given-names></name><article-title>Development of an in
Silico Consensus Model for the Prediction of the Phospholipigenic
Potential of Small Molecules</article-title>. <source>Comput. Toxicol.</source><year>2022</year>, <volume>22</volume>, <elocation-id>100226</elocation-id><pub-id pub-id-type="doi">10.1016/j.comtox.2022.100226</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref29">
      <mixed-citation publication-type="journal" id="cit29"><name><surname>Przybylak</surname><given-names>K. R.</given-names></name>; <name><surname>Alzahrani</surname><given-names>A. R.</given-names></name>; <name><surname>Cronin</surname><given-names>M. T. D.</given-names></name><article-title>How Does the Quality of Phospholipidosis
Data Influence the Predictivity of Structural Alerts?</article-title>. <source>J. Chem. Inf. Model.</source><year>2014</year>, <volume>54</volume> (<issue>8</issue>), <fpage>2224</fpage>–<lpage>2232</lpage>. <pub-id pub-id-type="doi">10.1021/ci500233k</pub-id>.<pub-id pub-id-type="pmid">25062434</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref30">
      <mixed-citation publication-type="journal" id="cit30"><name><surname>Lagorce</surname><given-names>D.</given-names></name>; <name><surname>Bouslama</surname><given-names>L.</given-names></name>; <name><surname>Becot</surname><given-names>J.</given-names></name>; <name><surname>Miteva</surname><given-names>M. A.</given-names></name>; <name><surname>Villoutreix</surname><given-names>B. O.</given-names></name><article-title>FAF-Drugs4:
Free ADME-Tox Filtering Computations for Chemical Biology and Early
Stages Drug Discovery</article-title>. <source>Bioinformatics</source><year>2017</year>, <volume>33</volume> (<issue>22</issue>), <fpage>3658</fpage>–<lpage>3660</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/btx491</pub-id>.<pub-id pub-id-type="pmid">28961788</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref31">
      <mixed-citation publication-type="journal" id="cit31"><name><surname>Creanza</surname><given-names>T. M.</given-names></name>; <name><surname>Lamanna</surname><given-names>G.</given-names></name>; <name><surname>Delre</surname><given-names>P.</given-names></name>; <name><surname>Contino</surname><given-names>M.</given-names></name>; <name><surname>Corriero</surname><given-names>N.</given-names></name>; <name><surname>Saviano</surname><given-names>M.</given-names></name>; <name><surname>Mangiatordi</surname><given-names>G. F.</given-names></name>; <name><surname>Ancona</surname><given-names>N.</given-names></name><article-title>DeLA-Drug: A Deep Learning
Algorithm for Automated Design of Druglike Analogues</article-title>. <source>J. Chem. Inf. Model.</source><year>2022</year>, <volume>62</volume> (<issue>6</issue>), <fpage>1411</fpage>–<lpage>1424</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.2c00205</pub-id>.<pub-id pub-id-type="pmid">35294184</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref32">
      <mixed-citation publication-type="journal" id="cit32"><name><surname>Delre</surname><given-names>P.</given-names></name>; <name><surname>Contino</surname><given-names>M.</given-names></name>; <name><surname>Alberga</surname><given-names>D.</given-names></name>; <name><surname>Saviano</surname><given-names>M.</given-names></name>; <name><surname>Corriero</surname><given-names>N.</given-names></name>; <name><surname>Mangiatordi</surname><given-names>G. F.</given-names></name><article-title>ALPACA:
A Machine Learning Platform for Affinity and
Selectivity Profiling of CAnnabinoids Receptors Modulators</article-title>. <source>Comput. Biol. Med.</source><year>2023</year>, <volume>164</volume>, <elocation-id>107314</elocation-id><pub-id pub-id-type="doi">10.1016/j.compbiomed.2023.107314</pub-id>.<pub-id pub-id-type="pmid">37572442</pub-id></mixed-citation>
    </ref>
    <ref id="ref33">
      <mixed-citation publication-type="journal" id="cit33"><name><surname>Delre</surname><given-names>P.</given-names></name>; <name><surname>Lavado</surname><given-names>G. J.</given-names></name>; <name><surname>Lamanna</surname><given-names>G.</given-names></name>; <name><surname>Saviano</surname><given-names>M.</given-names></name>; <name><surname>Roncaglioni</surname><given-names>A.</given-names></name>; <name><surname>Benfenati</surname><given-names>E.</given-names></name>; <name><surname>Mangiatordi</surname><given-names>G. F.</given-names></name>; <name><surname>Gadaleta</surname><given-names>D.</given-names></name><article-title>Ligand-Based Prediction
of hERG-Mediated Cardiotoxicity Based on the Integration of Different
Machine Learning Techniques</article-title>. <source>Front. Pharmacol.</source><year>2022</year>, <volume>13</volume>, <elocation-id>951083</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2022.951083</pub-id>.<pub-id pub-id-type="pmid">36133824</pub-id></mixed-citation>
    </ref>
    <ref id="ref34">
      <mixed-citation publication-type="undeclared" id="cit34"><person-group person-group-type="allauthors"><name><surname>Benhenda</surname><given-names>M.</given-names></name></person-group><article-title>ChemGAN Challenge
for Drug Discovery: Can AI Reproduce Natural Chemical Diversity?</article-title><source>arXiv</source><year>2017</year><pub-id pub-id-type="doi">10.48550/arXiv.1708.08227</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref35">
      <mixed-citation publication-type="book" id="cit35"><article-title>RDKit Diversity Picker - RDKit Nodes Feature
- KNIME</article-title>. <source>Knime relase 4.6.1: RDKit Nodes Feature</source>; <publisher-name>NIBR</publisher-name><year>2022</year>.</mixed-citation>
    </ref>
    <ref id="ref36">
      <mixed-citation publication-type="journal" id="cit36"><name><surname>Zhu</surname><given-names>R.</given-names></name>; <name><surname>Guo</surname><given-names>Y.</given-names></name>; <name><surname>Xue</surname><given-names>J.-H.</given-names></name><article-title>Adjusting the Imbalance Ratio by
the Dimensionality
of Imbalanced Data</article-title>. <source>Pattern Recognition Letters</source><year>2020</year>, <volume>133</volume>, <fpage>217</fpage>–<lpage>223</lpage>. <pub-id pub-id-type="doi">10.1016/j.patrec.2020.03.004</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref37">
      <mixed-citation publication-type="book" id="cit37"><article-title>Ensamble Learning Wrappers - KNIME</article-title>. In <source>Knime
Relase 4.6.1: KNIME Ensamble Learning Wrappers</source>; <publisher-name>KNIME AG</publisher-name>: <publisher-loc>Zurich</publisher-loc>, <year>2022</year>.</mixed-citation>
    </ref>
    <ref id="ref38">
      <mixed-citation publication-type="book" id="cit38"><article-title>K Nearest Neighbor
- Base Nodes - KNIME</article-title>. In <source>Knime Relase 4.6.1:
KNIME Base nodes</source>; <publisher-name>KNIME
AG</publisher-name>: <publisher-loc>Zurich</publisher-loc>, <year>2022</year>.</mixed-citation>
    </ref>
    <ref id="ref39">
      <mixed-citation publication-type="book" id="cit39"><article-title>XGBoost Integration
- KNIME</article-title>. In <source>Knime Relase
4.6.1: KNIME XGBoost Integration</source>; <publisher-name>KNIME AG</publisher-name>: <publisher-loc>Zurich</publisher-loc>, <year>2022</year>.</mixed-citation>
    </ref>
    <ref id="ref40">
      <mixed-citation publication-type="journal" id="cit40"><name><surname>Capecchi</surname><given-names>A.</given-names></name>; <name><surname>Probst</surname><given-names>D.</given-names></name>; <name><surname>Reymond</surname><given-names>J.-L.</given-names></name><article-title>One Molecular Fingerprint
to Rule
Them All: Drugs, Biomolecules, and the Metabolome</article-title>. <source>J. Cheminf.</source><year>2020</year>, <volume>12</volume> (<issue>1</issue>), <fpage>43</fpage><pub-id pub-id-type="doi">10.1186/s13321-020-00445-4</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref41">
      <mixed-citation publication-type="journal" id="cit41"><name><surname>Lu</surname><given-names>W.</given-names></name>; <name><surname>Li</surname><given-names>Z.</given-names></name>; <name><surname>Chu</surname><given-names>J.</given-names></name><article-title>Adaptive Ensemble Undersampling-Boost:
A Novel Learning
Framework for Imbalanced Data</article-title>. <source>J. Syst. Software</source><year>2017</year>, <volume>132</volume>, <fpage>272</fpage>–<lpage>282</lpage>. <pub-id pub-id-type="doi">10.1016/j.jss.2017.07.006</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref42">
      <mixed-citation publication-type="book" id="cit42"><person-group person-group-type="allauthors"><name><surname>Agrawal</surname><given-names>T.</given-names></name></person-group><article-title>Introduction to
Hyperparameters</article-title>. In <source>Hyperparameter Optimization
in Machine Learning: Make Your Machine Learning and Deep Learning
Models More Efficient</source>; <person-group person-group-type="editor"><name><surname>Agrawal</surname><given-names>T.</given-names></name></person-group>, Ed.; <publisher-name>Apress</publisher-name>: <publisher-loc>Berkeley,
CA</publisher-loc>, <year>2021</year>; pp <fpage>1</fpage>–<lpage>30</lpage><pub-id pub-id-type="doi">10.1007/978-1-4842-6579-6_1</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref43">
      <mixed-citation publication-type="undeclared" id="cit43"><person-group person-group-type="allauthors"><name><surname>Probst</surname><given-names>P.</given-names></name>; <name><surname>Bischl</surname><given-names>B.</given-names></name>; <name><surname>Boulesteix</surname><given-names>A.-L.</given-names></name></person-group><article-title>Tunability:
Importance of Hyperparameters of Machine Learning Algorithms</article-title>. <year>2018</year><pub-id pub-id-type="doi">10.48550/arXiv.1802.09596</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref44">
      <mixed-citation publication-type="journal" id="cit44"><name><surname>Gadaleta</surname><given-names>D.</given-names></name>; <name><surname>Mangiatordi</surname><given-names>G. F.</given-names></name>; <name><surname>Catto</surname><given-names>M.</given-names></name>; <name><surname>Carotti</surname><given-names>A.</given-names></name>; <name><surname>Nicolotti</surname><given-names>O.</given-names></name><article-title>Applicability
Domain for QSAR Models: Where Theory Meets Reality</article-title>. <source>Int. J. Quant. Struct.-Prop. Relat.</source><year>2016</year>, <volume>1</volume> (<issue>1</issue>), <fpage>45</fpage>–<lpage>63</lpage>. <pub-id pub-id-type="doi">10.4018/IJQSPR.2016010102</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref45">
      <mixed-citation publication-type="journal" id="cit45"><name><surname>Melagraki</surname><given-names>G.</given-names></name>; <name><surname>Afantitis</surname><given-names>A.</given-names></name>; <name><surname>Sarimveis</surname><given-names>H.</given-names></name>; <name><surname>Igglessi-Markopoulou</surname><given-names>O.</given-names></name>; <name><surname>Koutentis</surname><given-names>P. A.</given-names></name>; <name><surname>Kollias</surname><given-names>G.</given-names></name><article-title>In Silico Exploration for Identifying
Structure–Activity Relationship of MEK Inhibition and Oral
Bioavailability for Isothiazole Derivatives</article-title>. <source>Chem. Biol. Drug Des.</source><year>2010</year>, <volume>76</volume> (<issue>5</issue>), <fpage>397</fpage>–<lpage>406</lpage>. <pub-id pub-id-type="doi">10.1111/j.1747-0285.2010.01029.x</pub-id>.<pub-id pub-id-type="pmid">20925691</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref46">
      <mixed-citation publication-type="book" id="cit46"><article-title>ROC Curve - JavaScript Views - KNIME</article-title>. In <source>Knime Relase 4.6.1: KNIME JavaScript Views</source>; <publisher-name>KNIME AG</publisher-name>: <publisher-loc>Zurich</publisher-loc>, <year>2022</year>.</mixed-citation>
    </ref>
    <ref id="ref47">
      <mixed-citation publication-type="book" id="cit47"><person-group person-group-type="allauthors"><name><surname>Ling</surname><given-names>C. X.</given-names></name>; <name><surname>Huang</surname><given-names>J.</given-names></name>; <name><surname>Zhang</surname><given-names>H.</given-names></name></person-group><article-title>AUC: A Better Measure than
Accuracy in Comparing Learning Algorithms</article-title>. In <source>Advances in Artificial Intelligence</source>; <person-group person-group-type="editor"><name><surname>Xiang</surname><given-names>Y.</given-names></name>; <name><surname>Chaib-draa</surname><given-names>B.</given-names></name></person-group>, Eds.; <publisher-name>Springer</publisher-name>: <publisher-loc>Berlin, Heidelberg</publisher-loc>, <year>2003</year>; pp <fpage>329</fpage>–<lpage>341</lpage><pub-id pub-id-type="doi">10.1007/3-540-44886-1_25</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref48">
      <mixed-citation publication-type="journal" id="cit48"><name><surname>Carhart</surname><given-names>R. E.</given-names></name>; <name><surname>Smith</surname><given-names>D. H.</given-names></name>; <name><surname>Venkataraghavan</surname><given-names>R.</given-names></name><article-title>Atom Pairs
as Molecular Features
in Structure-Activity Studies: Definition and Applications</article-title>. <source>J. Chem. Inf. Comput. Sci.</source><year>1985</year>, <volume>25</volume> (<issue>2</issue>), <fpage>64</fpage>–<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1021/ci00046a002</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref49">
      <mixed-citation publication-type="journal" id="cit49"><name><surname>Bienfait</surname><given-names>B.</given-names></name>; <name><surname>Ertl</surname><given-names>P.</given-names></name><article-title>JSME: A Free Molecule
Editor in JavaScript</article-title>. <source>J. Cheminf.</source><year>2013</year>, <volume>5</volume> (<issue>1</issue>), <fpage>24</fpage><pub-id pub-id-type="doi">10.1186/1758-2946-5-24</pub-id>.</mixed-citation>
    </ref>
  </ref-list>
</back>
<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//ACS//DTD ACS Journal DTD v1.02 20061031//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName ACSJournal-v102.dtd?>
<?SourceDTD.Version 1.02?>
<?ConverterInfo.XSLTName acs2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Mol Pharm</journal-id>
    <journal-id journal-id-type="iso-abbrev">Mol Pharm</journal-id>
    <journal-id journal-id-type="publisher-id">mp</journal-id>
    <journal-id journal-id-type="coden">mpohbp</journal-id>
    <journal-title-group>
      <journal-title>Molecular Pharmaceutics</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1543-8384</issn>
    <issn pub-type="epub">1543-8392</issn>
    <publisher>
      <publisher-name>American Chemical Society</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">10853961</article-id>
    <article-id pub-id-type="pmid">38134445</article-id>
    <article-id pub-id-type="doi">10.1021/acs.molpharmaceut.3c00964</article-id>
    <article-categories>
      <subj-group>
        <subject>Article</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>AMALPHI:
A Machine Learning Platform for Predicting
Drug-Induced PhospholIpidosis</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" id="ath1">
        <name>
          <surname>Lomuscio</surname>
          <given-names>Maria
Cristina</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">†</xref>
      </contrib>
      <contrib contrib-type="author" id="ath2">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9292-884X</contrib-id>
        <name>
          <surname>Abate</surname>
          <given-names>Carmen</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">†</xref>
        <xref rid="aff2" ref-type="aff">‡</xref>
      </contrib>
      <contrib contrib-type="author" id="ath3">
        <name>
          <surname>Alberga</surname>
          <given-names>Domenico</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">†</xref>
      </contrib>
      <contrib contrib-type="author" id="ath4">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6221-6155</contrib-id>
        <name>
          <surname>Laghezza</surname>
          <given-names>Antonio</given-names>
        </name>
        <xref rid="aff2" ref-type="aff">‡</xref>
      </contrib>
      <contrib contrib-type="author" id="ath5">
        <name>
          <surname>Corriero</surname>
          <given-names>Nicola</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">†</xref>
      </contrib>
      <contrib contrib-type="author" id="ath6">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5639-7746</contrib-id>
        <name>
          <surname>Colabufo</surname>
          <given-names>Nicola Antonio</given-names>
        </name>
        <xref rid="aff2" ref-type="aff">‡</xref>
      </contrib>
      <contrib contrib-type="author" id="ath7">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5086-2459</contrib-id>
        <name>
          <surname>Saviano</surname>
          <given-names>Michele</given-names>
        </name>
        <xref rid="aff3" ref-type="aff">§</xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes" id="ath8">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4523-2759</contrib-id>
        <name>
          <surname>Delre</surname>
          <given-names>Pietro</given-names>
        </name>
        <xref rid="cor1" ref-type="other">*</xref>
        <xref rid="aff1" ref-type="aff">†</xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes" id="ath9">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4042-2841</contrib-id>
        <name>
          <surname>Mangiatordi</surname>
          <given-names>Giuseppe Felice</given-names>
        </name>
        <xref rid="cor2" ref-type="other">*</xref>
        <xref rid="aff1" ref-type="aff">†</xref>
      </contrib>
      <aff id="aff1"><label>†</label><institution>CNR—Institute
of Crystallography</institution>, Via Amendola 122/o, 70126 Bari, <country>Italy</country></aff>
      <aff id="aff2"><label>‡</label>Department
of Pharmacy-Pharmaceutical Sciences, <institution>University
of the Studies of Bari “Aldo Moro”</institution>, Via E.Orabona 4, 70125 Bari, <country>Italy</country></aff>
      <aff id="aff3"><label>§</label><institution>CNR—Institute
of Crystallography</institution>, Via
Vivaldi 43, 81100 Caserta, <country>Italy</country></aff>
    </contrib-group>
    <author-notes>
      <corresp id="cor1"><label>*</label>Email: <email>pietro.delre@ic.cnr.it</email>.</corresp>
      <corresp id="cor2"><label>*</label>Email: <email>giuseppe.mangiatordi@ic.cnr.it</email>.</corresp>
    </author-notes>
    <pub-date pub-type="epub">
      <day>22</day>
      <month>12</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="collection">
      <day>05</day>
      <month>02</month>
      <year>2024</year>
    </pub-date>
    <volume>21</volume>
    <issue>2</issue>
    <fpage>864</fpage>
    <lpage>872</lpage>
    <history>
      <date date-type="received">
        <day>17</day>
        <month>10</month>
        <year>2023</year>
      </date>
      <date date-type="accepted">
        <day>05</day>
        <month>12</month>
        <year>2023</year>
      </date>
      <date date-type="rev-recd">
        <day>24</day>
        <month>11</month>
        <year>2023</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© 2023 American Chemical Society</copyright-statement>
      <copyright-year>2023</copyright-year>
      <copyright-holder>American Chemical Society</copyright-holder>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
        <license-p>Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>).</license-p>
      </license>
    </permissions>
    <abstract>
      <p content-type="toc-graphic">
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mp3c00964_0005" id="ab-tgr1"/>
      </p>
      <p>Drug-induced phospholipidosis (PLD) involves the accumulation
of
phospholipids in cells of multiple tissues, particularly within lysosomes,
and it is associated with prolonged exposure to druglike compounds,
predominantly cationic amphiphilic drugs (CADs). PLD affects a significant
portion of drugs currently in development and has recently been proven
to be responsible for confounding antiviral data during drug repurposing
for SARS-CoV-2. In these scenarios, it has become crucial to identify
potential safe drug candidates in advance and distinguish them from
those that may lead to false in vitro antiviral activity. In this
work, we developed a series of machine learning classifiers with the
aim of predicting the PLD-inducing potential of drug candidates. The
models were built on a high-quality chemical collection comprising <bold>545</bold> curated small molecules extracted from ChEMBL v30. The
most effective model, obtained using the balanced random forest algorithm,
achieved high performance, including an AUC value computed in validation
as high as 0.90. The model was made freely available through a user-friendly
web platform named AMALPHI (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ba.ic.cnr.it/softwareic/amalphiportal/">https://www.ba.ic.cnr.it/softwareic/amalphiportal/</uri>), which can represent a valuable tool for medicinal chemists interested
in conducting an early evaluation of PLD inducer potential.</p>
    </abstract>
    <kwd-group>
      <kwd>phospholipidosis</kwd>
      <kwd>ligand-based classifiers</kwd>
      <kwd>machine learning</kwd>
      <kwd>SARS-CoV-2</kwd>
    </kwd-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution>Consiglio Nazionale delle Ricerche</institution>
            <institution-id institution-id-type="doi">10.13039/501100004462</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>NA</award-id>
      </award-group>
    </funding-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution>Ministero dell''UniversitÃ  e della Ricerca</institution>
            <institution-id institution-id-type="doi">10.13039/501100021856</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>2022Z3BBPE</award-id>
      </award-group>
    </funding-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution>Regione Puglia</institution>
            <institution-id institution-id-type="doi">10.13039/501100009886</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>NA</award-id>
      </award-group>
    </funding-group>
    <custom-meta-group>
      <custom-meta>
        <meta-name>document-id-old-9</meta-name>
        <meta-value>mp3c00964</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>document-id-new-14</meta-name>
        <meta-value>mp3c00964</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>ccc-price</meta-name>
        <meta-value/>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
</front>
<body>
  <sec id="sec1">
    <title>Introduction</title>
    <p>Phospholipidosis (PLD) is a lysosomal
storage disorder characterized
by excessive accumulation of phospholipids in liver, kidney, brain,
cornea, lung, and other organs.<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> While
it is widely recognized that this phenomenon can arise from prolonged
treatment with cationic amphiphilic drugs (CADs), the exact mechanism
behind this process remains unclear. Various hypotheses have been
explored in the literature, including direct inhibition of lysosomal
phospholipases,<sup><xref ref-type="bibr" rid="ref2">2</xref></sup> binding to phospholipids,<sup><xref ref-type="bibr" rid="ref3">3</xref></sup> the potential regulation of phospholipid synthesis,<sup><xref ref-type="bibr" rid="ref4">4</xref></sup> and the enhanced cholesterol biosynthesis.<sup><xref ref-type="bibr" rid="ref5">5</xref></sup> For a comprehensive review on this topic, the
reader is referred to the recent paper by Breiden et al.<sup><xref ref-type="bibr" rid="ref6">6</xref></sup> Given that a notable proportion (∼5%<sup><xref ref-type="bibr" rid="ref7">7</xref></sup>) of drugs can induce PLD, there has been a growing
interest in recent years to assess the potential of drug candidates
to be inducers of PLD during the early stages of a drug discovery
(DD) process. This proactive evaluation is recognized as valuable,
as compounds that lead to PLD have a reduced likelihood of being successfully
brought to market.<sup><xref ref-type="bibr" rid="ref8">8</xref></sup> Recently, highly significant
correlations have been demonstrated between lipophilicity, the ability
of CADs to induce PLD, and the antiviral activity that these cationic
amphiphilic drugs have shown against multiple viruses such as hepatitis
C virus (HCV), Japanese encephalitis virus (JEV), severe acute respiratory
syndrome coronavirus (SARS-CoV), and Epstein–Barr virus (EBV).<sup><xref ref-type="bibr" rid="ref9">9</xref></sup> In light of the recent COVID-19 pandemic, a publication
in Science by Tummino et al.<sup><xref ref-type="bibr" rid="ref10">10</xref></sup> presented
findings that highlight the pivotal role of PLD in the context of
drugs with anti-SARS-CoV-2 activity, revealing that most of the molecules
return antiviral activity during the drug repurposing campaigns conducted
during the pandemic induce PLD. This adds another layer of complexity
and importance to the understanding and evaluation of PLD in drug
development efforts, particularly in the context of the recent global
health crisis. Based on these data, Tummino et al. speculated that
the anti-SARS-CoV-2 activity observed in vitro for many molecules
would be the consequence of their ability to induce PLD rather than
activity on a specific target (false anti-SARS-CoV-2 activity<sup><xref ref-type="bibr" rid="ref10">10</xref></sup>). This hypothesis was supported by the evidence
that many molecules exhibiting antiviral activity in vitro lost such
activity when transitioning to in vivo conditions. Further support
came from the lack of correlation between the antiviral activity and
the affinity of some ligands that interact with host targets identified
as important in combating SARS-CoV-2 replication (e.g., sigma-1 receptor).<sup><xref ref-type="bibr" rid="ref11">11</xref></sup> Some molecules with high affinity for sigma-1,
for instance, show no antiviral activity.<sup><xref ref-type="bibr" rid="ref12">12</xref></sup> Although PLD in the context of SARS-CoV-2 antiviral assays remains
a subject of ongoing scientific debate with contradictory data,<sup><xref ref-type="bibr" rid="ref13">13</xref>,<xref ref-type="bibr" rid="ref14">14</xref></sup> its importance in the drug development process has been further
underscored. Unfortunately, the available in vitro assays able to
measure the PLD-inducing potential of drug candidates are laborious,
time-consuming, expensive, and, for these reasons, poorly applied
despite the fact that several CADs agents are in clinical use/development.
Furthermore, the gold standard method (transmission electron microscope—TEM)
does not allow the screening of a large number of molecules.<sup><xref ref-type="bibr" rid="ref15">15</xref></sup> Other in vitro approaches include a method consisting
of measuring the binding of dyes to the phospholipids by flow cytometry
or fluorescence microscopy,<sup><xref ref-type="bibr" rid="ref16">16</xref>−<xref ref-type="bibr" rid="ref20">20</xref></sup> as well as a method based on quantifying gene biomarkers linked
to PLD.<sup><xref ref-type="bibr" rid="ref15">15</xref></sup> All these approaches are particularly
expensive and often yield conflicting data.<sup><xref ref-type="bibr" rid="ref21">21</xref>−<xref ref-type="bibr" rid="ref23">23</xref></sup> The development
of in-silico tools able to prioritize safe drug candidates is, therefore,
highly desirable, although it is worth noting that they are not free
from limitations. Especially when not used in conjunction with experiments
or when not starting from highly curated experimental data, they can
lead to a considerable number of false positives, as was clearly seen
during the COVID-19 pandemic.<sup><xref ref-type="bibr" rid="ref24">24</xref></sup> In the
context of antiviral design, if developed effectively, these tools
would provide valid support to the identification of those compounds
with a low probability to provide false antiviral activities during
in vitro assays. Accordingly, several models have been developed in
the past few years to predict the PLD-inducing potential of drug candidates,
based on ligand-based approaches<sup><xref ref-type="bibr" rid="ref7">7</xref>,<xref ref-type="bibr" rid="ref25">25</xref>−<xref ref-type="bibr" rid="ref28">28</xref></sup> or substructure search methods.<sup><xref ref-type="bibr" rid="ref29">29</xref>,<xref ref-type="bibr" rid="ref30">30</xref></sup> Valuable examples
can be found in the papers by Kruhlak et al.<sup><xref ref-type="bibr" rid="ref7">7</xref></sup> and Orogo et al.,<sup><xref ref-type="bibr" rid="ref26">26</xref></sup> reporting quantitative
structure–activity relationship (QSAR) models based on <bold>583</bold> and <bold>743</bold> compounds, respectively, extracted
from the published literature, existing pharmaceutical databases,
and Food and Drug Administration (FDA) internal reports. Of note are
also the papers by Fusani et al. and Schieferdecker et al.<sup><xref ref-type="bibr" rid="ref27">27</xref>,<xref ref-type="bibr" rid="ref28">28</xref></sup> Based on in-house in vitro data, the authors developed machine learning-based
models of PLD-inducing potential. However, despite their good performance
(accuracy &gt; 80%), the developed models are not available; hence,
their
accessibility to potentially interested users is strongly limited.
Building on this background, in the present study, new classifiers
of PLD-inducing potential were developed using four algorithms, namely,
random forest (RF), K-nearest neighbors (KNN), gradient boosting (GB),
and extreme gradient boosting (XGB) starting from <bold>545</bold> compounds extracted from ChEMBL version (v) 30 (PLD-DB) and then
splitting into a training set (TS) and a validation set (VS). The
top-performing classifier was also tested on two external sets (ESs).
Despite the limited data availability, these models demonstrated satisfactory
performance, as evidenced by widely accepted quality metrics, such
as the area under the receiver operating characteristic curve (AUC)
and balanced accuracy (BA). Following an approach successfully employed
by our team for predicting other chemical properties,<sup><xref ref-type="bibr" rid="ref31">31</xref>,<xref ref-type="bibr" rid="ref32">32</xref></sup> the most effective model was incorporated into a user-friendly web
platform named AMALPHI (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ba.ic.cnr.it/softwareic/amalphiportal/">https://www.ba.ic.cnr.it/softwareic/amalphiportal/</uri>). Significantly, this platform does not necessitate expertise in
cheminformatics or programming and can be a valuable resource for
medicinal chemists interested in early evaluations of the PLD inducer
potential. To the best of our knowledge, AMALPHI is the first freely
accessible tool able to efficiently predict the PLD potential of drug
candidates.</p>
  </sec>
  <sec id="sec2">
    <title>Materials and Methods</title>
    <sec id="sec2.1">
      <title>Data Set Preparation</title>
      <p>We extracted <bold>851</bold> entries
from ChEMBL v30 according to the Target ID (CHEMBL1626541) assigned
to the PLD phenotype. Following an approach described elsewhere,<sup><xref ref-type="bibr" rid="ref32">32</xref>,<xref ref-type="bibr" rid="ref33">33</xref></sup> we checked the validity of each SMILES string using an in-house
semiautomated procedure implemented in the KNIME platform. In particular,
this procedure allows for the removal of organometallic and inorganic
compounds, chemicals characterized by unusual elements and mixtures,
neutralizing salts, and stereochemistry. Finally, the OpenBabel node
implemented in KNIME allowed the conversion of retrieved SMILES in
a standardized QSAR-ready format. In doing that, we created the PLD-DB,
consisting of <bold>545</bold> curated entries. It is worth noting
that 70% of the compounds belonging to the PLD-DB data set are approved
drugs, while the remaining ones have yet to progress to the clinical
phase.</p>
      <p>Furthermore, to assess the diversity of molecules in
our data set, we employed a metric called internal diversity (ID—defined
as the mean over the Tanimoto distances between each molecule and
all the others belonging to the same set<sup><xref ref-type="bibr" rid="ref34">34</xref></sup>), which effectively measures the similarity of molecules within
the data set. The resulting ID value of 0.82 indicates that the compounds
in our data set exhibit a high degree of diversity. To classify the
entries as either PLD inducers (P+) or noninducers (P−), we
analyzed the comments field based on the reference CHEMBL ID document.
Annotations selected as referring to P+ were: “active”/
“positive”/ “positive: inducer confirmed by electron
microscopy”/ “positive: weak inducer based on foamy
macrophages and cytoplasmic vacuolations.” Instead, comments
selected as indicating no PLD induction (P−) were: “not
active”/“negative”/“negative: confirmed
by electron microscopy”/“negative: based on the absence
of positive reported data from WMDD.” <bold>295</bold> duplicates
were removed, keeping the P+ or P– class as the most frequent
one. Finally, <bold>11</bold> chemicals were excluded, as their activity
was indicated as “Not determined” in ChEMBL v30. In
doing that, the final curated data set (PDL-DB) comprises <bold>104</bold> P+ and <bold>441</bold> P– for a total of <bold>545</bold> compounds.</p>
    </sec>
    <sec id="sec2.2">
      <title>External Set Preparation</title>
      <p>Two different external sets
(ESs), one consisting of <bold>117</bold> (ES1) and the other consisting
of <bold>20</bold> (ES2) compounds, were built and used in this work.
In particular, Orogo et al.<sup><xref ref-type="bibr" rid="ref26">26</xref></sup> made available
a data set (Or-ds) consisting of <bold>743</bold> compounds that we
used to create ES1. Noteworthy, Or-ds comprises compounds along with
their associated PLD activity and a corresponding data confidence
rate expressed as either high or medium. Compounds associated with
keywords related to electron microscopy confirmation of PLD are considered
to have high confidence, while those associated with keywords and
phrases indicating only the presence of foamy macrophages are considered
to have medium confidence. We kept only those compounds with a high
confidence rating and processed the SMILES strings using the same
semiautomated procedure described above to remove duplicates and compounds
already included in PLD-DB. The second external set (ES2) was built
based on the work by Przybylak et al.<sup><xref ref-type="bibr" rid="ref29">29</xref></sup> The authors used two curated data sets comprising <bold>185</bold> and <bold>331</bold> compounds. These two data sets were merged
and processed following the already described data curation approach.</p>
    </sec>
    <sec id="sec2.3">
      <title>Data Set Splitting</title>
      <p>We employed a rational approach
to split PLD-DB into a TS and a VS. To this aim, we applied the RDkit
Diversity Picker node separately on the two classes (i.e., P+ and
P−). This node automatically generates Morgan fingerprints
(radius 2–2048 bits) for each SMILES string and then picks
80% of the most diverse molecules for each class based on the Tanimoto
distance.<sup><xref ref-type="bibr" rid="ref35">35</xref></sup> In this way, a TS of <bold>431</bold> compounds (80% of each class) and a VS that includes the
remaining <bold>114</bold> compounds were obtained. <xref rid="tbl2" ref-type="other">Table <xref rid="tbl2" ref-type="other">2</xref></xref> summarizes the composition
of the starting TS, VS, and ES as well as the relative imbalanced
ratio (IR) calculated as the ratio between the number of majority
and minority instances.<sup><xref ref-type="bibr" rid="ref36">36</xref></sup> Note that such
a procedure allowed us to keep the ratio between the classes in each
subset. To depict the chemical space covered by TS, VS, and ESs, a
principal component analysis (PCA) was performed based on 36 physicochemical
properties of the molecules calculated by the RDKit Descriptor Calculation
KNIME node and then standardized using the Normalizer KNIME node (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>). The score plot
of the first three principal components (PC1, PC2, and PC3) that account
for 80.8% of the variance shows each ligand belonging to the different
data sets in the resulting 3D chemical space.</p>
      <fig id="fig1" position="float">
        <label>Figure 1</label>
        <caption>
          <p>PCA based on the physicochemical
properties returned by the compounds
belonging to TS, VS, ES1, and ES2.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mp3c00964_0001" id="gr1" position="float"/>
      </fig>
    </sec>
  </sec>
  <sec id="sec3">
    <title>Development of Statistically Based Models</title>
    <sec id="sec3.1">
      <title>Development and Validation</title>
      <p>In this work, four classification
algorithms were used: RF, KNN, GB, and XGB. We employed the following
KNIME nodes: tree ensemble learner, tree ensemble predictor, K-nearest
neighbor, gradient boosted trees learner, gradient boosted trees predictor,
XGBoost tree ensemble learner, XGBoost predictor.<sup><xref ref-type="bibr" rid="ref37">37</xref>−<xref ref-type="bibr" rid="ref39">39</xref></sup> AtomPair fingerprints
(AP—1024 bits) calculated by the RDKit Fingerprint KNIME node
were used to represent each chemical structure belonging to PLD-DB.</p>
      <p>It is worth noting that we opted for AP fingerprints instead of
the previously used Morgan fingerprints due to their acknowledged
higher sensitivity to molecular global features, such as size and
shape.<sup><xref ref-type="bibr" rid="ref40">40</xref></sup></p>
      <p>Noteworthy, an IR equal
to 4.4 was computed for the TS. For this
reason, we created an additional set of models using an undersampling
ensemble learning model (UELM), employing KNN, GB, and XGB. This technique
presents two advantages as it (i) avoids the convergence of algorithms
trained on the majority class ignoring classes with fewer samples,<sup><xref ref-type="bibr" rid="ref41">41</xref></sup> and (ii) preserves information from the majority
class using the ensemble technique. In particular, we used the equal
size sampling node to generate, from the original TS, 50 sub-TS (characterized
by an IR equal to 1) to train 50 models and generate the final ensemble
model, able to make predictions on external data (i.e., VS and ES)
following a majority voting approach. In all cases, we found the optimal
setting (shown in <xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>) for the final model training through hyperparameter tuning performed
based on a 5-fold cross-validation (5-CV). Note that, for each algorithm,
the hyperparameters known to be responsible for the higher impact
on the overall performance<sup><xref ref-type="bibr" rid="ref42">42</xref>,<xref ref-type="bibr" rid="ref43">43</xref></sup> were considered.</p>
      <table-wrap id="tbl1" position="float">
        <label>Table 1</label>
        <caption>
          <title>Optimized Parameters for Each Algorithm</title>
        </caption>
        <table frame="hsides" rules="groups" border="0">
          <colgroup>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
          </colgroup>
          <thead>
            <tr>
              <th style="border:none;" align="center">algorithm</th>
              <th style="border:none;" align="center">optimized
parameters</th>
              <th style="border:none;" align="center">unbalanced TS</th>
              <th style="border:none;" align="center">equal size models</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="6" style="border:none;" align="left">RF</td>
              <td style="border:none;" align="left">split criterion</td>
              <td style="border:none;" align="left">gini index</td>
              <td rowspan="6" style="border:none;" align="left"> </td>
            </tr>
            <tr>
              <td style="border:none;" align="left">attribute
sampling</td>
              <td style="border:none;" align="left">square root</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">set of
attributes for each tree</td>
              <td style="border:none;" align="left">different</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">number of trees</td>
              <td style="border:none;" align="left">423</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">tree depth</td>
              <td style="border:none;" align="left">6</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">equal size sampling</td>
              <td style="border:none;" align="left">yes</td>
            </tr>
            <tr>
              <td rowspan="2" style="border:none;" align="left">kNN</td>
              <td style="border:none;" align="left">number of neighbors to consider</td>
              <td style="border:none;" align="left">5</td>
              <td style="border:none;" align="left">7</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">weight neighbors by distance</td>
              <td style="border:none;" align="left">yes</td>
              <td style="border:none;" align="left">no</td>
            </tr>
            <tr>
              <td rowspan="5" style="border:none;" align="left">GB</td>
              <td style="border:none;" align="left">number
of trees</td>
              <td style="border:none;" align="left">280</td>
              <td style="border:none;" align="left">100</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">learning rate</td>
              <td style="border:none;" align="left">0.98</td>
              <td style="border:none;" align="left">1</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">attribute sampling</td>
              <td style="border:none;" align="left">square root</td>
              <td rowspan="3" style="border:none;" align="left"> </td>
            </tr>
            <tr>
              <td style="border:none;" align="left">set of attributes for each
tree</td>
              <td style="border:none;" align="left">same</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">maximum tree depth</td>
              <td style="border:none;" align="left">8</td>
            </tr>
            <tr>
              <td rowspan="6" style="border:none;" align="left">XGB</td>
              <td style="border:none;" align="left">eta</td>
              <td style="border:none;" align="left">0.589</td>
              <td style="border:none;" align="left">0.28</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">boosting
rounds</td>
              <td style="border:none;" align="left">253</td>
              <td style="border:none;" align="left">100</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">gamma</td>
              <td style="border:none;" align="left">0.182</td>
              <td rowspan="4" style="border:none;" align="left"> </td>
            </tr>
            <tr>
              <td style="border:none;" align="left">lamba</td>
              <td style="border:none;" align="left">4.842</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">alpha</td>
              <td style="border:none;" align="left">0.211</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">maximum depth</td>
              <td style="border:none;" align="left">6</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>To do that, we employed a Bayesian optimization algorithm
for RF
and XGB and a grid search for KNN and GB. Finally, after performance
evaluation, we selected the best-performing model.</p>
    </sec>
    <sec id="sec3.2">
      <title>Applicability Domain</title>
      <p>An applicability domain (AD) was
defined for the TS in order to increase confidence in the predictions.
Notably, AD represents the chemical space from which the models are
built and, therefore, where a prediction can be considered reliable.<sup><xref ref-type="bibr" rid="ref44">44</xref></sup> The domain-similarity KNIME node was employed
to define the AD. This node measures the Euclidean distances between
the compounds belonging to the TS and those subjected to prediction.
In particular, this approach allows defining an AD threshold (ADP)
following these steps: (i) the computation of all the Euclidean distances
between all the possible pairs of compounds belonging to TS, based
on representative descriptors (AP fingerprint in our case); (ii) the
creation of a set of distances that are lower than the average distance
calculated in step 1; (iii) the computation of the mean (d) and standard
deviation (σ) of the distances in the set created in step 2;
and (iv) the definition the ADP (AD threshold) using the equation<disp-formula id="eq1"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mp3c00964_m001" position="anchor"/><label>1</label></disp-formula>where <italic>Z</italic> is an empirical cutoff
value equal to 0.5 by default.<sup><xref ref-type="bibr" rid="ref45">45</xref></sup> In doing
that, we excluded 2 compounds from VS and 16 compounds from ES1, while
all the compounds belonging to ES2 resulted within the AD. <xref rid="tbl2" ref-type="other">Table <xref rid="tbl2" ref-type="other">2</xref></xref> reports the VS, ES1, and ES2 compositions after the application
of the AD filter.</p>
      <table-wrap id="tbl2" position="float">
        <label>Table 2</label>
        <caption>
          <title>Partitioning Schemes Before (Top)
and After (Bottom) the Application of the AD<xref rid="t2fn1" ref-type="table-fn">a</xref></title>
        </caption>
        <table frame="hsides" rules="groups" border="0">
          <colgroup>
            <col align="left"/>
            <col align="char" char="."/>
            <col align="char" char="."/>
            <col align="char" char="."/>
            <col align="char" char="."/>
          </colgroup>
          <thead>
            <tr>
              <th style="border:none;" align="center">data set</th>
              <th style="border:none;" align="center" char=".">#</th>
              <th style="border:none;" align="center" char=".">P–</th>
              <th style="border:none;" align="center" char=".">P+</th>
              <th style="border:none;" align="center" char=".">IR</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td style="border:none;" align="left">TS</td>
              <td style="border:none;" align="char" char=".">431</td>
              <td style="border:none;" align="char" char=".">351</td>
              <td style="border:none;" align="char" char=".">80</td>
              <td style="border:none;" align="char" char=".">4.4</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">VS</td>
              <td style="border:none;" align="char" char=".">114</td>
              <td style="border:none;" align="char" char=".">90</td>
              <td style="border:none;" align="char" char=".">24</td>
              <td style="border:none;" align="char" char=".">3.7</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">ES1</td>
              <td style="border:none;" align="char" char=".">133</td>
              <td style="border:none;" align="char" char=".">112</td>
              <td style="border:none;" align="char" char=".">21</td>
              <td style="border:none;" align="char" char=".">5.3</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">ES2</td>
              <td style="border:none;" align="char" char=".">20</td>
              <td style="border:none;" align="char" char=".">11</td>
              <td style="border:none;" align="char" char=".">9</td>
              <td style="border:none;" align="char" char=".">1.2</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">within the AD</td>
              <td style="border:none;" align="char" char="."> </td>
              <td style="border:none;" align="char" char="."> </td>
              <td style="border:none;" align="char" char="."> </td>
              <td style="border:none;" align="char" char="."> </td>
            </tr>
            <tr>
              <td style="border:none;" align="left">VS</td>
              <td style="border:none;" align="char" char=".">112</td>
              <td style="border:none;" align="char" char=".">88</td>
              <td style="border:none;" align="char" char=".">24</td>
              <td style="border:none;" align="char" char=".">3.6</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">ES1</td>
              <td style="border:none;" align="char" char=".">117</td>
              <td style="border:none;" align="char" char=".">99</td>
              <td style="border:none;" align="char" char=".">18</td>
              <td style="border:none;" align="char" char=".">5.5</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">ES2</td>
              <td style="border:none;" align="char" char=".">20</td>
              <td style="border:none;" align="char" char=".">11</td>
              <td style="border:none;" align="char" char=".">9</td>
              <td style="border:none;" align="char" char=".">1.2</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="t2fn1">
            <label>a</label>
            <p>For PLD-DB, the number of noninducers
(P−) and inducers (P+) chemicals is reported for the training
set (TS), validation set (VS), largest (ES1), and smallest (ES2) external
sets. Notably, the total number of chemicals (#) is also reported.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
    </sec>
    <sec id="sec3.3">
      <title>Performance Evaluation</title>
      <p>Each classifier was evaluated
by using Coopers statistics. In particular, sensitivity (SE), specificity
(SP), and BA were computed as follows<disp-formula id="eq2"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mp3c00964_m002" position="anchor"/><label>2</label></disp-formula><disp-formula id="eq3"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mp3c00964_m003" position="anchor"/><label>3</label></disp-formula><disp-formula id="eq4"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mp3c00964_m004" position="anchor"/><label>4</label></disp-formula>where TP (true positives) and TN (true negatives)
are, respectively, the positive and negative samples correctly classified
by the trained model, whereas FP (false positives) and FN (false negatives)
are the misclassified positive and negative samples, respectively.
Another quality metric, namely, the Matthews correlation coefficient
(MCC), was considered to evaluate model performance. MCC indicates
the quality of binary classification and is generally recognized as
a reliable metric, although it deteriorates when the TS is unbalanced.
MCC ranges between −1 and +1, where a value of +1 means a perfect
classification, 0 indicates a random classification, and −1
is a complete misclassification.<disp-formula id="eq5"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mp3c00964_m005" position="anchor"/><label>5</label></disp-formula>The AUC was also computed by the ROC curve
node<sup><xref ref-type="bibr" rid="ref46">46</xref></sup> to measure the ability of a model
to distinguish P+ from P– samples. This metric ranges between
0 (miss-classifiers) and 1 (ideal-classifiers), reflecting the probability
of positive compounds being ranked earlier than decoy compounds according
to the prediction confidence value estimated by the KNIME Predictor
nodes with respect to each specific algorithm used.<sup><xref ref-type="bibr" rid="ref37">37</xref>−<xref ref-type="bibr" rid="ref39">39</xref></sup> The ROC curve
and, consequently, the AUC will be one of the key metrics we will
primarily consider for selecting the most effective model.<sup><xref ref-type="bibr" rid="ref47">47</xref></sup></p>
      <p>Finally, the positive (+LR) and the negative
likelihood ratio (−LR) were considered and computed as follows<disp-formula id="eq6"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mp3c00964_m006" position="anchor"/><label>6</label></disp-formula>and<disp-formula id="eq7"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mp3c00964_m007" position="anchor"/><label>7</label></disp-formula>The classification model becomes more informative
as the +LR value increases (or the −LR value decreases).</p>
    </sec>
  </sec>
  <sec id="sec4">
    <title>Results and Discussion</title>
    <p>In this work, different classifiers
of PLD-inducing potential were
developed using four ML classification algorithms, namely, RF, KNN,
GB, and XGB, all available in the KNIME analytics platform. To this
end, a highly curated data set (PLD-DB) consisting of <bold>545</bold> compounds was used to train and then to validate the models. More
specifically, PLD-DB was divided into a TS used to perform hyperparameter
tuning based on a 5-fold cross-validation (5-CV) and a VS used to
validate the models obtained with the best parameters identified.
Each compound was described by binary fingerprints, namely, AtomPair
FP.<sup><xref ref-type="bibr" rid="ref48">48</xref></sup> As already mentioned, PLD-DB is an
unbalanced data set with an IR approximately equal to 4. To address
the problem and therefore prevent a significant discrepancy between
SE and SP, different techniques were undertaken. The RF algorithm
was combined with a uniform size sampling strategy (hereinafter referred
to as balanced random forest–BRF) to reduce the bias toward
the majority class while an additional technique named UELM (see the
section <xref rid="sec2" ref-type="other">Materials and Methods</xref> for methodological
details) was implemented for KNN (hereinafter referred to as uKNN),
GB (uGB), and XGB (uXGB) algorithms. In particular, using the equal
size KNIME node, we developed, for each of these algorithms, a final
ensemble model following the approach described in the section “<xref rid="sec3.1" ref-type="other">Models Development and Validation</xref>”. The
final prediction was performed following a majority vote approach.
Furthermore, to wisely evaluate real-life model predictivity, VS was
kept imbalanced, and only compounds within the AD were considered.
Finally, two different ESs were employed to assess the predictivity
of the best model in a real-life case study. The following section
will focus on analyzing the key quality metrics (SE, SP, BA, MCC,
and AUC) calculated for each validation process (internal and external),
aiming to identify the top-performing classifier.</p>
    <sec id="sec4.1">
      <title>Hyperparameterization</title>
      <p><xref rid="tbl3" ref-type="other">Table <xref rid="tbl3" ref-type="other">3</xref></xref> displays the performances achieved using
5-fold cross-validation (5-CV) for each employed algorithm using the
TS extracted from PLD-DB for hyperparameter optimization tuning. In
this step, ensuring satisfactory performance is critical to guarantee
the capability of model generalization, meaning that models fit the
data set accurately, avoiding overfitting or underfitting. As expected,
the classifiers built based on RF, KNN, GB, and XGB returned SP values
significantly higher than SE ones (difference ranging from 0.55 to
0.78). Moreover, in all cases, BA values lower than 0.70 were computed.
A remarkable performance improvement is instead observed when a proper
treatment of the TS imbalance is undertaken as evident looking at
the quality metrics returned by BRF, uKNN, uGB, and uXGB (<xref rid="tbl3" ref-type="other">Table <xref rid="tbl3" ref-type="other">3</xref></xref>). More specifically,
no significant difference is observed between the SE and SP, ranging
from 0.01 (BRF) to 0.08 (uKNN). Furthermore, higher BA and AUC values
were also detected, with BRF returning the best performance (BA =
0.73 and AUC = 0.78). As mentioned in the introduction, building models
of PLD-inducing potential has, as a primary aim, that of directing
the experimental efforts toward safe (P−) molecules. Building
on that, the prediction of dangerous substances as safe should be
avoided. In light of that, we also focused our attention on the computed
−LR values. Notice that this quality metric is independent
of the TS data distribution and is able to provide an estimation of
the decrease in the probability of a compound being a P– with
respect to the initial condition (before querying the relative classifier).
Again, BRF (−LR = 0.37) returned the best performance, followed
by uGB (0.39), uXGB (0.44), and uKNN (0.48), while significantly worse
values were returned by RF (0.84), KNN (0.70), GB (0.80), and XGB
(0.63). In summary, the performed 5-CV provided clear evidence that
resembling approaches are required to reach satisfactory performances.</p>
      <table-wrap id="tbl3" position="float">
        <label>Table 3</label>
        <caption>
          <title>Performances in 5-CV Returned by All
of the Developed Classifiers<xref rid="t3fn1" ref-type="table-fn">a</xref></title>
        </caption>
        <table frame="hsides" rules="groups" border="0">
          <colgroup>
            <col align="left"/>
            <col align="char" char="."/>
            <col align="char" char="."/>
            <col align="char" char="."/>
            <col align="char" char="."/>
            <col align="char" char="."/>
            <col align="char" char="."/>
            <col align="char" char="."/>
            <col align="char" char="."/>
            <col align="char" char="."/>
            <col align="char" char="."/>
            <col align="char" char="."/>
          </colgroup>
          <thead>
            <tr>
              <th style="border:none;" align="center"> </th>
              <th style="border:none;" align="center" char=".">SE</th>
              <th style="border:none;" align="center" char=".">SP</th>
              <th style="border:none;" align="center" char=".">BA</th>
              <th style="border:none;" align="center" char=".">AUC</th>
              <th style="border:none;" align="center" char=".">–LR</th>
              <th style="border:none;" align="center" char=".">+LR</th>
              <th style="border:none;" align="center" char=".">MCC</th>
              <th style="border:none;" align="center" char=".">TP</th>
              <th style="border:none;" align="center" char=".">FP</th>
              <th style="border:none;" align="center" char=".">TN</th>
              <th style="border:none;" align="center" char=".">FN</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td style="border:none;" align="left">RF</td>
              <td style="border:none;" align="char" char=".">0.19</td>
              <td style="border:none;" align="char" char=".">0.97</td>
              <td style="border:none;" align="char" char=".">0.58</td>
              <td style="border:none;" align="char" char=".">0.77</td>
              <td style="border:none;" align="char" char=".">0.84</td>
              <td style="border:none;" align="char" char=".">6.58</td>
              <td style="border:none;" align="char" char=".">0.26</td>
              <td style="border:none;" align="char" char=".">15</td>
              <td style="border:none;" align="char" char=".">10</td>
              <td style="border:none;" align="char" char=".">341</td>
              <td style="border:none;" align="char" char=".">65</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">KNN</td>
              <td style="border:none;" align="char" char=".">0.31</td>
              <td style="border:none;" align="char" char=".">0.95</td>
              <td style="border:none;" align="char" char=".">0.63</td>
              <td style="border:none;" align="char" char=".">0.70</td>
              <td style="border:none;" align="char" char=".">0.72</td>
              <td style="border:none;" align="char" char=".">6.86</td>
              <td style="border:none;" align="char" char=".">0.35</td>
              <td style="border:none;" align="char" char=".">25</td>
              <td style="border:none;" align="char" char=".">16</td>
              <td style="border:none;" align="char" char=".">335</td>
              <td style="border:none;" align="char" char=".">55</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">GB</td>
              <td style="border:none;" align="char" char=".">0.23</td>
              <td style="border:none;" align="char" char=".">0.97</td>
              <td style="border:none;" align="char" char=".">0.60</td>
              <td style="border:none;" align="char" char=".">0.75</td>
              <td style="border:none;" align="char" char=".">0.80</td>
              <td style="border:none;" align="char" char=".">6.58</td>
              <td style="border:none;" align="char" char=".">0.30</td>
              <td style="border:none;" align="char" char=".">18</td>
              <td style="border:none;" align="char" char=".">12</td>
              <td style="border:none;" align="char" char=".">339</td>
              <td style="border:none;" align="char" char=".">62</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">XGB</td>
              <td style="border:none;" align="char" char=".">0.40</td>
              <td style="border:none;" align="char" char=".">0.95</td>
              <td style="border:none;" align="char" char=".">0.68</td>
              <td style="border:none;" align="char" char=".">0.78</td>
              <td style="border:none;" align="char" char=".">0.63</td>
              <td style="border:none;" align="char" char=".">8.26</td>
              <td style="border:none;" align="char" char=".">0.43</td>
              <td style="border:none;" align="char" char=".">32</td>
              <td style="border:none;" align="char" char=".">17</td>
              <td style="border:none;" align="char" char=".">334</td>
              <td style="border:none;" align="char" char=".">48</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">BRF</td>
              <td style="border:none;" align="char" char=".">0.73</td>
              <td style="border:none;" align="char" char=".">0.74</td>
              <td style="border:none;" align="char" char=".">0.73</td>
              <td style="border:none;" align="char" char=".">0.78</td>
              <td style="border:none;" align="char" char=".">0.37</td>
              <td style="border:none;" align="char" char=".">2.77</td>
              <td style="border:none;" align="char" char=".">0.38</td>
              <td style="border:none;" align="char" char=".">58</td>
              <td style="border:none;" align="char" char=".">92</td>
              <td style="border:none;" align="char" char=".">259</td>
              <td style="border:none;" align="char" char=".">22</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">uKNN</td>
              <td style="border:none;" align="char" char=".">0.65</td>
              <td style="border:none;" align="char" char=".">0.73</td>
              <td style="border:none;" align="char" char=".">0.69</td>
              <td style="border:none;" align="char" char=".">0.72</td>
              <td style="border:none;" align="char" char=".">0.48</td>
              <td style="border:none;" align="char" char=".">2.41</td>
              <td style="border:none;" align="char" char=".">0.31</td>
              <td style="border:none;" align="char" char=".">52</td>
              <td style="border:none;" align="char" char=".">96</td>
              <td style="border:none;" align="char" char=".">255</td>
              <td style="border:none;" align="char" char=".">28</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">uGB</td>
              <td style="border:none;" align="char" char=".">0.73</td>
              <td style="border:none;" align="char" char=".">0.70</td>
              <td style="border:none;" align="char" char=".">0.71</td>
              <td style="border:none;" align="char" char=".">0.73</td>
              <td style="border:none;" align="char" char=".">0.39</td>
              <td style="border:none;" align="char" char=".">2.43</td>
              <td style="border:none;" align="char" char=".">0.34</td>
              <td style="border:none;" align="char" char=".">58</td>
              <td style="border:none;" align="char" char=".">105</td>
              <td style="border:none;" align="char" char=".">246</td>
              <td style="border:none;" align="char" char=".">22</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">uXGB</td>
              <td style="border:none;" align="char" char=".">0.68</td>
              <td style="border:none;" align="char" char=".">0.72</td>
              <td style="border:none;" align="char" char=".">0.70</td>
              <td style="border:none;" align="char" char=".">0.72</td>
              <td style="border:none;" align="char" char=".">0.44</td>
              <td style="border:none;" align="char" char=".">2.43</td>
              <td style="border:none;" align="char" char=".">0.32</td>
              <td style="border:none;" align="char" char=".">54</td>
              <td style="border:none;" align="char" char=".">98</td>
              <td style="border:none;" align="char" char=".">253</td>
              <td style="border:none;" align="char" char=".">26</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="t3fn1">
            <label>a</label>
            <p>For each model, the following statistics
are reported: sensitivity (SE), specificity (SP), balanced accuracy
(BA), area under the ROC (AUC), negative likelihood ratio (−LR),
positive likelihood ratio (+LR), Matthews correlation coefficient
(MCC), number of true positives (TPs), false positives (FPs), true
negatives (TNs), and false negatives (FNs).</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
    </sec>
    <sec id="sec4.2">
      <title>Validation</title>
      <p>Aimed at selecting the top-performing classifier,
the models built using BRF, uGB, uXGB, and uKNN were subjected to
a validation using the VS previously extracted from PLD-DB and comprising <bold>112</bold> compounds. Notice that to judiciously evaluate the predictiveness
of the model in real-life scenarios, VS was deliberately left imbalanced,
and the performances were computed considering only those compounds
within the AD. As evident in <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>A, the good performance observed in 5-CV is herein
confirmed for all the models, as indicated by the computed BA values
≈ 0.80, AUC &gt; 0.85, and very low −LR (ranging from
0.07
to 0.18). Importantly, acceptable differences were observed between
SE and SP, ranging from 0.20 to 0.32. <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>B displays a radar plot constructed with
the aim of selecting the top-performing classifier. Taking as a whole,
the obtained data put forward BRF, whose ROC curve is displayed in <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>C, as the model to
be selected, being able to provide the best AUC (0.90), BA (0.81),
and MCC (0.50) values. It is important to emphasize that we conducted
an additional analysis to assess the stability of the built models.
This analysis involved creating an additional set of 100 classifiers
by using different, randomly selected training sets (TS) and validation
sets (VS) while adhering to the data splitting methodology outlined
in the <xref rid="sec2" ref-type="other">Materials and Methods Section</xref>. For
each of these models, we calculated key metrics, including BA, SE,
and SP, and then examined their relative standard deviations to gauge
the stability of the classifiers. The obtained results unequivocally
demonstrate that all of the classifiers exhibit robustness and independence
from the TS and VS composition (standard deviations ≤ 0.07).
To further challenge the BRF model, an additional validation with
two different external sets (ES1 and ES2) was performed. As reported
in <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>A, an acceptable
balance between SE and SP was observed as well as high values of BA
(0.72 and 0.90 for ES1 and ES2, respectively) and AUC (0.75 and 0.94,
respectively). This is also supported by the relative ROC curves displayed
in <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>B,C.</p>
      <fig id="fig2" position="float">
        <label>Figure 2</label>
        <caption>
          <p>Selection of
the top-performing model was based on the performance
obtained in validation. (A) Table reporting the quality metrics returned
by all the developed models: sensitivity (SE), specificity (SP), balanced
accuracy (BA), area under the ROC (AUC), negative likelihood ratio
(−LR), positive likelihood ratio (+LR), Matthews correlation
coefficient (MCC), number of true positives (TPs), false positives
(FPs), true negatives (TNs), and false negatives (FNs); (B) radar
plot comparing the performance of the models; and (C) ROC curve derived
from the probability-based ranking returned by the selected classifier
(BRF).</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mp3c00964_0002" id="gr2" position="float"/>
      </fig>
      <fig id="fig3" position="float">
        <label>Figure 3</label>
        <caption>
          <p>Performance of the selected BRF model on external sets
ES1 and
ES2. (A) Table reporting the computed sensitivity (SE), specificity
(SP), balanced accuracy (BA), area under the ROC (AUC), negative likelihood
ratio (−LR), positive likelihood ratio (+LR), Matthews correlation
coefficient (MCC), number of true positives (TPs), false positives
(FPs), true negatives (TNs), and false negatives (FNs); (B, C) ROC
curve derived from the probability-based ranking returned by BRF on
ES1 and ES2, respectively.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mp3c00964_0003" id="gr3" position="float"/>
      </fig>
    </sec>
  </sec>
  <sec id="sec5">
    <title>AMALPHI: A Freely Accessible Web Platform</title>
    <p>We made available
the top-performing classifier, built using the
BRF algorithm, in a freely accessible web platform called AMALPHI
(A machine learning platform for predicting drug-induced phospholipidosis—<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ba.ic.cnr.it/softwareic/amalphiportal/">https://www.ba.ic.cnr.it/softwareic/amalphiportal/</uri>). Following an approach already employed for other web platforms
developed by our group,<sup><xref ref-type="bibr" rid="ref31">31</xref>,<xref ref-type="bibr" rid="ref32">32</xref></sup> the user can draw a
2D structure of her/his query molecule using the JSME canvas applet<sup><xref ref-type="bibr" rid="ref49">49</xref></sup> or, alternatively, insert the relative SMILES
string directly into the provided text field. Additionally, to facilitate
the use of the platform for virtual screening applications, the user
can upload a .txt file containing a list of SMILES strings. This can
be achieved by clicking on the “MASSIVE” button. Once
the file is uploaded or the query molecule is drawn, AMALPHI generates
predictions regarding the PLD inducer potential of each compound used
as input. The results are displayed as “YES” if the
BRF model predicts the query to be a PLD inducer and conversely as
“NO” if it is not. Notably, information on the reliability
of the performed predictions is also provided, based on the considered
AD. Finally, the user can download the produced output as .csv file.
It is worth noting that a link to download the predictions is sent
to the user’s registered email address. Additionally, the “History”
page maintains a record of all user executions, preserving input SMILES
files and their corresponding output. <xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref> shows an example of an output page generated
by the tool.</p>
    <fig id="fig4" position="float">
      <label>Figure 4</label>
      <caption>
        <p>Example of the output page returned by the AMALPHI web
platform.</p>
      </caption>
      <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mp3c00964_0004" id="gr4" position="float"/>
    </fig>
  </sec>
  <sec id="sec6">
    <title>Conclusions</title>
    <p>In an era where accurate prediction of
pharmacological and toxicological
properties of organic molecules is becoming fundamental to significantly
expedite the drug discovery process in both academia and industry,
expensive and time-consuming traditional approaches are increasingly
giving way to the use of computational technologies. In this regard,
this study focuses on the development of multiple machine learning
models capable of predicting the PLD-inducing potential, employing
different ML algorithms (RF, KNN, GB, and XGB). Following data extraction
from ChEMBL v30 and subsequent analysis of experimental phospholipidosis
data concerning <bold>851</bold> compounds, we applied rigorous data
curation practices to create PLD-DB comprising <bold>545</bold> compounds
and used them to build different PLD-inducing potential classifiers.
The analysis of the obtained validation performances in validation
yields similar values for all of the models trained using techniques
that consider data imbalance (BRF, uKNN, uGB, and uXGB), among which
the top-performing one was BRF, capable of providing the best AUC
(0.90), BA (0.81), and MCC (0.50). Furthermore, external validation
using two different external sets (ES1 and ES2) returned high values
of BA (0.72 and 0.9, respectively) and AUC (0.75 and 0.94, respectively).
Collectively, these promising results led us to make the top-performing
classifier available through a user-friendly web platform developed
by our group and named AMALPHI (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ba.ic.cnr.it/softwareic/amalphiportal/">https://www.ba.ic.cnr.it/softwareic/amalphiportal/</uri>). AMALPHI is the first freely accessible tool capable of efficiently
predicting the PLD potential of drug candidates. It can assist medicinal
chemists in proactively identifying safe drug candidates during the
research and development of pharmacologically active molecules and
in prioritizing drugs with a low probability of exhibiting false in
vitro antiviral activity.</p>
  </sec>
</body>
<back>
  <notes id="notes-1" notes-type="si">
    <title>Supporting Information Available</title>
    <p>The Supporting Information
is available free of charge at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/10.1021/acs.molpharmaceut.3c00964?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.molpharmaceut.3c00964</ext-link>.<list id="silist" list-type="simple"><list-item><p>PLDBD excel file containing the <bold>545</bold> SMILES
strings of the chemicals belonging to the PLDBD data set and the corresponding
experimental values (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.molpharmaceut.3c00964/suppl_file/mp3c00964_si_001.xlsx">XLSX</ext-link>)</p></list-item><list-item><p>ES1 file containing the 117 SMILES strings of the chemicals
belonging to the ES1 data set and the corresponding experimental values
(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.molpharmaceut.3c00964/suppl_file/mp3c00964_si_002.xlsx">XLSX</ext-link>)</p></list-item><list-item><p>ES2
excel file containing the 20 SMILES strings of the
chemicals belonging to the ES2 data set and the corresponding experimental
values (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.molpharmaceut.3c00964/suppl_file/mp3c00964_si_003.xlsx">XLSX</ext-link>)</p></list-item></list></p>
  </notes>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material content-type="local-data" id="sifile1">
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mp3c00964_si_001.xlsx">
        <caption>
          <p>mp3c00964_si_001.xlsx</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="sifile2">
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mp3c00964_si_002.xlsx">
        <caption>
          <p>mp3c00964_si_002.xlsx</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="sifile3">
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mp3c00964_si_003.xlsx">
        <caption>
          <p>mp3c00964_si_003.xlsx</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
  <notes notes-type="COI-statement" id="notes-2">
    <p>The authors
declare no competing financial interest.</p>
  </notes>
  <ack>
    <title>Acknowledgments</title>
    <p>This work was funded by the National Research Council (CNR–Italy)
under the program “PROGETTI DI RICERCA @CNR” (acronym
DATIAMO) and by the European Union (Next Generation EU) under the
program PRIN of the Ministero Dell'Università e della
Ricerca
(Progetti di ricerca di Rilevante Interesse Nazionale 2022–2022Z3BBPE—Development
of broad-spectrum coronavirus antiviral agents acting as allosteric
modulators of the host protein sigma-1). The salary of Dr. Maria Cristina
Lomuscio was funded by REGIONE PUGLIA under the program RIPARTI (assegni
di RIcerca in PARTenariato con le Imprese). The authors thank Dr.
Ivan Mercurio for providing graphical support in creating the AMALPHI
logo and Biofordrug srl (via Dante 95/99, 70019, Triggiano, Bari)
for scientific and technological support.</p>
  </ack>
  <ref-list>
    <title>References</title>
    <ref id="ref1">
      <mixed-citation publication-type="journal" id="cit1"><name><surname>Lüllmann</surname><given-names>H.</given-names></name>; <name><surname>Lüllmann-Rauch</surname><given-names>R.</given-names></name>; <name><surname>Wassermann</surname><given-names>O.</given-names></name><article-title>Drug-Induced
Phospholipidoses. II. Tissue Distribution of the Amphiphilic Drug
Chlorphentermine</article-title>. <source>CRC Crit. Rev. Toxicol.</source><year>1975</year>, <volume>4</volume> (<issue>2</issue>), <fpage>185</fpage>–<lpage>218</lpage>. <pub-id pub-id-type="doi">10.1080/10408447509164014</pub-id>.<pub-id pub-id-type="pmid">2448</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref2">
      <mixed-citation publication-type="journal" id="cit2"><name><surname>Kubo</surname><given-names>M.</given-names></name>; <name><surname>Hostetler</surname><given-names>K. Y.</given-names></name><article-title>Mechanism
of Cationic Amphiphilic Drug Inhibition of
Purified Lysosomal Phospholipase A1</article-title>. <source>Biochemistry</source><year>1985</year>, <volume>24</volume> (<issue>23</issue>), <fpage>6515</fpage>–<lpage>6520</lpage>. <pub-id pub-id-type="doi">10.1021/bi00344a031</pub-id>.<pub-id pub-id-type="pmid">4084534</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref3">
      <mixed-citation publication-type="journal" id="cit3"><name><surname>Lüllmann</surname><given-names>H.</given-names></name>; <name><surname>Lüllmann-Rauch</surname><given-names>R.</given-names></name>; <name><surname>Wassermann</surname><given-names>O.</given-names></name><article-title>Lipidosis
Induced by Amphiphilic Cationic Drugs</article-title>. <source>Biochem.
Pharmacol.</source><year>1978</year>, <volume>27</volume> (<issue>8</issue>), <fpage>1103</fpage>–<lpage>1108</lpage>. <pub-id pub-id-type="doi">10.1016/0006-2952(78)90435-5</pub-id>.<pub-id pub-id-type="pmid">358990</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref4">
      <mixed-citation publication-type="journal" id="cit4"><name><surname>Pappu</surname><given-names>A.</given-names></name>; <name><surname>Hostetler</surname><given-names>K. Y.</given-names></name><article-title>Effect of Cationic Amphiphilic Drugs
on the Hydrolysis
of Acidic and Neutral Phospholipids by Liver Lysosomal Phospholipase
A</article-title>. <source>Biochem. Pharmacol.</source><year>1984</year>, <volume>33</volume> (<issue>10</issue>), <fpage>1639</fpage>–<lpage>1644</lpage>. <pub-id pub-id-type="doi">10.1016/0006-2952(84)90286-7</pub-id>.<pub-id pub-id-type="pmid">6732837</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref5">
      <mixed-citation publication-type="journal" id="cit5"><name><surname>Lowe</surname><given-names>R.</given-names></name>; <name><surname>Mussa</surname><given-names>H. Y.</given-names></name>; <name><surname>Nigsch</surname><given-names>F.</given-names></name>; <name><surname>Glen</surname><given-names>R. C.</given-names></name>; <name><surname>Mitchell</surname><given-names>J. B.</given-names></name><article-title>Predicting
the Mechanism of Phospholipidosis</article-title>. <source>J. Cheminf.</source><year>2012</year>, <volume>4</volume> (<issue>1</issue>), <fpage>2</fpage><pub-id pub-id-type="doi">10.1186/1758-2946-4-2</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref6">
      <mixed-citation publication-type="journal" id="cit6"><name><surname>Breiden</surname><given-names>B.</given-names></name>; <name><surname>Sandhoff</surname><given-names>K.</given-names></name><article-title>Emerging Mechanisms
of Drug-Induced Phospholipidosis</article-title>. <source>Biol. Chem.</source><year>2019</year>, <volume>401</volume> (<issue>1</issue>), <fpage>31</fpage>–<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1515/hsz-2019-0270</pub-id>.<pub-id pub-id-type="pmid">31408430</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref7">
      <mixed-citation publication-type="journal" id="cit7"><name><surname>Kruhlak</surname><given-names>N. L.</given-names></name>; <name><surname>Choi</surname><given-names>S. S.</given-names></name>; <name><surname>Contrera</surname><given-names>J. F.</given-names></name>; <name><surname>Weaver</surname><given-names>J. L.</given-names></name>; <name><surname>Willard</surname><given-names>J. M.</given-names></name>; <name><surname>Hastings</surname><given-names>K. L.</given-names></name>; <name><surname>Sancilio</surname><given-names>L. F.</given-names></name><article-title>Development of a Phospholipidosis
Database and Predictive Quantitative Structure-Activity Relationship
(QSAR) Models</article-title>. <source>Toxicol. Mech. Methods</source><year>2008</year>, <volume>18</volume> (<issue>2–3</issue>), <fpage>217</fpage>–<lpage>227</lpage>. <pub-id pub-id-type="doi">10.1080/15376510701857262</pub-id>.<pub-id pub-id-type="pmid">20020916</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref8">
      <mixed-citation publication-type="journal" id="cit8"><name><surname>Ettlin</surname><given-names>R. A.</given-names></name>; <name><surname>Kuroda</surname><given-names>J.</given-names></name>; <name><surname>Plassmann</surname><given-names>S.</given-names></name>; <name><surname>Hayashi</surname><given-names>M.</given-names></name>; <name><surname>Prentice</surname><given-names>D. E.</given-names></name><article-title>Successful
Drug Development Despite Adverse Preclinical Findings Part 2: Examples</article-title>. <source>J. Toxicol. Pathol.</source><year>2010</year>, <volume>23</volume> (<issue>4</issue>), <fpage>213</fpage>–<lpage>234</lpage>. <pub-id pub-id-type="doi">10.1293/tox.23.213</pub-id>.<pub-id pub-id-type="pmid">22272032</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref9">
      <mixed-citation publication-type="journal" id="cit9"><name><surname>Gunesch</surname><given-names>A. P.</given-names></name>; <name><surname>Zapatero-Belinchón</surname><given-names>F. J.</given-names></name>; <name><surname>Pinkert</surname><given-names>L.</given-names></name>; <name><surname>Steinmann</surname><given-names>E.</given-names></name>; <name><surname>Manns</surname><given-names>M. P.</given-names></name>; <name><surname>Schneider</surname><given-names>G.</given-names></name>; <name><surname>Pietschmann</surname><given-names>T.</given-names></name>; <name><surname>Brönstrup</surname><given-names>M.</given-names></name>; <name><surname>von Hahn</surname><given-names>T.</given-names></name><article-title>Filovirus Antiviral
Activity of Cationic
Amphiphilic Drugs Is Associated with Lipophilicity and Ability To
Induce Phospholipidosis</article-title>. <source>Antimicrob. Agents
Chemother.</source><year>2020</year>, <volume>64</volume> (<issue>8</issue>), <fpage>10</fpage>–<lpage>1128</lpage>. <pub-id pub-id-type="doi">10.1128/aac.00143-20</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref10">
      <mixed-citation publication-type="journal" id="cit10"><name><surname>Tummino</surname><given-names>T. A.</given-names></name>; <name><surname>Rezelj</surname><given-names>V. V.</given-names></name>; <name><surname>Fischer</surname><given-names>B.</given-names></name>; <name><surname>Fischer</surname><given-names>A.</given-names></name>; <name><surname>O’Meara</surname><given-names>M. J.</given-names></name>; <name><surname>Monel</surname><given-names>B.</given-names></name>; <name><surname>Vallet</surname><given-names>T.</given-names></name>; <name><surname>White</surname><given-names>K. M.</given-names></name>; <name><surname>Zhang</surname><given-names>Z.</given-names></name>; <name><surname>Alon</surname><given-names>A.</given-names></name>; <name><surname>Schadt</surname><given-names>H.</given-names></name>; <name><surname>O’Donnell</surname><given-names>H. R.</given-names></name>; <name><surname>Lyu</surname><given-names>J.</given-names></name>; <name><surname>Rosales</surname><given-names>R.</given-names></name>; <name><surname>McGovern</surname><given-names>B. L.</given-names></name>; <name><surname>Rathnasinghe</surname><given-names>R.</given-names></name>; <name><surname>Jangra</surname><given-names>S.</given-names></name>; <name><surname>Schotsaert</surname><given-names>M.</given-names></name>; <name><surname>Galarneau</surname><given-names>J.-R.</given-names></name>; <name><surname>Krogan</surname><given-names>N. J.</given-names></name>; <name><surname>Urban</surname><given-names>L.</given-names></name>; <name><surname>Shokat</surname><given-names>K. M.</given-names></name>; <name><surname>Kruse</surname><given-names>A. C.</given-names></name>; <name><surname>García-Sastre</surname><given-names>A.</given-names></name>; <name><surname>Schwartz</surname><given-names>O.</given-names></name>; <name><surname>Moretti</surname><given-names>F.</given-names></name>; <name><surname>Vignuzzi</surname><given-names>M.</given-names></name>; <name><surname>Pognan</surname><given-names>F.</given-names></name>; <name><surname>Shoichet</surname><given-names>B. K.</given-names></name><article-title>Drug-Induced
Phospholipidosis Confounds
Drug Repurposing for SARS-CoV-2</article-title>. <source>Science</source><year>2021</year>, <volume>373</volume> (<issue>6554</issue>), <fpage>541</fpage>–<lpage>547</lpage>. <pub-id pub-id-type="doi">10.1126/science.abi4708</pub-id>.<pub-id pub-id-type="pmid">34326236</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref11">
      <mixed-citation publication-type="journal" id="cit11"><name><surname>Gordon</surname><given-names>D. E.</given-names></name>; <name><surname>Jang</surname><given-names>G. M.</given-names></name>; <name><surname>Bouhaddou</surname><given-names>M.</given-names></name>; <name><surname>Xu</surname><given-names>J.</given-names></name>; <name><surname>Obernier</surname><given-names>K.</given-names></name>; <name><surname>White</surname><given-names>K. M.</given-names></name>; <name><surname>O’Meara</surname><given-names>M. J.</given-names></name>; <name><surname>Rezelj</surname><given-names>V. V.</given-names></name>; <name><surname>Guo</surname><given-names>J. Z.</given-names></name>; <name><surname>Swaney</surname><given-names>D. L.</given-names></name>; <name><surname>Tummino</surname><given-names>T. A.</given-names></name>; <name><surname>Hüttenhain</surname><given-names>R.</given-names></name>; <name><surname>Kaake</surname><given-names>R. M.</given-names></name>; <name><surname>Richards</surname><given-names>A. L.</given-names></name>; <name><surname>Tutuncuoglu</surname><given-names>B.</given-names></name>; <name><surname>Foussard</surname><given-names>H.</given-names></name>; <name><surname>Batra</surname><given-names>J.</given-names></name>; <name><surname>Haas</surname><given-names>K.</given-names></name>; <name><surname>Modak</surname><given-names>M.</given-names></name>; <name><surname>Kim</surname><given-names>M.</given-names></name>; <name><surname>Haas</surname><given-names>P.</given-names></name>; <name><surname>Polacco</surname><given-names>B. J.</given-names></name>; <name><surname>Braberg</surname><given-names>H.</given-names></name>; <name><surname>Fabius</surname><given-names>J. M.</given-names></name>; <name><surname>Eckhardt</surname><given-names>M.</given-names></name>; <name><surname>Soucheray</surname><given-names>M.</given-names></name>; <name><surname>Bennett</surname><given-names>M. J.</given-names></name>; <name><surname>Cakir</surname><given-names>M.</given-names></name>; <name><surname>McGregor</surname><given-names>M. J.</given-names></name>; <name><surname>Li</surname><given-names>Q.</given-names></name>; <name><surname>Meyer</surname><given-names>B.</given-names></name>; <name><surname>Roesch</surname><given-names>F.</given-names></name>; <name><surname>Vallet</surname><given-names>T.</given-names></name>; <name><surname>Mac Kain</surname><given-names>A.</given-names></name>; <name><surname>Miorin</surname><given-names>L.</given-names></name>; <name><surname>Moreno</surname><given-names>E.</given-names></name>; <name><surname>Naing</surname><given-names>Z. Z. C.</given-names></name>; <name><surname>Zhou</surname><given-names>Y.</given-names></name>; <name><surname>Peng</surname><given-names>S.</given-names></name>; <name><surname>Shi</surname><given-names>Y.</given-names></name>; <name><surname>Zhang</surname><given-names>Z.</given-names></name>; <name><surname>Shen</surname><given-names>W.</given-names></name>; <name><surname>Kirby</surname><given-names>I. T.</given-names></name>; <name><surname>Melnyk</surname><given-names>J. E.</given-names></name>; <name><surname>Chorba</surname><given-names>J. S.</given-names></name>; <name><surname>Lou</surname><given-names>K.</given-names></name>; <name><surname>Dai</surname><given-names>S. A.</given-names></name>; <name><surname>Barrio-Hernandez</surname><given-names>I.</given-names></name>; <name><surname>Memon</surname><given-names>D.</given-names></name>; <name><surname>Hernandez-Armenta</surname><given-names>C.</given-names></name>; <name><surname>Lyu</surname><given-names>J.</given-names></name>; <name><surname>Mathy</surname><given-names>C. J. P.</given-names></name>; <name><surname>Perica</surname><given-names>T.</given-names></name>; <name><surname>Pilla</surname><given-names>K. B.</given-names></name>; <name><surname>Ganesan</surname><given-names>S. J.</given-names></name>; <name><surname>Saltzberg</surname><given-names>D. J.</given-names></name>; <name><surname>Rakesh</surname><given-names>R.</given-names></name>; <name><surname>Liu</surname><given-names>X.</given-names></name>; <name><surname>Rosenthal</surname><given-names>S. B.</given-names></name>; <name><surname>Calviello</surname><given-names>L.</given-names></name>; <name><surname>Venkataramanan</surname><given-names>S.</given-names></name>; <name><surname>Liboy-Lugo</surname><given-names>J.</given-names></name>; <name><surname>Lin</surname><given-names>Y.</given-names></name>; <name><surname>Huang</surname><given-names>X.-P.</given-names></name>; <name><surname>Liu</surname><given-names>Y.</given-names></name>; <name><surname>Wankowicz</surname><given-names>S. A.</given-names></name>; <name><surname>Bohn</surname><given-names>M.</given-names></name>; <name><surname>Safari</surname><given-names>M.</given-names></name>; <name><surname>Ugur</surname><given-names>F. S.</given-names></name>; <name><surname>Koh</surname><given-names>C.</given-names></name>; <name><surname>Savar</surname><given-names>N. S.</given-names></name>; <name><surname>Tran</surname><given-names>Q. D.</given-names></name>; <name><surname>Shengjuler</surname><given-names>D.</given-names></name>; <name><surname>Fletcher</surname><given-names>S. J.</given-names></name>; <name><surname>O’Neal</surname><given-names>M. C.</given-names></name>; <name><surname>Cai</surname><given-names>Y.</given-names></name>; <name><surname>Chang</surname><given-names>J. C. J.</given-names></name>; <name><surname>Broadhurst</surname><given-names>D. J.</given-names></name>; <name><surname>Klippsten</surname><given-names>S.</given-names></name>; <name><surname>Sharp</surname><given-names>P. P.</given-names></name>; <name><surname>Wenzell</surname><given-names>N. A.</given-names></name>; <name><surname>Kuzuoglu-Ozturk</surname><given-names>D.</given-names></name>; <name><surname>Wang</surname><given-names>H.-Y.</given-names></name>; <name><surname>Trenker</surname><given-names>R.</given-names></name>; <name><surname>Young</surname><given-names>J. M.</given-names></name>; <name><surname>Cavero</surname><given-names>D. A.</given-names></name>; <name><surname>Hiatt</surname><given-names>J.</given-names></name>; <name><surname>Roth</surname><given-names>T. L.</given-names></name>; <name><surname>Rathore</surname><given-names>U.</given-names></name>; <name><surname>Subramanian</surname><given-names>A.</given-names></name>; <name><surname>Noack</surname><given-names>J.</given-names></name>; <name><surname>Hubert</surname><given-names>M.</given-names></name>; <name><surname>Stroud</surname><given-names>R. M.</given-names></name>; <name><surname>Frankel</surname><given-names>A. D.</given-names></name>; <name><surname>Rosenberg</surname><given-names>O. S.</given-names></name>; <name><surname>Verba</surname><given-names>K. A.</given-names></name>; <name><surname>Agard</surname><given-names>D. A.</given-names></name>; <name><surname>Ott</surname><given-names>M.</given-names></name>; <name><surname>Emerman</surname><given-names>M.</given-names></name>; <name><surname>Jura</surname><given-names>N.</given-names></name>; <name><surname>von Zastrow</surname><given-names>M.</given-names></name>; <name><surname>Verdin</surname><given-names>E.</given-names></name>; <name><surname>Ashworth</surname><given-names>A.</given-names></name>; <name><surname>Schwartz</surname><given-names>O.</given-names></name>; <name><surname>d’Enfert</surname><given-names>C.</given-names></name>; <name><surname>Mukherjee</surname><given-names>S.</given-names></name>; <name><surname>Jacobson</surname><given-names>M.</given-names></name>; <name><surname>Malik</surname><given-names>H. S.</given-names></name>; <name><surname>Fujimori</surname><given-names>D. G.</given-names></name>; <name><surname>Ideker</surname><given-names>T.</given-names></name>; <name><surname>Craik</surname><given-names>C. S.</given-names></name>; <name><surname>Floor</surname><given-names>S. N.</given-names></name>; <name><surname>Fraser</surname><given-names>J. S.</given-names></name>; <name><surname>Gross</surname><given-names>J. D.</given-names></name>; <name><surname>Sali</surname><given-names>A.</given-names></name>; <name><surname>Roth</surname><given-names>B. L.</given-names></name>; <name><surname>Ruggero</surname><given-names>D.</given-names></name>; <name><surname>Taunton</surname><given-names>J.</given-names></name>; <name><surname>Kortemme</surname><given-names>T.</given-names></name>; <name><surname>Beltrao</surname><given-names>P.</given-names></name>; <name><surname>Vignuzzi</surname><given-names>M.</given-names></name>; <name><surname>García-Sastre</surname><given-names>A.</given-names></name>; <name><surname>Shokat</surname><given-names>K. M.</given-names></name>; <name><surname>Shoichet</surname><given-names>B. K.</given-names></name>; <name><surname>Krogan</surname><given-names>N. J.</given-names></name><article-title>A SARS-CoV-2
Protein Interaction Map Reveals Targets for Drug Repurposing</article-title>. <source>Nature</source><year>2020</year>, <volume>583</volume> (<issue>7816</issue>), <fpage>459</fpage>–<lpage>468</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2286-9</pub-id>.<pub-id pub-id-type="pmid">32353859</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref12">
      <mixed-citation publication-type="journal" id="cit12"><name><surname>Abatematteo</surname><given-names>F. S.</given-names></name>; <name><surname>Delre</surname><given-names>P.</given-names></name>; <name><surname>Mercurio</surname><given-names>I.</given-names></name>; <name><surname>Rezelj</surname><given-names>V. V.</given-names></name>; <name><surname>Siliqi</surname><given-names>D.</given-names></name>; <name><surname>Beaucourt</surname><given-names>S.</given-names></name>; <name><surname>Lattanzi</surname><given-names>G.</given-names></name>; <name><surname>Colabufo</surname><given-names>N. A.</given-names></name>; <name><surname>Leopoldo</surname><given-names>M.</given-names></name>; <name><surname>Saviano</surname><given-names>M.</given-names></name>; <name><surname>Vignuzzi</surname><given-names>M.</given-names></name>; <name><surname>Mangiatordi</surname><given-names>G. F.</given-names></name>; <name><surname>Abate</surname><given-names>C.</given-names></name><article-title>A Conformational Rearrangement
of the SARS-CoV-2 Host Protein Sigma-1
Is Required for Antiviral Activity: Insights from a Combined in-Silico/in-Vitro
Approach</article-title>. <source>Sci. Rep.</source><year>2023</year>, <volume>13</volume> (<issue>1</issue>), <elocation-id>12798</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-023-39662-w</pub-id>.<pub-id pub-id-type="pmid">37550340</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref13">
      <mixed-citation publication-type="journal" id="cit13"><name><surname>Diesendorf</surname><given-names>V.</given-names></name>; <name><surname>Roll</surname><given-names>V.</given-names></name>; <name><surname>Geiger</surname><given-names>N.</given-names></name>; <name><surname>Fähr</surname><given-names>S.</given-names></name>; <name><surname>Obernolte</surname><given-names>H.</given-names></name>; <name><surname>Sewald</surname><given-names>K.</given-names></name>; <name><surname>Bodem</surname><given-names>J.</given-names></name><article-title>Drug-Induced Phospholipidosis
Is Not Correlated with the Inhibition of SARS-CoV-2 - Inhibition of
SARS-CoV-2 Is Cell Line-Specific</article-title>. <source>Front. Cell
Infect. Microbiol.</source><year>2023</year>, <volume>13</volume>, <elocation-id>1100028</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2023.1100028</pub-id>.<pub-id pub-id-type="pmid">37637460</pub-id></mixed-citation>
    </ref>
    <ref id="ref14">
      <mixed-citation publication-type="journal" id="cit14"><name><surname>Lane</surname><given-names>T. R.</given-names></name>; <name><surname>Ekins</surname><given-names>S.</given-names></name><article-title>Defending Antiviral Cationic Amphiphilic
Drugs That May Cause Drug-Induced
Phospholipidosis</article-title>. <source>J. Chem. Inf. Model.</source><year>2021</year>, <volume>61</volume> (<issue>9</issue>), <fpage>4125</fpage>–<lpage>4130</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.1c00903</pub-id>.<pub-id pub-id-type="pmid">34516123</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref15">
      <mixed-citation publication-type="journal" id="cit15"><name><surname>Atienzar</surname><given-names>F.</given-names></name>; <name><surname>Gerets</surname><given-names>H.</given-names></name>; <name><surname>Dufrane</surname><given-names>S.</given-names></name>; <name><surname>Tilmant</surname><given-names>K.</given-names></name>; <name><surname>Cornet</surname><given-names>M.</given-names></name>; <name><surname>Dhalluin</surname><given-names>S.</given-names></name>; <name><surname>Ruty</surname><given-names>B.</given-names></name>; <name><surname>Rose</surname><given-names>G.</given-names></name>; <name><surname>Canning</surname><given-names>M.</given-names></name><article-title>Determination
of Phospholipidosis Potential Based on Gene Expression Analysis in
HepG2 Cells</article-title>. <source>Toxicol. Sci.</source><year>2006</year>, <volume>96</volume> (<issue>1</issue>), <fpage>101</fpage>–<lpage>114</lpage>. <pub-id pub-id-type="doi">10.1093/toxsci/kfl184</pub-id>.<pub-id pub-id-type="pmid">17175557</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref16">
      <mixed-citation publication-type="journal" id="cit16"><name><surname>Ulrich</surname><given-names>R. G.</given-names></name>; <name><surname>Kilgore</surname><given-names>K. S.</given-names></name>; <name><surname>Sun</surname><given-names>E. L.</given-names></name>; <name><surname>Cramer</surname><given-names>C. T.</given-names></name>; <name><surname>Ginsberg</surname><given-names>L. C.</given-names></name><article-title>An in Vitro
Fluorescence Assay for the Detection of Drug-Induced Cytoplasmic Lamellar
Bodies</article-title>. <source>Toxicol. Methods</source><year>1991</year>, <volume>1</volume> (<issue>2</issue>), <fpage>89</fpage>–<lpage>105</lpage>. <pub-id pub-id-type="doi">10.3109/15376519109044560</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref17">
      <mixed-citation publication-type="journal" id="cit17"><name><surname>Gum</surname><given-names>R. J.</given-names></name>; <name><surname>Hickman</surname><given-names>D.</given-names></name>; <name><surname>Fagerland</surname><given-names>J. A.</given-names></name>; <name><surname>Heindel</surname><given-names>M. A.</given-names></name>; <name><surname>Gagne</surname><given-names>G. D.</given-names></name>; <name><surname>Schmidt</surname><given-names>J. M.</given-names></name>; <name><surname>Michaelides</surname><given-names>M. R.</given-names></name>; <name><surname>Davidsen</surname><given-names>S. K.</given-names></name>; <name><surname>Ulrich</surname><given-names>R. G.</given-names></name><article-title>Analysis
of Two Matrix Metalloproteinase Inhibitors and Their Metabolites for
Induction of Phospholipidosis in Rat and Human Hepatocytes(1)</article-title>. <source>Biochem. Pharmacol.</source><year>2001</year>, <volume>62</volume> (<issue>12</issue>), <fpage>1661</fpage>–<lpage>1673</lpage>. <pub-id pub-id-type="doi">10.1016/S0006-2952(01)00823-1</pub-id>.<pub-id pub-id-type="pmid">11755120</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref18">
      <mixed-citation publication-type="journal" id="cit18"><name><surname>Casartelli</surname><given-names>A.</given-names></name>; <name><surname>Bonato</surname><given-names>M.</given-names></name>; <name><surname>Cristofori</surname><given-names>P.</given-names></name>; <name><surname>Crivellente</surname><given-names>F.</given-names></name>; <name><surname>Dal Negro</surname><given-names>G.</given-names></name>; <name><surname>Masotto</surname><given-names>I.</given-names></name>; <name><surname>Mutinelli</surname><given-names>C.</given-names></name>; <name><surname>Valko</surname><given-names>K.</given-names></name>; <name><surname>Bonfante</surname><given-names>V.</given-names></name><article-title>A Cell-Based Approach for the Early
Assessment of the Phospholipidogenic Potential in Pharmaceutical Research
and Drug Development</article-title>. <source>Cell Biol. Toxicol.</source><year>2003</year>, <volume>19</volume> (<issue>3</issue>), <fpage>161</fpage>–<lpage>176</lpage>. <pub-id pub-id-type="doi">10.1023/A:1024778329320</pub-id>.<pub-id pub-id-type="pmid">12945744</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref19">
      <mixed-citation publication-type="journal" id="cit19"><name><surname>Kasahara</surname><given-names>T.</given-names></name>; <name><surname>Tomita</surname><given-names>K.</given-names></name>; <name><surname>Murano</surname><given-names>H.</given-names></name>; <name><surname>Harada</surname><given-names>T.</given-names></name>; <name><surname>Tsubakimoto</surname><given-names>K.</given-names></name>; <name><surname>Ogihara</surname><given-names>T.</given-names></name>; <name><surname>Ohnishi</surname><given-names>S.</given-names></name>; <name><surname>Kakinuma</surname><given-names>C.</given-names></name><article-title>Establishment of an
in Vitro High-Throughput Screening Assay for Detecting Phospholipidosis-Inducing
Potential</article-title>. <source>Toxicol. Sci.</source><year>2006</year>, <volume>90</volume> (<issue>1</issue>), <fpage>133</fpage>–<lpage>141</lpage>. <pub-id pub-id-type="doi">10.1093/toxsci/kfj067</pub-id>.<pub-id pub-id-type="pmid">16338956</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref20">
      <mixed-citation publication-type="journal" id="cit20"><name><surname>Morelli</surname><given-names>J. K.</given-names></name>; <name><surname>Buehrle</surname><given-names>M.</given-names></name>; <name><surname>Pognan</surname><given-names>F.</given-names></name>; <name><surname>Barone</surname><given-names>L. R.</given-names></name>; <name><surname>Fieles</surname><given-names>W.</given-names></name>; <name><surname>Ciaccio</surname><given-names>P. J.</given-names></name><article-title>Validation of an
in Vitro Screen for Phospholipidosis
Using a High-Content Biology Platform</article-title>. <source>Cell
Biol. Toxicol.</source><year>2006</year>, <volume>22</volume> (<issue>1</issue>), <fpage>15</fpage>–<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1007/s10565-006-0176-z</pub-id>.<pub-id pub-id-type="pmid">16463016</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref21">
      <mixed-citation publication-type="journal" id="cit21"><name><surname>Sawada</surname><given-names>H.</given-names></name>; <name><surname>Takami</surname><given-names>K.</given-names></name>; <name><surname>Asahi</surname><given-names>S.</given-names></name><article-title>A Toxicogenomic Approach
to Drug-Induced
Phospholipidosis: Analysis of Its Induction Mechanism and Establishment
of a Novel in Vitro Screening System</article-title>. <source>Toxicol.
Sci.</source><year>2004</year>, <volume>83</volume> (<issue>2</issue>), <fpage>282</fpage>–<lpage>292</lpage>. <pub-id pub-id-type="doi">10.1093/toxsci/kfh264</pub-id>.<pub-id pub-id-type="pmid">15342952</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref22">
      <mixed-citation publication-type="journal" id="cit22"><name><surname>Reasor</surname><given-names>M. J.</given-names></name>; <name><surname>Hastings</surname><given-names>K. L.</given-names></name>; <name><surname>Ulrich</surname><given-names>R. G.</given-names></name><article-title>Drug-Induced
Phospholipidosis: Issues
and Future Directions</article-title>. <source>Expert Opin. Drug Saf.</source><year>2006</year>, <volume>5</volume> (<issue>4</issue>), <fpage>567</fpage>–<lpage>583</lpage>. <pub-id pub-id-type="doi">10.1517/14740338.5.4.567</pub-id>.<pub-id pub-id-type="pmid">16774494</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref23">
      <mixed-citation publication-type="journal" id="cit23"><name><surname>Goracci</surname><given-names>L.</given-names></name>; <name><surname>Ceccarelli</surname><given-names>M.</given-names></name>; <name><surname>Bonelli</surname><given-names>D.</given-names></name>; <name><surname>Cruciani</surname><given-names>G.</given-names></name><article-title>Modeling Phospholipidosis
Induction: Reliability and Warnings</article-title>. <source>J. Chem.
Inf. Model.</source><year>2013</year>, <volume>53</volume> (<issue>6</issue>), <fpage>1436</fpage>–<lpage>1446</lpage>. <pub-id pub-id-type="doi">10.1021/ci400113t</pub-id>.<pub-id pub-id-type="pmid">23692521</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref24">
      <mixed-citation publication-type="journal" id="cit24"><name><surname>Macip</surname><given-names>G.</given-names></name>; <name><surname>Garcia-Segura</surname><given-names>P.</given-names></name>; <name><surname>Mestres-Truyol</surname><given-names>J.</given-names></name>; <name><surname>Saldivar-Espinoza</surname><given-names>B.</given-names></name>; <name><surname>Ojeda-Montes</surname><given-names>M. J.</given-names></name>; <name><surname>Gimeno</surname><given-names>A.</given-names></name>; <name><surname>Cereto-Massagué</surname><given-names>A.</given-names></name>; <name><surname>Garcia-Vallvé</surname><given-names>S.</given-names></name>; <name><surname>Pujadas</surname><given-names>G.</given-names></name><article-title>Haste Makes Waste: A Critical Review
of Docking-based Virtual Screening in Drug Repurposing for SARS-CoV-2
Main Protease (M-pro) Inhibition</article-title>. <source>Med. Res.
Rev.</source><year>2022</year>, <volume>42</volume> (<issue>2</issue>), <fpage>744</fpage>–<lpage>769</lpage>. <pub-id pub-id-type="doi">10.1002/med.21862</pub-id>.<pub-id pub-id-type="pmid">34697818</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref25">
      <mixed-citation publication-type="journal" id="cit25"><name><surname>Lowe</surname><given-names>R.</given-names></name>; <name><surname>Glen</surname><given-names>R. C.</given-names></name>; <name><surname>Mitchell</surname><given-names>J. B. O.</given-names></name><article-title>Predicting Phospholipidosis Using
Machine Learning</article-title>. <source>Mol. Pharm.</source><year>2010</year>, <volume>7</volume> (<issue>5</issue>), <fpage>1708</fpage>–<lpage>1714</lpage>. <pub-id pub-id-type="doi">10.1021/mp100103e</pub-id>.<pub-id pub-id-type="pmid">20799726</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref26">
      <mixed-citation publication-type="journal" id="cit26"><name><surname>Orogo</surname><given-names>A. M.</given-names></name>; <name><surname>Choi</surname><given-names>S. S.</given-names></name>; <name><surname>Minnier</surname><given-names>B. L.</given-names></name>; <name><surname>Kruhlak</surname><given-names>N. L.</given-names></name><article-title>Construction and
Consensus Performance of (Q)SAR Models for Predicting Phospholipidosis
Using a Dataset of 743 Compounds</article-title>. <source>Mol. Inf.</source><year>2012</year>, <volume>31</volume> (<issue>10</issue>), <fpage>725</fpage>–<lpage>739</lpage>. <pub-id pub-id-type="doi">10.1002/minf.201200048</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref27">
      <mixed-citation publication-type="journal" id="cit27"><name><surname>Fusani</surname><given-names>L.</given-names></name>; <name><surname>Brown</surname><given-names>M.</given-names></name>; <name><surname>Chen</surname><given-names>H.</given-names></name>; <name><surname>Ahlberg</surname><given-names>E.</given-names></name>; <name><surname>Noeske</surname><given-names>T.</given-names></name><article-title>Predicting
the Risk of Phospholipidosis with in Silico Models and an Image-Based
in Vitro Screen</article-title>. <source>Mol. Pharm.</source><year>2017</year>, <volume>14</volume> (<issue>12</issue>), <fpage>4346</fpage>–<lpage>4352</lpage>. <pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.7b00388</pub-id>.<pub-id pub-id-type="pmid">29077420</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref28">
      <mixed-citation publication-type="journal" id="cit28"><name><surname>Schieferdecker</surname><given-names>S.</given-names></name>; <name><surname>Eberlein</surname><given-names>A.</given-names></name>; <name><surname>Vock</surname><given-names>E.</given-names></name>; <name><surname>Beilmann</surname><given-names>M.</given-names></name><article-title>Development of an in
Silico Consensus Model for the Prediction of the Phospholipigenic
Potential of Small Molecules</article-title>. <source>Comput. Toxicol.</source><year>2022</year>, <volume>22</volume>, <elocation-id>100226</elocation-id><pub-id pub-id-type="doi">10.1016/j.comtox.2022.100226</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref29">
      <mixed-citation publication-type="journal" id="cit29"><name><surname>Przybylak</surname><given-names>K. R.</given-names></name>; <name><surname>Alzahrani</surname><given-names>A. R.</given-names></name>; <name><surname>Cronin</surname><given-names>M. T. D.</given-names></name><article-title>How Does the Quality of Phospholipidosis
Data Influence the Predictivity of Structural Alerts?</article-title>. <source>J. Chem. Inf. Model.</source><year>2014</year>, <volume>54</volume> (<issue>8</issue>), <fpage>2224</fpage>–<lpage>2232</lpage>. <pub-id pub-id-type="doi">10.1021/ci500233k</pub-id>.<pub-id pub-id-type="pmid">25062434</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref30">
      <mixed-citation publication-type="journal" id="cit30"><name><surname>Lagorce</surname><given-names>D.</given-names></name>; <name><surname>Bouslama</surname><given-names>L.</given-names></name>; <name><surname>Becot</surname><given-names>J.</given-names></name>; <name><surname>Miteva</surname><given-names>M. A.</given-names></name>; <name><surname>Villoutreix</surname><given-names>B. O.</given-names></name><article-title>FAF-Drugs4:
Free ADME-Tox Filtering Computations for Chemical Biology and Early
Stages Drug Discovery</article-title>. <source>Bioinformatics</source><year>2017</year>, <volume>33</volume> (<issue>22</issue>), <fpage>3658</fpage>–<lpage>3660</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/btx491</pub-id>.<pub-id pub-id-type="pmid">28961788</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref31">
      <mixed-citation publication-type="journal" id="cit31"><name><surname>Creanza</surname><given-names>T. M.</given-names></name>; <name><surname>Lamanna</surname><given-names>G.</given-names></name>; <name><surname>Delre</surname><given-names>P.</given-names></name>; <name><surname>Contino</surname><given-names>M.</given-names></name>; <name><surname>Corriero</surname><given-names>N.</given-names></name>; <name><surname>Saviano</surname><given-names>M.</given-names></name>; <name><surname>Mangiatordi</surname><given-names>G. F.</given-names></name>; <name><surname>Ancona</surname><given-names>N.</given-names></name><article-title>DeLA-Drug: A Deep Learning
Algorithm for Automated Design of Druglike Analogues</article-title>. <source>J. Chem. Inf. Model.</source><year>2022</year>, <volume>62</volume> (<issue>6</issue>), <fpage>1411</fpage>–<lpage>1424</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.2c00205</pub-id>.<pub-id pub-id-type="pmid">35294184</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref32">
      <mixed-citation publication-type="journal" id="cit32"><name><surname>Delre</surname><given-names>P.</given-names></name>; <name><surname>Contino</surname><given-names>M.</given-names></name>; <name><surname>Alberga</surname><given-names>D.</given-names></name>; <name><surname>Saviano</surname><given-names>M.</given-names></name>; <name><surname>Corriero</surname><given-names>N.</given-names></name>; <name><surname>Mangiatordi</surname><given-names>G. F.</given-names></name><article-title>ALPACA:
A Machine Learning Platform for Affinity and
Selectivity Profiling of CAnnabinoids Receptors Modulators</article-title>. <source>Comput. Biol. Med.</source><year>2023</year>, <volume>164</volume>, <elocation-id>107314</elocation-id><pub-id pub-id-type="doi">10.1016/j.compbiomed.2023.107314</pub-id>.<pub-id pub-id-type="pmid">37572442</pub-id></mixed-citation>
    </ref>
    <ref id="ref33">
      <mixed-citation publication-type="journal" id="cit33"><name><surname>Delre</surname><given-names>P.</given-names></name>; <name><surname>Lavado</surname><given-names>G. J.</given-names></name>; <name><surname>Lamanna</surname><given-names>G.</given-names></name>; <name><surname>Saviano</surname><given-names>M.</given-names></name>; <name><surname>Roncaglioni</surname><given-names>A.</given-names></name>; <name><surname>Benfenati</surname><given-names>E.</given-names></name>; <name><surname>Mangiatordi</surname><given-names>G. F.</given-names></name>; <name><surname>Gadaleta</surname><given-names>D.</given-names></name><article-title>Ligand-Based Prediction
of hERG-Mediated Cardiotoxicity Based on the Integration of Different
Machine Learning Techniques</article-title>. <source>Front. Pharmacol.</source><year>2022</year>, <volume>13</volume>, <elocation-id>951083</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2022.951083</pub-id>.<pub-id pub-id-type="pmid">36133824</pub-id></mixed-citation>
    </ref>
    <ref id="ref34">
      <mixed-citation publication-type="undeclared" id="cit34"><person-group person-group-type="allauthors"><name><surname>Benhenda</surname><given-names>M.</given-names></name></person-group><article-title>ChemGAN Challenge
for Drug Discovery: Can AI Reproduce Natural Chemical Diversity?</article-title><source>arXiv</source><year>2017</year><pub-id pub-id-type="doi">10.48550/arXiv.1708.08227</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref35">
      <mixed-citation publication-type="book" id="cit35"><article-title>RDKit Diversity Picker - RDKit Nodes Feature
- KNIME</article-title>. <source>Knime relase 4.6.1: RDKit Nodes Feature</source>; <publisher-name>NIBR</publisher-name><year>2022</year>.</mixed-citation>
    </ref>
    <ref id="ref36">
      <mixed-citation publication-type="journal" id="cit36"><name><surname>Zhu</surname><given-names>R.</given-names></name>; <name><surname>Guo</surname><given-names>Y.</given-names></name>; <name><surname>Xue</surname><given-names>J.-H.</given-names></name><article-title>Adjusting the Imbalance Ratio by
the Dimensionality
of Imbalanced Data</article-title>. <source>Pattern Recognition Letters</source><year>2020</year>, <volume>133</volume>, <fpage>217</fpage>–<lpage>223</lpage>. <pub-id pub-id-type="doi">10.1016/j.patrec.2020.03.004</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref37">
      <mixed-citation publication-type="book" id="cit37"><article-title>Ensamble Learning Wrappers - KNIME</article-title>. In <source>Knime
Relase 4.6.1: KNIME Ensamble Learning Wrappers</source>; <publisher-name>KNIME AG</publisher-name>: <publisher-loc>Zurich</publisher-loc>, <year>2022</year>.</mixed-citation>
    </ref>
    <ref id="ref38">
      <mixed-citation publication-type="book" id="cit38"><article-title>K Nearest Neighbor
- Base Nodes - KNIME</article-title>. In <source>Knime Relase 4.6.1:
KNIME Base nodes</source>; <publisher-name>KNIME
AG</publisher-name>: <publisher-loc>Zurich</publisher-loc>, <year>2022</year>.</mixed-citation>
    </ref>
    <ref id="ref39">
      <mixed-citation publication-type="book" id="cit39"><article-title>XGBoost Integration
- KNIME</article-title>. In <source>Knime Relase
4.6.1: KNIME XGBoost Integration</source>; <publisher-name>KNIME AG</publisher-name>: <publisher-loc>Zurich</publisher-loc>, <year>2022</year>.</mixed-citation>
    </ref>
    <ref id="ref40">
      <mixed-citation publication-type="journal" id="cit40"><name><surname>Capecchi</surname><given-names>A.</given-names></name>; <name><surname>Probst</surname><given-names>D.</given-names></name>; <name><surname>Reymond</surname><given-names>J.-L.</given-names></name><article-title>One Molecular Fingerprint
to Rule
Them All: Drugs, Biomolecules, and the Metabolome</article-title>. <source>J. Cheminf.</source><year>2020</year>, <volume>12</volume> (<issue>1</issue>), <fpage>43</fpage><pub-id pub-id-type="doi">10.1186/s13321-020-00445-4</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref41">
      <mixed-citation publication-type="journal" id="cit41"><name><surname>Lu</surname><given-names>W.</given-names></name>; <name><surname>Li</surname><given-names>Z.</given-names></name>; <name><surname>Chu</surname><given-names>J.</given-names></name><article-title>Adaptive Ensemble Undersampling-Boost:
A Novel Learning
Framework for Imbalanced Data</article-title>. <source>J. Syst. Software</source><year>2017</year>, <volume>132</volume>, <fpage>272</fpage>–<lpage>282</lpage>. <pub-id pub-id-type="doi">10.1016/j.jss.2017.07.006</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref42">
      <mixed-citation publication-type="book" id="cit42"><person-group person-group-type="allauthors"><name><surname>Agrawal</surname><given-names>T.</given-names></name></person-group><article-title>Introduction to
Hyperparameters</article-title>. In <source>Hyperparameter Optimization
in Machine Learning: Make Your Machine Learning and Deep Learning
Models More Efficient</source>; <person-group person-group-type="editor"><name><surname>Agrawal</surname><given-names>T.</given-names></name></person-group>, Ed.; <publisher-name>Apress</publisher-name>: <publisher-loc>Berkeley,
CA</publisher-loc>, <year>2021</year>; pp <fpage>1</fpage>–<lpage>30</lpage><pub-id pub-id-type="doi">10.1007/978-1-4842-6579-6_1</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref43">
      <mixed-citation publication-type="undeclared" id="cit43"><person-group person-group-type="allauthors"><name><surname>Probst</surname><given-names>P.</given-names></name>; <name><surname>Bischl</surname><given-names>B.</given-names></name>; <name><surname>Boulesteix</surname><given-names>A.-L.</given-names></name></person-group><article-title>Tunability:
Importance of Hyperparameters of Machine Learning Algorithms</article-title>. <year>2018</year><pub-id pub-id-type="doi">10.48550/arXiv.1802.09596</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref44">
      <mixed-citation publication-type="journal" id="cit44"><name><surname>Gadaleta</surname><given-names>D.</given-names></name>; <name><surname>Mangiatordi</surname><given-names>G. F.</given-names></name>; <name><surname>Catto</surname><given-names>M.</given-names></name>; <name><surname>Carotti</surname><given-names>A.</given-names></name>; <name><surname>Nicolotti</surname><given-names>O.</given-names></name><article-title>Applicability
Domain for QSAR Models: Where Theory Meets Reality</article-title>. <source>Int. J. Quant. Struct.-Prop. Relat.</source><year>2016</year>, <volume>1</volume> (<issue>1</issue>), <fpage>45</fpage>–<lpage>63</lpage>. <pub-id pub-id-type="doi">10.4018/IJQSPR.2016010102</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref45">
      <mixed-citation publication-type="journal" id="cit45"><name><surname>Melagraki</surname><given-names>G.</given-names></name>; <name><surname>Afantitis</surname><given-names>A.</given-names></name>; <name><surname>Sarimveis</surname><given-names>H.</given-names></name>; <name><surname>Igglessi-Markopoulou</surname><given-names>O.</given-names></name>; <name><surname>Koutentis</surname><given-names>P. A.</given-names></name>; <name><surname>Kollias</surname><given-names>G.</given-names></name><article-title>In Silico Exploration for Identifying
Structure–Activity Relationship of MEK Inhibition and Oral
Bioavailability for Isothiazole Derivatives</article-title>. <source>Chem. Biol. Drug Des.</source><year>2010</year>, <volume>76</volume> (<issue>5</issue>), <fpage>397</fpage>–<lpage>406</lpage>. <pub-id pub-id-type="doi">10.1111/j.1747-0285.2010.01029.x</pub-id>.<pub-id pub-id-type="pmid">20925691</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref46">
      <mixed-citation publication-type="book" id="cit46"><article-title>ROC Curve - JavaScript Views - KNIME</article-title>. In <source>Knime Relase 4.6.1: KNIME JavaScript Views</source>; <publisher-name>KNIME AG</publisher-name>: <publisher-loc>Zurich</publisher-loc>, <year>2022</year>.</mixed-citation>
    </ref>
    <ref id="ref47">
      <mixed-citation publication-type="book" id="cit47"><person-group person-group-type="allauthors"><name><surname>Ling</surname><given-names>C. X.</given-names></name>; <name><surname>Huang</surname><given-names>J.</given-names></name>; <name><surname>Zhang</surname><given-names>H.</given-names></name></person-group><article-title>AUC: A Better Measure than
Accuracy in Comparing Learning Algorithms</article-title>. In <source>Advances in Artificial Intelligence</source>; <person-group person-group-type="editor"><name><surname>Xiang</surname><given-names>Y.</given-names></name>; <name><surname>Chaib-draa</surname><given-names>B.</given-names></name></person-group>, Eds.; <publisher-name>Springer</publisher-name>: <publisher-loc>Berlin, Heidelberg</publisher-loc>, <year>2003</year>; pp <fpage>329</fpage>–<lpage>341</lpage><pub-id pub-id-type="doi">10.1007/3-540-44886-1_25</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref48">
      <mixed-citation publication-type="journal" id="cit48"><name><surname>Carhart</surname><given-names>R. E.</given-names></name>; <name><surname>Smith</surname><given-names>D. H.</given-names></name>; <name><surname>Venkataraghavan</surname><given-names>R.</given-names></name><article-title>Atom Pairs
as Molecular Features
in Structure-Activity Studies: Definition and Applications</article-title>. <source>J. Chem. Inf. Comput. Sci.</source><year>1985</year>, <volume>25</volume> (<issue>2</issue>), <fpage>64</fpage>–<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1021/ci00046a002</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref49">
      <mixed-citation publication-type="journal" id="cit49"><name><surname>Bienfait</surname><given-names>B.</given-names></name>; <name><surname>Ertl</surname><given-names>P.</given-names></name><article-title>JSME: A Free Molecule
Editor in JavaScript</article-title>. <source>J. Cheminf.</source><year>2013</year>, <volume>5</volume> (<issue>1</issue>), <fpage>24</fpage><pub-id pub-id-type="doi">10.1186/1758-2946-5-24</pub-id>.</mixed-citation>
    </ref>
  </ref-list>
</back>
